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ABSTRACT 
Benzodiazepines are a class of medications with a broad range of pharmacological 
actions including anti-anxiety, muscle-relaxant, antiepileptic, hypnotic, and memory 
impairing effects. Benzodiazepines became a popular medication due to their 
relative safety of use and their fast-acting effects. However, increasingly research 
has established a range of detrimental effects, including reduced efficacy over time, 
and cognitive and psychomotor impairment. New benzodiazepine users commonly 
experience cognitive side-effects including sedation, inattention, and memory 
problems. In recognition of the risks of using benzodiazepines, they are rarely 
indicated as a first line treatment, and clinical guidelines suggest that when needed 
they are used for the shortest duration possible and at the lowest dose required. 
Despite this, there is evidence that benzodiazepine use still regularly occurs for 
extended durations and at high dosages within Australia. Most of the research to 
date has examined once-off or short duration benzodiazepine use in young, healthy, 
benzodiazepine-naïve individuals – a group far removed from the usual 
benzodiazepine using population who are more often older, have a variety of health 
conditions, and have used benzodiazepines regularly for an extended period of 
time. The current study aimed to overcome some of these gaps in the literature by 
examining benzodiazepine use among existing consumers, as it naturally occurs in 
the Australian population, specifically focusing on those who use in an ongoing, 
chronic manner, rather than amongst carefully selected research samples.  
Understanding the impact of benzodiazepine use on experience of accidents, 
particularly whilst driving, is an important area of research. This thesis aimed to add 
to the existing accident literature by examining the influence of benzodiazepine use 
on a range of different incident severities including: cognitive failures (everyday 
cognitive slips or errors), minor injuries not requiring medical attention, and major 
accidents requiring medical attention. Three studies were undertaken: (1) an online, 
general population survey of chronic benzodiazepine users and their experiences of 
accidents, injuries, and cognitive failures (n=129), (2) an interview based study 
examining the unique effects of benzodiazepines on safety incidents in people who 
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inject drugs (n=170) and (3) using the same methods and population group as Study 
1, the subjective experiences and perceptions of this group were explored through 
a qualitative design (n=129).  
In both Study 1 and Study 3, respondents were divided into three categories of 
benzodiazepine chronicity; short-term (length of use ≤ year; daily/occasional 
frequency), intermittent (length of use > year; occasional frequency) and chronic 
(length of use > year; daily frequency). Reported benzodiazepine use was often 
daily, of a high dosage, and for an extended period of time. For example, the 
chronic users in this study had on average a duration of use spanning 8 years, used 
most days within a month, and had an average diazepam equivalent dosage per 
month of 900mg. This usage is inconsistent with recommendations from current 
clinical guidelines. Logistic regression, used in Study 1 showed that chronic, daily, 
users were at significantly increased risk of general accidents, and retrospective and 
prospective memory problems, compared to intermittent users. Study 3 aimed to 
complement the findings of Study 1, by providing information about the self-
reported experience, knowledge, and perceptions of chronic benzodiazepine users. 
Attitudes towards benzodiazepines reported in Study 3 were mixed, although a 
large proportion of the sample reported negative experiences, such as dependence, 
withdrawal, and cognitive effects. Side-effects were regularly experienced by the 
group, and often did not abate, particularly for the most chronic users. Tested 
knowledge of benzodiazepines in the sample was low, and many respondents 
stated that they felt they had received inadequate information about the risks 
associated with benzodiazepine use. Findings from Study 1 and Study 3 indicate that 
benzodiazepines have a considerable impact on both the subjective and objective 
safety experiences of chronic users.   
Study 2 examined the unique impact of benzodiazepine use on cognitive failures, 
minor injuries, and major accidents, in a group of people who inject drugs (PWID). It 
is recommended that benzodiazepines are best avoided in PWID, due to the high 
risk of dependence and additive sedative effects. However, it is known that 
benzodiazepines are still commonly used by PWID, and this was also evident in 
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Study 2. Despite the range of other substances used by this group, moderate-to-
regular benzodiazepine use independently contributed to an increased risk of 
retrospective memory problems (OR 8.21, 95%CI 1.03-65.41, p=0.047), and major 
accidents (OR 3.88, 95%CI 1.20-12.50, p=0.023) after controlling for a wide range of 
confounders. 
Overall, findings from this thesis suggest that benzodiazepine use in Australia 
remains inconsistent with clinical guidelines. After controlling for confounding 
variables, benzodiazepines had a considerable effect on safety in both the general, 
and a high risk population (PWID). Chronic benzodiazepine users cannot be 
assumed to be tolerant to the effects of benzodiazepines, and this thesis shows that 
they continue to experience ongoing, detrimental effects of benzodiazepine use on 
their safety. It is suggested that there should be more specialised services to assist 
those who are grappling with benzodiazepine withdrawal and dependence, and 
importantly to provide alternative treatments to the use of benzodiazepines. It is 
proposed that the use of a benzodiazepine contract, like those used for opioids, 
would ensure best practice prescribing occurs, and improve outcomes for both 
prescribers and patients.  
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CHAPTER 1: BENZODIAZEPINES – AN INTRODUCTION 
Benzodiazepines are among the world’s most widely prescribed psychotropic 
medications and are used to treat conditions such as anxiety, insomnia, panic 
disorders, epilepsy, muscle spasms, and alcohol withdrawal (Barker, Jackson, 
Greenwood, & Crowe, 2003). Common benzodiazepines prescribed within Australia 
are listed in Table 1. Benzodiazepines are often classified according to their half-life, 
that is, the time taken for the plasma concentration of a drug to decrease by half 
(Griffin, Kaye, Bueno, & Kaye, 2013).  The general pharmacological effects of 
benzodiazepines include anti-anxiety, muscle-relaxant, antiepileptic, hypnotic, and 
memory impairing actions (Bryant, 2007). It is likely that these effects are 
interdependent (Curran, 1992). The pharmacological actions of benzodiazepines are 
outlined in Table 2. 
Table 1. Common Benzodiazepines found in Australia and Classification according to 
Duration of Action 
Generic Name Common trade Names 
Short Duration of Action (median half-life <12 hours) 
Alprazolam Kalma, Alprax 
Oxazepam Serepax, Murelax, Alepam 
Temazepam Temaze, Temtabs, Normison 
Intermediate Duration of Action (median half-life 12-24 hours) 
Bromazepam Lexotan 
Lorazepam Ativan 
Long Duration of Action (median half-life >24 hours) 
Clobazam Frisium 
Clonazepam Rivotril 
Diazepam Valium, Ducene, Antenex, Valpam 
Flunitrazepam Hypnodorm 
Nitrazepam Mogadon, Alodorm 
 
 
 
Chapter 1: Benzodiazepines - An Introduction | 3 
 
 
 
Table 2. Pharmacological Action of Benzodiazepines (Ashton, 1995). 
Benzodiazepines act through potentiating the inhibitory effects of gamma-
aminobutyric acid (GABA) throughout the central nervous system (Gorenstein, 
Bernik, & Pompeia, 1994). GABA is the main inhibitory transmitter in the brain, 
found at approximately 30% of all central nervous system synapses, and in many 
pathways and brain areas (Bryant, 2007). Benzodiazepines do not occupy the entire 
GABA(a) receptor but act at a modulatory site to facilitate GABA binding to the 
GABA(a) receptors (Bryant, 2007). More simply, benzodiazepines enhance the 
action of GABA, which in turn slows down central nervous system electrical signals. 
Figure 1 provides a diagrammatic explanation of the effects of benzodiazepines on 
GABA activity. The anti-anxiety effects of benzodiazepines are posited to occur due 
to the highly dense area of benzodiazepine binding sites in the amygdala region of 
the limbic system – an area often associated with the regulation of emotional 
behaviour (Bryant, 2007).  
Pharmacological Action Clinical Uses 
Hypnotic Short-term treatment of insomnia 
Anxiolytic Short-term treatment of anxiety 
Short-term aid to alcohol/central nervous system 
depressant drug withdrawal 
Anticonvulsant Status Epilepticus 
Drug-induced Convulsions 
Short-term treatment for Epilepsy 
Amnesic Premedication before surgery 
Minor surgical procedures 
Muscle-relaxant Painful muscle spasms 
Some dystonia and involuntary movements 
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Figure 1. Mechanism of action of the neurotransmitter GABA (gamma-aminobutyric 
acid) and benzodiazepines on brain neurons (Ashton, 1995). 
The popularity of benzodiazepines, in comparison to their predecessors, such as 
barbiturates, has resulted primarily from their initial effectiveness, combined with a 
relatively good safety profile. Initially, benzodiazepines were claimed to offer the 
advantages of lower fatality rates following overdose, lower potential for abuse, 
more favourable adverse effect profiles and fewer potentially serious drug 
interactions (Ashton, 1995; Bryant, 2007). Despite this, benzodiazepines are capable 
of producing a wide variety of side effects due to the broad distribution of 
benzodiazepine receptors found in a number of areas such as the spinal cord, 
cerebellum, limbic areas, and the cerebral cortex (Gudex, 1991). Additionally, 
benzodiazepines can have additive and synergistic effects with other central 
nervous system depressants including; antidepressants, antipsychotics, 
anticonvulsants, sedative antihistamines, and alcohol (Ashton, 1995).  
(1, 2) Nerve impulse causes 
release of GABA from storage 
sites on neuron 1 
(3) GABA released into space 
between neurons  
(4) GABA reacts with receptors 
on neuron 2; the reaction 
allows chloride ions (Cl-) to 
enter the neuron  
(5) This effect inhibits further 
progress of the nerve impulse  
(6, 7) Benzodiazepines react 
with booster site on GABA 
receptors  
(8) This action enhances the 
inhibitory effects of GABA; the 
ongoing nerve impulse may be 
completely blocked  
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Benzodiazepine Prescription Rates 
Drug Utilisation Sub Committee Data 
Obtaining a true indication of benzodiazepine use within the community is difficult 
in part due to the lack of a comprehensive prescription record. In Australia, the 
Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical 
Benefits Scheme (RPBS), subsidise the cost of many medications. However, some 
preparations are not listed on the PBS, or they are listed but a subsidy is not claimed 
for them, and this means that data is not collected for these medications. From 
1989-2012, the Pharmacy Guild of Australia conducted an annual survey of selected 
pharmacies to estimate the numbers of prescriptions in non-subsidised categories. 
However this ceased in August 2012, meaning up-to-date data is no longer available 
(Department of Health, 2015). Private prescriptions are often used when pill 
quantity, repeat number, or clinical usage is outside of PBS indications (Australian 
Government Department of Human Services, 2016). As this data is not recorded, 
there is a significant gap in understanding benzodiazepine use within Australia. The 
Drug Utilisation Sub Committee (DUSC) of the Pharmaceutical Benefits Advisory 
Committee collates data from PBS/RPBS prescriptions, and formerly for non-
subsidised prescriptions (estimated through the Pharmacy Guild survey). The 
following information is based on data collected by the DUSC. 
When examining the most commonly prescribed benzodiazepines listed on the PBS 
(whether paid for in part or fully by the patient) prescription numbers are high. In 
2014, when the Australian population was estimated to be 23.5 million people 
(Australian Bureau of Statistics, 2014), there were the following script numbers (for 
all types and strengths): diazepam - 2,429,619, temazepam - 2,205,859, oxazepam - 
1,063,978, and alprazolam - 304,720 (Department of Health, 2015). The highest 
volume individual item was temazepam 5mg tablets, which accounted for 2,164,117 
scripts (Department of Health, 2015). 
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Approaches to Understanding Benzodiazepine Usage 
Defined Daily Dose: Drug consumption is often expressed in terms of dosage, cost, 
or number of prescriptions. However, these measures can vary across different 
times and locations. To overcome this problem, the World Health Organisation 
developed a unit of measurement called defined daily dose (DDD). A defined daily 
dose (DDD) is the assumed average maintenance dose per day for a drug used for 
its main indication in adults (World Health Organisation, 2011).The advantage of the 
DDD approach is that it provides a fixed unit of measurement that can be used to 
compare across samples. However, a defined daily dose is not necessarily the same 
as the recommended dose or a dose prescribed for a particular individual. The 
defined daily dose, for diazepam as an example is 10mg orally. Defined daily dosage 
is often presented as the DDDs/1000 population/day figure, which provides an 
approximate estimate of the amount of population treated daily with a particular 
drug. Table 3 shows DDD/1000 population/day for benzodiazepines dispensed in 
the community between 2012-2014 (Department of Health, 2015). This includes 
both scripts whose costs were covered entirely by the PBS or contributed to by the 
patient. 
Table 3. Benzodiazepine DDD/1000 population/day from 2012-2014 (Department of 
Health, 2015). 
  2012 2013 2014 
Alprazolam 4.267 3.845 2.507 
Bromazepam 0.004 0.003 0.003 
Diazepam 5.850 5.920 6.029 
Flunitrazepam 0.024 0.020 0.018 
Nitrazepam 1.300 1.207 1.099 
Oxazepam 1.736 1.663 1.602 
Temazepam 3.484 3.426 3.236 
*DDD=defined daily dose: the assumed average maintenance dose 
per day for a drug used for its main indication in adults 
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Diazepam Equivalent Dosage: Another method of understanding benzodiazepine 
consumption is the use of diazepam equivalent doses. Because benzodiazepines 
differ greatly in dose and potency, there have been attempts made to estimate 
equivalent dosages across the different preparations. Based on research and clinical 
experience, estimates are made for each preparation as to a comparative dose of 
diazepam. The ability to convert doses is useful in clinical practice if transfer from 
one benzodiazepine to another is required. In research, the simplification of various 
active ingredients into one standard measure allows for easier comparisons to be 
made (Inada & Inagaki, 2015). Whilst conversion tables are available (e.g., Ashton, 
2002), they are often not in agreement, and provide only an approximate of a 
diazepam equivalent dose. This process does not account for other variabilities in 
benzodiazepines, such as time to onset and duration.  
Trends in Benzodiazepine Use 
Stephenson, Karanges, and McGregor (2013) investigated trends in psychotropic 
medication use in Australia over an 11 year period (2000-2011). Data was obtained 
from the Drug Utilisation Sub Committee, and included both PBS/RPBS data and 
estimates of non-subsidised prescriptions. Overall, the use of psychotropics in 
Australia increased by 58.2% during this time period; antidepressants accounted for 
a significant proportion of this growth. Benzodiazepines were included in both the 
anxiolytic (alprazolam, bromazepam, clobazam, diazepam, lorazepam, oxazepam) 
and sedative (flunitrazepam, midazolam, nitrazepam, temazepam, triazolam, plus Z-
drugs) drug classes in this study. There was minimal change in the dispensing of 
anxiolytics during the study period; DDD/1000/day increased from 14.0 in 2000, to 
14.9 in 2011. Dispensing of sedatives decreased from a DDD/1000/day of 9.8 in 
2000, to 7.2 in 2011. Temazepam was the most commonly used sedative in 2011, 
accounting for 54.1% of the total sedative DDD/1000/day, although use decreased 
from 2000 to 2011. Overall, there were minimal changes to the dispensing rates of 
benzodiazepines over this 11 year period. The authors acknowledge that a problem 
inherent in using defined daily dose approach, is that it is quite frequently 
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mismatched with the usual clinical dosage, which may result in a misestimation of 
benzodiazepine usage. 
Islam, Conigrave, Day, Nguyen, and Haber (2013) also reviewed data from the Drug 
Utilisation Sub Committee over a 20 year period (1992-2011). To overcome 
limitations with the defined daily dose approach, an additional comparison of 
diazepam equivalent/1000/day, using Ashton’s (2002) method was conducted. An 
overall significant reduction (p<0.01) in benzodiazepine dispensing was found, 
reducing from 27.7 DDD/1000/day in 1992 to 20.8 in 2011. However, piecewise 
regression showed that between 2002 and 2011, this trend was significant when 
using the WHO DDD/1000/day measure (p<0.001), but not significant when using 
the Ashton diazepam equivalent (p=0.49). Whilst trends show an overall decrease in 
prescription of benzodiazepines, after 1992 there was an increase in quantity of 
private prescriptions, and the defined daily dose per prescription had on average 
increased. The authors suggest this may indicate that larger quantities per script are 
being prescribed, and private prescriptions may be used to circumvent the 
limitations of PBS pack sizes. Overall, data from Stephenson et al. (2013), and Islam 
et al. (2013) indicates that despite a plateau in benzodiazepine prescription, use 
remains at a substantial level within the community. This is despite recent policy 
changes leading to more restrictive practices regarding benzodiazepine 
prescription. 
A fundamental problem with the use of PBS data, is that it simply indicates an item 
has been dispensed, but not whether it has been used, who has used it, or the 
method of use (e.g. as prescribed or illicit). Research suggests that the diversion of 
benzodiazepines to use outside of the medical context is common. The most recent 
National Drug Strategy Household Survey (2013), found that in those aged 18 years 
or older, 1.8% of males, 1.5% of females, and 1.7% of total people surveyed, had 
used ‘tranquilisers or sleeping pills’ in the last 12 months for non-medical purposes 
(Australian Institute of Health and Welfare, 2014). Similarly the Illicit Drug Reporting 
System (IDRS), found that in a national Australian sample of people who frequently 
Chapter 1: Benzodiazepines - An Introduction | 9 
 
 
 
inject drugs, around two-thirds of them had recently used benzodiazepines, with 
fairly equal proportions reporting licit or illicit use (Stafford & Burns, 2010; Stafford, 
Sindicich, & Burns, 2009). The IDRS cohort is not representative of illicit drug use in 
the general population, but it does provide an indication of trends in people who 
regularly inject drugs. The use of benzodiazepines with illicit drugs is associated 
with adverse outcomes. For example, benzodiazepines were detected in 55% of 
heroin-related deaths that occurred in Victoria between 2004 and 2008 (Woods, 
Gerostamoulos, & Drummer, 2009). This likely reflects the additive effect between 
benzodiazepines and other sedatives, such as opioids, wherein their combined use 
results in a high risk of central nervous system depression and death (Royal 
Australian College of General Practitioners, 2015b). Understanding the unique 
effect of benzodiazepines when used illicitly, and/or in combination with illicit drugs 
is important to reduce associated harm.  
Overall, benzodiazepines remain a commonly used class of medications throughout 
Australia. There is no one source of data that accurately captures benzodiazepine 
use; particularly usage outside of the pharmaceutical benefits scheme. Decreases in 
benzodiazepine use is attributed in part to the emergence of more efficacious 
treatments for anxiety, including selective serotonin reuptake inhibitors (SSRIs) and 
serotonin-norepinephrine reuptake inhibitors (SNRIs). The use of SSRIs has more 
than doubled in use between 2000 and 2011 (Islam et al., 2013). However, the 
magnitude of increase in SSRIs and SNRIs has not been accompanied by the same 
decrease in benzodiazepine use, suggesting a straightforward replacement of 
medications is not occurring.   
Ensuring Safe Use of Benzodiazepines  
Clinical Guidelines for Prescribing 
An increasing body of literature documenting negative outcomes associated with 
benzodiazepine use, has led to clinical guidelines that recommend limiting their 
prescription. The first benzodiazepine guidelines were developed in 1980 
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(Committee on the Review of Medicines, 1980). Over 35 years later, there have 
been many different iterations of these principles. Generally, guidelines 
recommend that the use of benzodiazepines is best avoided, or if necessary, that 
they should only be prescribed for the shortest time period possible and at the 
lowest viable dose (National Health and Medical Research Council, 1991). The Royal 
Australian College of General Practitioners (2000), recommends advising patients of 
the risks associated with use, regular reviews of continued usage, and using non-
pharmacological treatments where appropriate. The recent guidelines produced by 
the Royal Australian College of General Practitioners (2015b), provide a thorough 
summary of the research to date. These guidelines outline evidence based 
recommendations, preferred treatment options, and provide practical materials for 
those prescribing benzodiazepines. The key reasons for the development of these 
guidelines were: (1) the risk of dependence, (2) associated cognitive and 
psychomotor harms, and (3) the poor efficacy with ongoing treatment. These 
subjects are briefly discussed here, and are elaborated on throughout this review. 
Risk of Dependence: Even with normal therapeutic doses benzodiazepines are 
capable of producing physical and psychological components of dependence. The 
physical component of dependence is evidenced by tolerance (a need for increased 
amounts of the substance), and a withdrawal syndrome on cessation of use (Barker 
et al., 2003). Withdrawal from benzodiazepines is characterised by central nervous 
system stimulation, producing symptoms such as anxiety, sleep disorders, aching 
limbs, palpitations, nervousness, and seizures (Ashton, 2002). Psychological 
components of dependence occur when a drug becomes central to a person's 
thoughts, emotions, and activities, with the experience of impaired control related 
to their use (World Health Organisation, 2017). This dependence syndrome means 
that risk of benzodiazepine misuse is high; this can range from occasional use 
beyond the reason for prescription, to regular, high quantity recreational use 
(Lader, 2011). 
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Cognitive and Psychomotor Side-effects: It is commonly acknowledged that new 
benzodiazepine users will be at greatest risk of side-effects as they have not yet 
developed tolerance to the effects of the drug. However, side-effects do not linearly 
decrease with continued use, and in fact long-term users may face more insidious 
effects than short-term users (Lader, 2011). A review by Barker, Greenwood, 
Jackson, and Crowe (2005) suggests that there is a slow, but not complete recovery 
of cognitive function, even after extended benzodiazepine abstinence in chronic 
consumers. Research is increasingly examining benzodiazepines as a risk factor for 
cognitive decline and dementia (Gray et al., 2016; Mura et al., 2013). Throughout all 
stages of use, benzodiazepine patients are at an increased risk of detrimental 
cognitive deficits. 
Low Ongoing Treatment Efficacy: It is known that tolerance to the different effects 
of benzodiazepines develops differentially. Tolerance is defined as a person’s 
diminished response to a drug that results from repeated use (Hussar, 2017). The 
development of tolerance to benzodiazepines is discussed at length in Chapter 2. 
Importantly, it has become evident that benzodiazepine users can become tolerant 
to the intended treatment effects - making benzodiazepines unsuitable for the 
longer-term management of many conditions (Vinkers & Olivier, 2012).  
Optimal Duration of Benzodiazepine Treatment 
In addition to general prescribing guidelines for benzodiazepines, there are often 
recommendations made regarding the optimal length of prescribing, depending on 
the condition being treated. A duration of 1-4 weeks is generally recommended for 
benzodiazepine use, as this negates the risk of dependence and cognitive 
impairment (Royal Australian College of General Practitioners, 2015b). 
There are also guidelines that direct practitioners in the treatment of specific 
conditions, based on the available evidence (for example: National Institute for 
Health and Care Excellence, 2014; Royal Australian College of General Practitioners, 
2015b). In the treatment of insomnia and anxiety, cognitive behavioural therapies 
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are indicated as the first line treatment. Benzodiazepines are recommended to be 
used for short or intermittent use only, up to a period of four weeks, and only when 
other treatment options have not been successful. Conversely, in the use of acute 
alcohol withdrawal, benzodiazepines are usually the treatment of choice, but 
should only be used for a period of up to seven days (Royal Australian College of 
General Practitioners, 2015b). 
There are few specific indications for the ongoing use of benzodiazepines. It is 
suggested that benzodiazepines should only be used for longer-term use when it is 
clearly considered that the benefits outweigh the risks. Continual risk-benefit 
analyses should guide the decision to use benzodiazepines as an ongoing treatment 
(Royal Australian College of General Practitioners, 2015b).  
Chronic Benzodiazepine Use  
Historically it has been argued that benzodiazepine overuse has been exaggerated, 
and that high prescription levels are simply attributable to the many disorders for 
which benzodiazepines are prescribed (Woods & Winger, 1995). However, there is 
some research, albeit dated, that indicates long-term benzodiazepine use occurs. 
An Australian longitudinal study of 337 people aged over 75, examined participants 
at intake, and then three and 4.5 years post-intake and found 16.6% of participants 
were using benzodiazepines at all three time points (Jorm, Grayson, Creasey, Waite, 
& Broe, 2000). Similar evidence of long-term use has been found in other countries 
also. In 2008, Olfson, King, and Schoenbaum (2015) examined a prescription 
database covering 60% of all retail prescriptions in the United States of America. In 
the sample 5.2% (n=11,491,677) had filled at least one benzodiazepine prescription. 
The proportion of this group that were using benzodiazepines long-term (defined as 
use greater than 120 days) increased with age from 14.7% in 18-35 year olds, to 
31.4% in 65-80 year olds. A longitudinal study of 395 Canadian benzodiazepine 
users interviewed respondents at two year intervals for a period of six years, 
beginning in 1994 (Neutel, 2005). It was found that approximately 50% of the 
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sample were using at more than one time point, and 16.7% of the group were using 
at all four time points in the study, meaning use spanned at least six years. In 
2006/2007, a review of psychotropic medication use in Tasmanian residential aged 
care facilities was undertaken (Westbury, Beld, Jackson, & Peterson, 2010). At the 
initial assessment, 42% of the 2,389 aged care residents reviewed were taking a 
benzodiazepine regularly, and the average diazepam equivalent dose was 10.4mg 
per day. Twelve months later, 1,307 of these residents were re-assessed, and 62.4% 
were using the same dose of benzodiazepines at both time points. Regular 
benzodiazepine use by aged care residents, for a period of greater than nine 
months, has also been shown to occur in other locations including: Sydney 
(Snowdon & Vaughan, 1997), Canada (Hagen et al., 2005), and Norway (Selbaek, 
Kirkevold, & Engedal, 2008). Regular benzodiazepine use in the elderly is of 
particular concern due to the high risk of adverse effects, including confusion and 
falls. Particularly in the elderly it is recommend that regular attempts at cessation 
occur, as cessation is associated with positive effects including improved mobility, 
alertness, continence, and well-being (Gilbert, Owen, Innes, & Sansom, 1993). 
These studies suggest that benzodiazepine use regularly extends far beyond the 
recommended four-week period. This is despite clinical guidelines being active for 
over thirty-five years. It would be expected that a reduction in chronic 
benzodiazepine prescribing in response to these guidelines, would have occurred by 
now, if it were going to. Future research cannot simply extend the results of acute 
benzodiazepine studies to chronic users, but must work to understand the unique 
impact of ongoing benzodiazepine use. 
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CHAPTER 2: THE ACUTE AND CHRONIC EFFECTS OF BENZODIAZEPINES 
Acute Effects of Benzodiazepine Use 
Cognitive and Psychomotor Impairment 
In respect to benzodiazepine studies, acute effects are those that occur rapidly 
following a single or brief dosing regimen usually in benzodiazepine-naïve patients. 
Whilst it is widely accepted that the short-term use of benzodiazepines can produce 
desirable anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects (Barker et 
al., 2003), there are also a considerable range of side-effects associated with short-
term use (Table 1). Effects that are considered adverse are dependent on reason for 
prescription, for example sedation may be a desired effect before surgery however, 
would be unwanted in a patient using a benzodiazepine for daytime anxiety. Most 
of the adverse effects associated with acute benzodiazepine use are extensions of 
the desired action of the drug, for example; drowsiness, ataxia, fatigue, confusion, 
weakness, and vertigo (Vgontzas, Kales, & Bixler, 1995). Benzodiazepines can also 
occasionally cause paradoxical stimulant effects such as increased anxiety, 
insomnia, nightmares, hypnogogic hallucinations at sleep onset, irritability, 
hyperactive or aggressive behaviour, and exacerbation of seizures in people with 
epilepsy (Ashton, 1995; Jones, Nielsen, Bruno, Frei, & Lubman, 2011).  
Table 1. Common Side-Effects of Benzodiazepines (Barker et al., 2003). 
Side-Effects 
Aggression Flushing Muscle Cramps 
Agitation Gastrointestinal Complaints Nausea 
Anorexia Genito-urinary complaints Palpitations 
Bitter or metallic taste Hallucinations Panic 
Bizarre, abnormal behaviour Headache Paranoid ideation 
Constipation Hiccups Shortness of breath 
Delirium Libido changes Swollen Tongue 
Depression Increased appetite Tachycardia 
Dry mouth Increased Salivation Visual Disturbances 
Dysarthria Joint pain Vivid dreams 
Failure to ovulate Menstrual irregularities Weight Loss 
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A review by Buffett-Jerrott and Stewart (2002) suggests that the most commonly 
occurring cognitive effects of short-term benzodiazepine use are sedation, 
inattention, and amnesia. Most of the reviewed studies included acute doses of 
benzodiazepines in healthy people, without a history of benzodiazepine use. Table 2 
presents a summary of the main cognitive areas investigated by Buffet-Jerrott and 
Stewart. The authors conclude that there are detrimental and independent effects 
of acute benzodiazepine use on sedation, attention, and memory capacity; 
however, they do acknowledge that these effects do not continue linearly as 
benzodiazepine use progresses.  
A similarly timed review (De Visser et al., 2002) examined the effect of 
benzodiazepine use in healthy volunteers. The review only included studies that 
used benzodiazepine doses targeted for anxiety. Benzodiazepine doses were pooled 
into one of three categories: ‘low’, ‘medium’, or ‘high’. The ‘medium’ category 
represented doses that were the lowest recommended therapeutic dose for that 
particular preparation. ‘Low’ and ‘high’ doses were those under and above this level 
respectively. A total of 56 studies were included, and the 173 different tests used 
were divided into neuropsychological tests, subjective measures, and 
neurophysiological measures. In order to summarise the findings, the 
neuropsychological tests were separated into core domains. These domains were: 
achievement, attention, executive function, memory, visual/motor, and motor. 
There were 58 different subjective assessments used, and clustering techniques 
found that scales measuring ‘alertness’, ‘mood,’ and ‘calmness’ were most 
commonly used. Neurophysiological measures included electroencephalograms 
(EEG), eye movement, evoked potential, and startle reflex tests. Approximately one-
third of all the tests used did not show any response to benzodiazepine dosing. 
However there was a dose dependent effect of benzodiazepine use: ‘high’ doses of 
benzodiazepines caused impairment across almost all categories (Table 3). 
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Table 2. The Effect of Acute Doses of Benzodiazepines on Cognition in Benzodiazepine-Naïve Individuals (As reviewed by: Buffett-Jerrott and 
Stewart, 2002). 
Area of 
cognition 
Sub-area Description 
(examples of measures used) 
Review conclusion 
(BZD=Benzodiazepine) 
Studies reviewed 
Sedation Subjective Self-rated measures of sedation, often 
using visual analogue scales. 
BZDs induce subjective 
feelings of sedation 
 
Allen, Curran, and Lader (1991); Buffett-Jerrott, Stewart, Bird, and 
Teehan (1998); Danion, Zimmermann, Willard-Schroeder, Grange, 
and Singer (1989); Stewart, Rioux, Connolly, Dunphy, and Teehan 
(1996) 
 Objective: 
- Experimental 
tests 
Cognitive processing and psychomotor 
speed (Digit Symbol Substitution Task, 
Discriminant Reaction Time Task, Finger 
Tapping Test) 
Impaired by BZD use Bishop, Curran, and Lader (1996); Boulenger et al. (1989); Curran 
and Gorenstein (1993); Curran, Pooviboonsuk, Dalton, and Lader 
(1998); Curran, Schifano, and Lader (1991); Curran, Schiwy, and 
Lader (1987); Danion et al. (1990); Fang, Hinrichs, and Ghoneim 
(1987); Preston et al. (1988) 
 Objective:  
- Physiological 
measures 
Biological indications of sedation 
(saccadic eye movements, Critical 
Flicker Fusion Threshold) 
Impaired by BZD use Curran et al. (1998); Green, McElholm, and King (1996); Lucki, 
Rickels, and Geller (1986); Preston et al. (1988) 
Attention Focused/execute 
attention 
Ability to direct attention to a stimuli 
(symbol, letter or digit cancellation 
tasks) 
Impaired by BZD use Coull, Middleton, Robbins, and Sahakian (1995); Fang et al. (1987); 
Vidailhet et al. (1994); Vidailhet, Kazes, Danion, Kauffmann-Muller, 
and Grange (1996) 
 Sustained 
attention 
Ability to attend to a stimulus and 
maintain focus over time (List 
Repetition Task) 
Impaired by BZD use Fleishaker, Garzone, Chambers, Sirocco, and Weingartner (1995); 
Hommer, Weingartner, and Breier (1993); Weingartner, Hommer, 
Lister, Thompson, and Wolkowitz (1992) 
 Encode attention Ability to perform multiple mental 
manipulation tasks (Paced Auditory 
Serial Addition Task, Digit Span) 
Impaired by BZD use Buffett-Jerrott, Stewart, Bird, et al. (1998); Fluck et al. (1998); 
Preston et al. (1988) 
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Area of 
cognition 
Sub-area Description 
(examples of measures used) 
Review conclusion 
(BZD=Benzodiazepine) 
Studies reviewed 
 Shift attention Ability to shift attention between tasks 
(Posner’s cued visual search paradigm) 
Impaired by BZD use Carter, Maddock, Chaderjian, and Post (1998); Johnson, 
Weingartner, Andreason, and George (1995) 
 Divided attention Ability to perform two or more tasks at 
once (dual tasks, e.g. word pair learning 
plus visual discrimination task) 
No BZD impairment Gorissen and Eling (1998) 
Memory Sensory memory Brief sensory impressions that remain 
after a stimulus is no longer present 
N/A No studies completed at time of review 
 Short-term 
memory 
Memory occurring whilst actively 
attending to a stimulus (digit span test) 
No BZD impairment Boulenger et al. (1989); Curran et al. (1987); Sellal et al. (1992) 
 Long-term 
memory 
Information stored for later use  BZDs impair anterograde 
amnesia (information 
acquired after drug 
ingestion) 
Curran (1986) 
 Long-term 
memory 
- Explicit                                                                                                      
memory 
Occurs when the participant is aware 
that their memory is being tested, and 
a conscious effort to remember is
made (free recall, cued recall, and 
recognition memory tasks) 
Impaired by BZD use Boulenger et al. (1989); Buffett-Jerrott, Stewart, Bird, et al. (1998); 
Buffett-Jerrott, Stewart, and Teehan (1998); Curran et al. (1994); 
Curran et al. (1987); Eves, Curran, Shine, and Lader (1988); Gorissen, 
Curran, and Eling (1998); Legrand et al. (1995); Weingartner et al. 
(1992); Weingartner, Rawlings, George, and Eckardt (1998) 
 Long-term 
memory 
- Implicit 
memory 
The participant is not aware that 
memory is being tested, and does not 
consciously attempt to remember 
(word-stem completion task, picture-
fragment completion task) 
Impaired by BZD use Bishop et al. (1996); Brown, Brown, and Bowes (1989); Buffett-
Jerrott, Stewart, Bird, et al. (1998); Buffett-Jerrott, Stewart, and 
Teehan (1998); Curran and Gorenstein (1993); Fang et al. (1987); 
Fleishaker et al. (1995); Greenblatt, Shader, Divoll, and Harmatz 
(1981); Legrand et al. (1995); Sellal et al. (1992); Stewart et al. 
(1996); Vidailhet et al. (1994) 
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Table 3. The Effects of Acute Benzodiazepine Use on Neuropsychological Functioning 
(As reviewed by De Visser et al., 2002) 
 
 
 
 
 
 
Low, Medium and High refer to whether the dose studied was either abelow, 
bequal to, or cabove, the recommended therapeutic dose for each particular 
preparation. ↓ Performance decreased when exposed to benzodiazepines, and 
95%CI did not cross zero. = Performance decreased when exposed to 
benzodiazepines, but 95%CI crossed zero. N/A - Not Assessed 
 
Limitations of Investigating Acute Doses 
Much of the research to date examines a single benzodiazepine dose in a naïve 
user. This information is useful to understand the effects on a person newly 
prescribed benzodiazepines, but these results cannot be generalised to those who 
are taking the medication regularly over a longer period. This is due in part to the 
development of tolerance to the drug’s effects. Tolerance occurs when a greater 
amount of the medication is required to produce the same effects, and may often 
lead to increased dosages, and thus prescriptions, being used to maintain the 
therapeutic effect (Royal Australian College of General Practitioners, 2015a). 
Development of tolerance to the various effects of benzodiazepines does not 
develop at an equal rate; the various actions are briefly reviewed below. 
Sedative and Hypnotic Effects: It is commonly accepted that tolerance to the 
sedative effect of benzodiazepines develops quite rapidly over 1-2 weeks, as 
observed by sleep patterns and reported daytime sleepiness. This effect occurs 
more slowly in the elderly due to slower metabolism and susceptibility to central 
nervous system depression (Ashton, 1995; Barker et al., 2003; Curran, 1992). 
Neuropsychological 
Domain 
All 
Doses 
Lowa Mediumb Highc 
Achievement = = N/A N/A 
Executive ↓ = = = 
Attention ↓ = = ↓ 
Memory ↓ = = ↓ 
Visual/motor ↓ ↓ = ↓ 
Motor = = = = 
Subjective ↓ = = ↓ 
Physiological ↓ = ↓ ↓ 
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Tolerance to sedative effects appears to occur most frequently in benzodiazepines 
with a short half-life (Vinkers & Olivier, 2012). 
Anticonvulsant Effects: Tolerance to the anticonvulsive effects can also occur in a 
short period of time (less than 6 months), which makes benzodiazepines unsuitable 
for the long term treatment of epilepsy (Barker et al., 2003). Using on an 
intermittent schedule may reduce the development of tolerance in these patients 
(Vinkers & Olivier, 2012). 
Amnestic Effects: Complete tolerance to the amnestic effects does not appear to 
occur. Episodic memory is impaired in long-term users, whilst semantic memory, 
immediate memory and long-term memory are less affected (Ashton, 1995; Curran, 
1992). Short-term memory continues to be affected after an acute benzodiazepine 
dose in chronic users (Curran et al., 1994; Lucki et al., 1986). A major concern is that 
memory loss associated with benzodiazepine use may persist beyond the duration 
of use (Barker, Greenwood, Jackson, & Crowe, 2004b; Tata, Rollings, Collins, 
Pickering, & Jacobson, 1994).  
Anxiolytic Effects: Whilst research is divided, it is likely that a slow tolerance to the 
anxiolytic effects of benzodiazepines occurs. Some authors suggest that this means 
benzodiazepines are unsuitable for the treatment of anxiety over a period greater 
than 4 months (Ashton, 1995). Curran (1992) found that in her population of 
chronic benzodiazepine users (average length of use of 10 years), a regular daily 
dose of a benzodiazepine led to significant increases in ratings of contentedness 
and calmness, and a decrease in state anxiety scores (as measured by the Spielberg 
Inventory). Curran states this may indicate tolerance to anxiolytic effects does not 
occur. However she also acknowledges that these findings could be explained by a 
heightening of anxiety immediately before a dose (as withdrawal occurs), thus 
leading to a significant decrease afterwards. It is also possible that simply taking a 
pill has a placebo effect leading to reduction in anxiety. 
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Despite an understanding that tolerance does develop differentially with 
benzodiazepine use, the exact mechanism by which this occurs is unclear. Whilst it 
is often assumed that benzodiazepine users are less at risk from acute effects after 
the first few weeks of dosing, it is likely that personal characteristics will complicate 
the development of tolerance (Vinkers & Olivier, 2012). It is possible that tolerance 
may develop more quickly to the therapeutic effects compared to the side-effects. 
As such, further research is required to understand the impact of tolerance in day-
to-day situations. The complex and individual development of tolerance means that 
acute and chronic users of benzodiazepines are not affected comparably. 
Cognitive Effects of Chronic Benzodiazepine Use 
As outlined above, the effects of long-term benzodiazepine use cannot simply be 
generalised from the known acute effects. However the existing research examining 
long-term benzodiazepine users is difficult to evaluate due to a variety of 
methodological issues. At the simplest level, there is often no distinction made 
between the different benzodiazepines, which can differ greatly in their 
pharmacokinetic properties. Much of the research to date is plagued by 
methodological issues such as small sample sizes, the use of poly-drug using 
subjects, the likelihood of anxiety and other pathology, and lack of double-blind, 
placebo controlled studies (Barker et al., 2005; Barker et al., 2003). Another 
difficulty is the wide range of different cognitive measures that are employed. The 
discrepancy in what is considered ‘long-term’ also makes research particularly 
difficult to integrate; use has ranged from 12 weeks (Romach et al., 1991) to in 
excess of 5 years (Gorenstein et al., 1994). Many studies do not consider length of 
time since last dose, meaning that any effects found may be due to acute or post-
acute drug effects, rather than a true ‘long-term’ effect (Barker, Greenwood, 
Jackson, & Crowe, 2004a). Similarly, studies often use a single testing time to 
investigate deficits; however, research by Ghoneim, Mewaldt, and Hinrichs (1984) 
found that multiple test times were more likely to reveal deficits that may be 
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masked on a single test occasion. Despite these difficulties there have been some 
attempts to summarise the findings of research to date. 
Barker and colleagues (2004a) undertook a meta-analysis of the research examining 
long-term benzodiazepine use and cognitive functioning. In order to make 
comparisons across studies, the average daily doses of benzodiazepines reported 
were converted to an equivalent diazepam dose. Length of benzodiazepine use 
ranged from 1-24 years (mean=9.9 years). Thirteen studies met inclusion criteria for 
the analysis, which included a total of 45 different cognitive tests. Each test and the 
cognitive function measured was grouped into one of 12 broad categories of 
cognitive function as identified by Lezak (1995), and Spreen and Strauss (1998): 
sensory processing, non-verbal memory, speed of processing, 
attention/concentration, general intelligence, working memory, psychomotor 
speed, visuospatial ability, problem-solving, verbal memory, motor 
control/performance, and verbal reasoning. The meta-analysis found moderate-to-
large effect sizes of benzodiazepines across each domain of cognition (Table 4), with 
none having a 95% confidence interval spanning zero. The authors concluded that 
long-term benzodiazepine users are impaired across many cognitive areas and that 
this impairment appears to be a generalised rather than specific effect. 
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Table 4. Meta-Analysis Results: Effects of Long-Term Benzodiazepine Use on 
Cognitive Function (Barker et al., 2004a). 
 
Cognitive Function Category Cohen’s d Weighted 
effect size d 
SD of 
weighted d 
Sensory processing     -0.84 -1.30 0.69 
Psychomotor speed   -1.10 -0.99 0.67 
Nonverbal memory   -1.18 -0.91 0.45 
Visuospatial -1.12 -0.86 0.39 
Speed of processing -0.76 -0.72 0.31 
Problem Solving -0.63 -0.68 0.16 
Attention/concentration -0.65 -0.67 0.40 
Verbal memory -0.58 -0.66 0.40 
General Intelligence -0.70 -0.64 0.28 
Motor Control/ Performance -0.45 -0.49 0.36 
Working Memory -0.48 -0.48 0.33 
Verbal Reasoning -0.21 -0.42 0.29 
Overall -0.72 -0.74 0.25 
SD=Standard Deviation 
Residual Effects of Benzodiazepines 
Evidence remains conflicted about the degree to which the negative effects of 
benzodiazepines may persist beyond the withdrawal period. Two meta-analyses by 
Barker, Greenwood, Jackson & Crowe (2004b), examined the recovery of function in 
long-term benzodiazepine users, and performance compared to controls. Both 
analyses used the same 12 cognitive categories as in the aforementioned study of 
current chronic users (Barker et al., 2004a). Key characteristics of these three 
samples are outlined in Table 5. Analysis A compared the cognitive performance of 
long-term benzodiazepine users, before and after ceasing use. Results for each 
cognitive category are shown in Table 6. Overall, effect sizes were positive which 
indicates a recovery of function. 95% confidence intervals spanned zero for 6 out of 
the 11 areas of cognition, suggesting results should be interpreted with caution; 
however, the authors conclude the direction and magnitude of the effect sizes 
should not be disregarded. Analysis B compared the cognitive performance of 
previous long-term benzodiazepine users, to normative data or control subjects (a 
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mix of normal and anxious controls). With the exception of sensory processing, all 
effect sizes were negative, meaning that previous benzodiazepine users performed 
more poorly than controls (Table 7). 95% confidence intervals did not span zero for 
8 out of 11 categories, suggesting that these effects are statistically significant. 
Table 5. Meta-Analyses examining Cognitive Function in Long-Term and Previous 
Benzodiazepine Users 
Study Characteristics Barker et al. 
(2004a) 
Barker et al. (2004b) 
  Analysis A Analysis B 
Comparison groups LT BZDa users; 
controls 
Pre- and Post- 
withdrawal; 
 
Abstinent LT 
BZD users; 
controls 
Number of studies 13 10 9 
Sample size 384 297 284 
Percentage; males 40.6% 37.1% 38.7% 
Mean age; years (range) 47.6 (21-75) 47.1 (21-75) 42.7 (21-75) 
Mean length of BZD use; 
years (range) 
9.9 (1-34) 10 (1-29) 8.9 (1-29) 
Mean daily BZD dose; 
milligramsb (SDc) 
17.2 (9.86) 15.3 (18.9) 16.7 (21.1) 
Time between testingd; 
months (range) 
N/A 3 (1-65) 3 (1-65) 
aLT=long-term, BZD=benzodiazepine. bDiazepam equivalent dose. cSD=Standard 
Deviation. dMedian time between withdrawal and assessment 
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Table 6. Meta-Analysis Results: Recovery of Cognitive Function in 
Abstinent Long-Term Benzodiazepine users (Barker et al., 2004b). 
Table 7. Meta-Analysis Results: Cognitive Function in Abstinent 
Benzodiazepine users Compared to Controls (Barker et al., 2004b). 
 SD=Standard Deviation. *95%CI does not span zero. ^only one problem-
solving test was used.  
SD=Standard Deviation. *95%CI does not span zero. ^only one problem-
solving test was used.  
Cognitive Function Category Cohen’s 
d 
Weighted 
effect 
size d 
SD of 
weighted 
d 
Sensory processing     0.47 0.37 0.46 
Psychomotor speed   0.51* 0.50 0.15 
Nonverbal memory   0.42* 0.34 0.29 
Visuospatial 0.67* 0.70 0.12 
Speed of processing 0.35 0.32 0.44 
Problem Solving 0.64* 0.64 n/a^ 
Attention/Concentration 0.69* 0.69 0.48 
Verbal memory 0.44 0.36 0.46 
General Intelligence 0.58* 0.62 0.21 
Motor Control/ Performance 0.28 0.21 0.27 
Working Memory 0.19 0.15 0.22 
Verbal Reasoning 0.08 0.06 0.07 
Overall 0.42* 0.41 0.22 
Cognitive Function Category Cohen’s 
d 
Weighted 
effect size 
d 
SD of 
weighted 
d 
Sensory processing     0.48 0.26 0.34 
Psychomotor speed   -0.87* -0.78 0.60 
Nonverbal memory   -0.36* -0.26 0.10 
Visuospatial -0.30* -0.49 0.45 
Speed of processing -0.59* -0.76 0.55 
Problem Solving -0.11* -0.11 n/a^ 
Attention/Concentration -0.63* -0.43 0.41 
Verbal memory -0.89* -2.50 0.88 
General Intelligence -0.34* -0.47 0.23 
Motor Control/ Performance -0.65* -0.62 0.04 
Working Memory -0.46 -0.58 0.42 
Verbal Reasoning -0.05 -0.02 0.05 
Overall -0.41* -0.48 0.45 
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Comparing these three meta-analyses by Barker and colleagues (Barker et al., 
2004a, 2004b), clarifies the cognitive impact of long-term benzodiazepine use 
(summarised in Table 8). There were moderate-to-large effects sizes of current 
long-term benzodiazepine use on all areas of cognitive function. Whilst cessation of 
long-term benzodiazepine use was associated with some recovery of function, this 
recovery in most instances was not equivalent to the performance of control 
subjects/normative data. Particularly, psychomotor speed and verbal memory were 
associated with a small recovery of function, and a large effect size indicated 
substantial residual impairment remains relative to controls. The small number of 
studies suitable for inclusion in these analyses led the authors to conclude that 
whilst results should be interpreted with caution, they are likely a conservative 
estimate of deficits experienced. Results support ceasing benzodiazepine use to 
reduce cognitive deficits. With deficits remaining for a period of at least 6 months, 
caution should be applied in the longer-term use of benzodiazepines. 
Table 8. Summary of Meta-Analytic findings from Barker et al., (2004a; 2004b) 
Cognitive Function Category LT BZDa users 
impairedb 
 
Recovery of 
function occurs 
after cessation 
of BZD usec 
Residual 
impairment 
remains, 
compared to 
controlsc 
Sensory processing        
Psychomotor speed    
Nonverbal memory    
Visuospatial    
Speed of processing    
Problem Solving    
Attention/Concentration    
Verbal memory    
General Intelligence    
Motor Control/ Performance    
Working Memory    
Verbal Reasoning    
Overall    
aLT=long-term, BZD=benzodiazepine; bBarker et al., 2004a; cBarker et al., 2004b =statistically 
significant result (95%CI did not cross zero). 
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In an attempt to overcome some of the limitations of the studies used in their 
previous meta-analyses, Barker et al., (2005) conducted a study comparing previous 
benzodiazepine users who had been abstinent for at least 6 months, to well-
matched comparison groups, on a limited number of cognitive measures. The 20 
benzodiazepine using participants were each matched to two benzodiazepine-naïve 
controls; one who had been diagnosed with anxiety, and one who had not. The 
benzodiazepine users had a mean diazepam equivalent of 33.1mg (SD=32.8, 
range=7.5-160). The mean length of use was 108.5 months (SD=95.5, range=12-348) 
and mean length of abstinence was 42.2 months (SD=50.8, range=6-174.5). Five 
cognitive areas were studied: attention/concentration, motor control/performance, 
non-verbal memory, verbal memory, and visuospatial skills. Significant, moderate-
to-large magnitude impairments were found for benzodiazepine users on verbal 
memory (d=-1.43), and motor control (d=-1.33) compared to both control groups 
(Barker et al., 2005). The anxious and control groups performed similarly and 
significantly better than the benzodiazepine group, suggesting that benzodiazepine 
use, rather than any confounding factor such as anxiety, was likely responsible for 
the difference in performance (Barker et al., 2005). Mean effect sizes for each 
category were also compared to the effect sizes found in the earlier meta-analysis 
examining long-term follow-up (Barker et al., 2004b). Rank order from largest to 
smallest effect size was very similar across the two studies, with both identifying 
verbal memory as the cognitive function most affected by previous benzodiazepine 
use.  
Health Consequences of Long-Term Benzodiazepine use 
In addition to the cognitive deficits associated with long-term benzodiazepine use, 
there is evidence that there are other health sequelae associated with chronic use. 
Understanding this association is complicated by the fact that many people who use 
benzodiazepines already have poor physical or mental health. Furthermore, overlap 
between withdrawal symptoms and affective/anxiety disorders, can make 
differential diagnosis of symptoms complicated. One area that is currently of high 
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interest is the possible link between benzodiazepine use and dementia; between 
1998 and 2015, there were 11 observational studies examining this association. 
Pariente, de Gage, Moore, and Bégaud (2015) reviewed these studies, and 
concluded that there was one study that showed a protective effect of 
benzodiazepine use on development of dementia (Fastbom, Forsell, & Winblad, 
1998), one with no association between the two (Imfeld, Bodmer, Jick, & Meier, 
2015), whilst nine showed a detrimental association between benzodiazepine use 
and the development of dementia (Billioti de Gage et al., 2014; Billioti deGage et al., 
2012; Chen, Lee, Sun, Oyang, & Fuh, 2012; Gallacher et al., 2012; Lagnaoui et al., 
2002; Lagnaoui et al., 2009; Wu, Ting, Wang, Chang, & Lin, 2011; Wu, Wang, Chang, 
& Lin, 2009). A problem inherent in these studies is that allocation to the group is 
not random, and a causal direction cannot be assumed. The mechanism by which 
benzodiazepines may be associated with dementia is unknown, and although there 
are several theories, these will remain speculative until there is more 
comprehensive research. Pariente et al. (2015) conclude that there is no established 
association between dementia and the short-term use of benzodiazepines (i.e. less 
than three months). This is important from a clinical viewpoint, and is another piece 
of evidence to support limiting the use of benzodiazepines to short time periods 
only.  
Summary 
The acute effects of benzodiazepines that occur after a single or brief dosing 
regimen are most commonly sedation, inattention, and amnesia. However, there 
are dose-dependent effects, and higher doses effect a range of cognitive functions. 
Tolerance to benzodiazepines occurs differentially for the various actions, thus the 
effects of benzodiazepines on chronic users cannot simply be assumed from the 
acute effects. Meta-analyses suggests that there is a generalised effect of long-term 
benzodiazepine use on cognition, and that there is some but not a complete 
recovery of function after a period of abstinence. 
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CHAPTER 3: BENZODIAZEPINES AND DRIVING 
Current evidence suggests that long-term benzodiazepine use results in various 
cognitive impairments. Considering this and given that the prevalence of 
benzodiazepine use is high and often inconsistent with therapeutic guidelines, there 
has been increasing attention paid to the effects that benzodiazepines have on 
safety in day-to-day living. An area of particular interest has been the impact on 
driving ability, which is a task with high psychomotor and cognitive demands. 
Benzodiazepine users are commonly urged to be cautious when undertaking 
activities such as driving, but are required to self-monitor their capacity to drive 
safely (Figure 1).  
 
Figure 1. Medication Labels required when Benzodiazepines are dispensed in 
Australia. 
Whilst the impairment that alcohol causes to driving ability is widely understood, it 
is only more recently that awareness about drug-driving has increased. Research 
examining drugged driving has used many methods including: telephone surveys of 
general populations, examining drivers held by police for ‘impaired’ driving, driving 
simulator studies, laboratory testing of relevant psychomotor skills, on-road driving 
tests, and internet surveys of specific populations. For a comprehensive list of the 
studies examining drug driving, see Kelly, Darke, and Ross (2004). Research relevant 
to benzodiazepines and driving will be briefly reviewed here. 
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Epidemiological Research 
Epidemiological research frequently examines blood samples of drivers involved in 
an accident or apprehended for impaired driving. This provides information about 
what drugs may have been used by the individual, but does not establish a causal 
relationship. A review by Kelly, Darke, and Ross (2004) examined all studies 
investigating drug use and driving completed post 1970. Across the studies 
reviewed, it was found that for drivers involved in motor vehicle accidents, cannabis 
was generally the most commonly detected drug (2-32%), followed by 
benzodiazepines (2-15%), cocaine (4-11%), amphetamines (2-6%), and opioids (3-
5%). For drivers detained for ‘driving under the influence’, cannabis was again the 
most prevalent drug, followed by benzodiazepines. Benzodiazepines were detected 
in drivers suspected or arrested for driving under the influence in higher rates (30-
65%) in Denmark, Norway, Switzerland, Scotland and the Netherlands, and lower 
rates (5-20%) were found in Australia, Finland, Slovenia, Northern Island, Sweden 
and the United States.  
A systematic review by Dassanayake, Michie, Carter, and Jones (2011) examined the 
effect of benzodiazepines, opioids, and anti-depressants, on driving ability. 
Research published between 1966 and 2010 was reviewed, and included both 
epidemiological studies (n=21), and experimental studies (n=69). Epidemiological 
research examining the association between benzodiazepine use and accidents 
were divided into case control studies (n=13), and cohort-studies (n=8). The meta-
analyses found that benzodiazepine users were 60-80% more likely to be involved in 
traffic accidents (for case-control studies: 59%, pooled OR 1.59; 95%CI 1.10-2.31, 
and for cohort studies: 81% pooled incidence rate ratio 1.81; 95%CI 1.35-2.43). 
When benzodiazepines were combined with alcohol, the risk of an accident was 
increased seven-fold (pooled OR 7.69; 95%CI 4.33-13.65). 
The Driving Under the Influence of Drugs, Alcohol and Medicines (DRUID) project, 
aimed to bring together experienced organisations in Europe, to provide a 
coordinated set of research and resources to combat the problems associated with 
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driving under the influence of substances. Epidemiological research data was 
gathered across 15 countries, during 2007-2009 (Houwing et al., 2011). General 
prevalence rates of substances detected in drivers, was collected from 48,545 
drivers randomly stopped in 13 countries. Participation was voluntary, and samples 
were collected of either saliva, blood, or both. The voluntary nature means research 
may have been susceptible to non-response bias, whereby drivers who knew they 
were under the influence of a substance were less likely to participate. Alcohol was 
the most commonly detected substance in the sample, found in 3.48% of those 
tested, followed by illicit drugs (1.90%) and medicinal drugs (1.36%). 
Benzodiazepines were detected in 0.9% of the drivers tested. These figures 
represent substances that were detected on their own, not in combination with 
another substance.  
In another DRUID project, drivers injured or killed in a car accident were tested for 
traces of substances (Isalberti et al., 2011). Data on seriously injured drivers 
(n=3,570) was collected from six countries, and for fatally injured drivers (n=1,293) 
from four countries. As expected, alcohol was the most regularly detected 
substance in both injured and killed drivers. In injured drivers, benzodiazepines 
were detected in a range between 0% (Netherlands) and 10.2% (Finland), and 
alongside cannabis, were the most commonly detected substances following 
alcohol. In the vast majority of these cases, benzodiazepines were detected in 
combination with alcohol, cannabis, amphetamines, and medicinal opioids. 
Detection rates in deceased drivers were similar, with the highest benzodiazepine 
detection rate again occurring in Finland (13.3%). After alcohol, benzodiazepines 
were the most commonly detected drug in these deceased drivers. Interestingly, 
amongst males, the highest detection of benzodiazepines occurred in the 25-34, 
and 35-49 year age groups, whilst in females, the highest rate occurred in those 
aged 50 years and over. There was a low rate of female subjects (17%), so these 
findings should be interpreted cautiously, but they may reflect differing patterns of 
benzodiazepine usage amongst different genders. In fatally injured drivers, 
benzodiazepines were commonly found in association with alcohol, amphetamines, 
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cannabis, and z-drugs (zolpidem and zopiclone). Estimates in the DRUID samples are 
likely to be conservative, as concentration cut-offs were chosen for blood samples, 
and if a blood sample was below the cut-off it was considered to be negative.  
Data from these two DRUID studies was then used to calculate the ‘relative risk’ of 
being seriously or fatally injured whilst positive for a substance. Relative risk is 
defined as the ratio of two risks; the risk of an event occurring in the group of 
exposed subjects and the risk of the event occurring in the group of non-exposed 
subjects. The risk estimate for those using benzodiazepines/Z-drugs, of being 
seriously injured was 1.99 (95%CI: 1.36-2.91) and fatally injured was 5.40 (95%CI: 
3.90-7.46). Based on the assessments of the odds ratio for injured and killed drivers, 
the authors compiled an estimate of risk for each substance class (Table 1). 
Benzodiazepines/Z-drugs fell in the medium risk category. Also in this category was 
a blood alcohol concentration greater than 0.5g/L; this blood alcohol level is 
equivalent to the 0.05% blood alcohol concentration that is used as a legal cut-off 
for safe driving in Australia. If this level of alcohol intoxication is considered 
dangerous, it does pose the question as to why driving under the influence of 
benzodiazepines, that has an equivalent level of risk, remains legal.  
Table 1. Relative Risk of getting Seriously Injured or Killed when using Various 
Substance groups (Hels et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aRisk Odds Ratio= Relative risk is defined as the ratio of two risks; the risk of an event occurring in the group 
of exposed subjects and the risk of the event occurring in the group of non-exposed subjects. The relative 
risk estimates were approximated to odds ratios. *This includes concentrations in blood/saliva detected at 
or above the relevant cut-off point; this does not indicate whether use was acute or ongoing. 
Risk Level (Injury or 
Fatality) 
Risk 
ORa 
Substance Group 
Slightly increased risk 1-3 ≥0.1<0.5g/L alcohol in blood  
Cannabis* 
Medium increased risk 2-10 ≥0.5<0.8g/L alcohol in blood  
Cocaine* 
Illicit or medicinal Opiates* 
Benzodiazepines and Z-drugs* 
Highly increased risk 5-30 ≥0.8<1.2g/L alcohol in blood  
Amphetamines* 
Multiple Drugs* 
Extremely increase risk 20-200 ≥1.2g/L alcohol in blood  
Alcohol in combination with drugs* 
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Prevalence studies have been extended upon by determining the responsibility of 
drivers involved in accidents. Culpability has been attributed in many Australian 
studies by using a method established by Robertson and Drummer (1994). This 
method involves identifying mitigating factors, such as road condition, and 
depending on the presence of these mitigating factors, drivers are deemed fully, 
partly, or not culpable. A meta-analysis by Dassanayake et al. (2011) examined 
whether benzodiazepines were more commonly detected in the blood of drivers 
who were responsible for an accident, compared to those who were not. This meta-
analysis used six case-control studies, including large population studies from 
Longo, Hunter, Lokan, White, and White (2000), involving 2,500 crash injured South 
Australian drivers, and Drummer et al. (2004), who included 3,398 fatally injured 
drivers. Importantly, testing positive for benzodiazepines was significantly 
associated with a 41% increase in accident responsibility (pooled OR 1.41; 95%CI 
1.03-1.94). 
Much of the literature examining the link between medicinal drug use and traffic 
accidents, has focused on the association between a whole class of drugs (e.g. 
benzodiazepines, opioids, antidepressants). This does not account for the potential 
differences between the individual drugs in these classes, and their variable 
impairment on driving ability. A recent study by Rudisill, Zhu, Kelley, Pilkerton, and 
Rudisill (2016) aimed to determine, through a systematic literature review, the risk 
of accidents associated with specific medications. The review included all studies 
that investigated individual preparations, and the associated odds or risk of a motor 
vehicle collision; this included cohort, case-control, and case-cross-over studies, and 
those using driving simulators. The review included 27 studies that spanned from 
1992 to 2013, and of these, seven studies investigated nine different 
benzodiazepines. It was found that chlordiazepoxide (not available in Australia) and 
oxazepam were not associated with a significantly increased risk of collisions. 
However, flunitrazepam, flurazepam, lorazepam, temazepam, and triazolam were 
associated with a statistically significant increased risk of traffic collisions. Diazepam 
was associated with a significantly increased risk in four out of the five studies 
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investigating its effects. The review concluded that across all drug categories, there 
was variation within each class, meaning some specific preparations had a higher 
association with crash risk than others; therefore investigating medications as a 
class may at times obscure valid findings. Furthermore, not all medications that 
were associated with an increased risk of vehicle accidents, were correlated with 
decreased driving ability, and vice versa, suggesting that neither measure should be 
used a sole indication of a medication’s impact on driver-impairment. However, 
some medications including; diazepam, flunitrazepam, flurazepam, lorazepam, 
temazepam, triazolam, and the Z-drugs - zopidem and zopiclone, were associated 
with both an increase in the risk of motor vehicle accidents and a decrease in 
driving ability, thus indicating these preparations are of particular importance to 
target for driver safety. 
Epidemiological studies are limited in that they examine a select sample, and thus 
do not provide an indication of the usual prevalence of drugged driving. The regular 
detection of benzodiazepines in drivers involved in accidents points to the impairing 
effects of these drugs, however, a causal effect cannot be assumed. Experimental 
research provides an alternative method of examining the link between 
benzodiazepine use, and subsequent impairment. 
Laboratory Tests 
Experimental Tests 
The impact of specific drugs on driving ability has often been explored using 
experimental laboratory testing. Laboratory testing, using tasks measuring specific 
abilities, such as reaction time or attention, allow the many abilities required for 
driving to be studied in a controlled environment. Kelly et al. (2004) reviewed the 
experimental research examining the association between benzodiazepine use and 
driving. Benzodiazepine use was associated with decreases in visual and speed 
perception, information processing, coordination, reaction time, memory, and 
attention. However, these effects were dose dependent, and there were not 
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consistent effects across the benzodiazepine types. The laboratory tests used in 
experimental research have often been chosen based on their ease of 
administration and sensitivity to drugs effects, rather than on face validity. These 
factors diminish the predictive ability of laboratory tests to on the road driving. 
The release of drugged driving research guidelines by a panel of experts aimed to 
standardise future drug driving research (Walsh, Verstraete, Huestis, & Mørland, 
2008). This panel identified that there are three core areas of behaviour most 
relevant to impaired driving. These domains include: (1) automative behaviour, or 
well-learned skills, including tracking, steering, and sustained attention; (2) control 
behaviours, such as motor performance, manoeuvres, divided attention, and 
perception; and (3) executive planning behaviours, for example, risk taking, 
impulsivity, information processing, and judgement. 
As discussed in Chapter 2, a large quantity of laboratory research has established 
the cognitive deficits associated with benzodiazepine use, including in the three 
domains relevant to driving ability listed above. For example, a review by De Visser 
et al. (2002), examined acute benzodiazepine use in naïve users, and found deficits 
in attention, motor control, and executive function. Similarly in current and 
previous chronic benzodiazepine users impairment has been found in relevant areas 
of cognitive function including psychomotor speed, visuospatial skills, 
attention/concentration, motor control/performance, speed of processing, and 
problem solving (Barker et al., 2004a, 2004b). Whilst experimental research lacks 
validity for driving ability, the research clearly shows benzodiazepines impair 
cognitive functions important for safe driving. 
Driving Simulators 
Driving simulators are a method of laboratory testing assumed to have greater 
predictive ability to real life driving. Driving simulators range from simple systems, 
with basic components, such as a steering wheel, foot pedals, and computer screen, 
through to complex structures with realistic car bodies, and computer-generated 
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systems with authentic road scenarios. Common outcomes measured in simulator 
studies include: speed, steering, deviation from lateral position, reaction time, 
braking accuracy, driving errors, and vehicle collisions.  
A study by Rapoport and Banina (2007) examined nine articles assessing the impact 
of psychotropic medications on computer simulated driving. Research was grouped 
according to when testing occurred in relation to drug ingestion; ≤ 2 hours post-
ingestion, 2-5 hours post-ingestion, next morning effects, and during stable dosing 
of benzodiazepines. The time period up to two hours after dosing was most 
commonly studied. During this time period, higher doses of benzodiazepines (such 
as 2mg of lorazepam, or 15mg of diazepam) were associated with an increase in 
reaction time, and tracking errors. At 2-5 hours post dosing, some but not all studies 
found impairments in coordination, reaction time, and tracking ability, associated 
with benzodiazepine use. Reaction time was impaired the morning after 5mg of 
nitrazepam, but this impairment reduced after the third dose. Coordination was 
impaired for up to 14 days of dosing with 30mg of flurazepam. None of the studies 
focusing on ‘morning after’ effects examined longer-acting benzodiazepines, such as 
diazepam, or clonazepam, which may be more likely to cause lasting effects. Two of 
the studies reviewed examined the immediate impact of an acute dose in regular 
benzodiazepine users. Whilst one study found no effects, the second found that 
patients who had been using various benzodiazepines for several years, showed an 
increase in speed variation when tested one hour post dosing. The studies reviewed 
by Rapoport and Banina (2007) were difficult to compare due to methodological 
differences, and varying benzodiazepine doses. However, whilst there were some 
differences amongst studies, reaction time and tracking were quite consistently 
impaired by the use of benzodiazepines. A later meta-analytic study by the same 
lead author (Rapoport et al., 2009), reviewed epidemiological and experimental 
data examining benzodiazepines and driving. It was reported that many of the 
experimental driving studies were too heterogeneous to meta-analyse, and there 
were no consistent findings from the studies using driving simulators.  
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The ecological validity of driving simulators in assessing on-road driving ability is not 
yet established; research indicates a benzodiazepine deficit on simulated tasks, but 
inconsistency in results means clear conclusions are lacking. 
Standard Deviation of Lateral Position and Road Based Driving Tests 
The most accurate ecological validity lies in the domain of road-based driving tests. 
Standard deviation of lateral position (SDLP) is a commonly used on-the-road 
driving test, conducted during normal traffic, although this outcome measure is also 
sometimes used in simulator studies (Verster & Roth, 2011). The primary aim of the 
task is to remain at a steady lateral position on the road at a speed of 95km/hour; 
accuracy is measured by the degree of weaving of the vehicle from the path and 
variability of speed control.  
A meta-analytic study by Roth, Eklov, Drake, and Verster (2014) examined 14 
studies using on-road SDLP as the outcome measure. Four meta-analyses were 
completed examining; benzodiazepine hypnotics compared to Z-drugs, drug dosage, 
time of day of testing, and benzodiazepine half-life. The meta-analysis showed that 
when combining all hypnotic drugs used to treat insomnia, there was a significant 
impairment in morning driving performance, as measured by SDLP (p<0.001). 
Benzodiazepines impacted on performance to a greater extent than Z-drugs 
(p<0.001). When benzodiazepines were given at the recommended dosage of a 
night-time, SDLP was impaired in the morning (p<0.001), but not in the afternoon 
(p=0.089). Greater impairment occurred in morning drives compared to afternoon 
drives, at both single (d=0.27, p=0.001) and double doses (d=0.59, p=0.001). 
However, provision of a double dose caused greater impairment than a single dose, 
whether testing occurred in the morning (d=0.49, p=0.001), or the afternoon 
(d=0.33, p=0.001). As would be expected, there was an effect of benzodiazepine 
half-life on performance impairment. Short-acting hypnotics, with a half-life of less 
than six hours, did not affect performance the next morning. However both 
intermediate half-life (half-life of 6-12 hours; p<.0001) and long-acting (half-life of 
greater than 12 hours; p<.0001) hypnotics had an effect on SDLP the next morning. 
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This meta-analysis by Roth et al. (2014), replicates and extends upon the work from 
two earlier meta-analyses (Rapoport et al., 2009; Verster, Veldhuijzen, Patat, 
Olivier, & Volkerts, 2006). Results indicate benzodiazepine impairment is increased 
when time between intake and driving is short, with higher dosages, and with 
benzodiazepines with a longer half-life. 
Most experimental driving studies are conducted using healthy individuals, 
however, this does not account for the underlying conditions for which 
benzodiazepines are prescribed. The ability to generalise from studies using healthy 
participants, to the effects on patients requiring benzodiazepine treatment remains 
limited. The Driving Under the Influence of Drugs, Alcohol, and Medicines (DRUID) 
group extended upon current studies by examining the effects of benzodiazepines 
in both healthy volunteers, and typical patient groups (those with anxiety or 
insomnia).  
Touliou (2011) examined driving performance in benzodiazepine-treated anxiety 
patients (n=15), untreated anxiety patients (n=18), and a healthy control group 
(n=18). Participants were matched for age, gender, and driving experience. The 
anxious patients had a diagnosis of anxiety, and a score on the Hamilton Anxiety 
Rating Scale (Hamilton, 1959) of greater than, or equal to 2; which is indicative of 
anxiety of mild to moderate severity. Those in the treatment group, had been using 
alprazolam regularly for the past two months. Participants in the untreated group 
had not received any type of treatment in the last two months. Two driving tasks 
were completed using a driving simulator; the first task was a standardised test of 
SDLP, and the second was a car following scenario. In the car following scenario, a 
safe distance had to be maintained from a lead vehicle travelling at a steady speed 
(90km/hour); four instances of abrupt braking from the lead vehicle occurred 
randomly. The car following scenario yielded two measures; percentage of time 
driving spent within certain time-to-collision values, and braking reaction time. A 
standardised battery of attentional performance tasks was administered after the 
driving tasks (winTAPP: Zimmermann & Fimm, 1993). Driving measures, and 
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cognitive and subjective assessments were conducted at baseline and 
approximately one hour after administration of 0.5mg alprazolam. Alprazolam 
impaired performance in all three groups on SDLP. Results from the car following 
scenario regarding time-to-collision were not conclusive, but compared to anxious 
patients, the healthy controls were actually less likely to keep safe distances, 
indicative of poorer performance. Alprazolam affected braking reaction time in both 
treated and untreated anxiety patients. The treated group showed the greatest 
impairment in reaction time, suggesting that repeated alprazolam dosing, may have 
a greater effect on reaction time than once-off dosing. In the neuropsychological 
battery, alprazolam significantly affected alertness in the control group, however, 
no other significant differences were found. Effect sizes were not reported in the 
study. Overall the authors conclude that alprazolam significantly affects 
performance in anxious and control subjects.  
Leufkens, Ramaekers, de Weerd, Riedel, and Vermeeren (2011) studied driving 
ability in elderly insomnia patients chronically using hypnotics (n=22), unmedicated 
elderly insomnia patients (n=20), and healthy age-matched controls (n=20). The age 
range of participants was 52-73 years, and insomnia patients met criteria for 
primary insomnia, according to the Diagnostic and Statistical Manual of Mental 
Disorders-IV (American Psychiatric Association, 2000). Use of hypnotics included 
both benzodiazepines, and zolpiclone, or zolpidem. The chronic hypnotic users had 
used a hypnotic at least four days a week, for at least three months. Average 
duration of hypnotic use was 7.7 years, with a mean frequency of use of 6.4 
nights/week. Two driving tasks were used; a standardised highway driving test 
(O'Hanlon, 1984), with standard deviation of lateral position (SDLP) as the main 
outcome, and the car following test (Brookhuis, Waard, & Mulder, 1994; Ramaekers 
& O'Hanlon, 1994). As in the earlier simulator study (Touliou, 2011) the car 
following test required participants to drive behind another car, and follow its 
speed movements; however, in this study the test was completed on road, and 
average reaction time to the movement of the lead vehicle was the main outcome 
variable. The on-road tests were administered in the morning, 10-11 hours after 
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dosing. No significant differences between groups were found on the road driving 
tasks. Similarly, there were no differences on experimental tasks (verbal memory, 
divided attention, psychomotor vigilance, and inhibitory control), which were 
completed before and the morning after dosing, with the exception of working 
memory (digit span) where chronic hypnotic users performed significantly worse 
compared to controls. Overall results showed that driving performance in patients 
with insomnia is not impaired relative to controls, irrespective of the use of 
hypnotic medication. It is suggested that the relative simplicity of these tasks meant 
insomnia patients were able to compensate for performance deficits by increasing 
their effort. The authors state that the absence of a deficit associated with hypnotic 
use is likely to be an effect of tolerance.  
Detection of Subjective Impairment  
There is some evidence that benzodiazepines are associated with an impairment in 
the ability to monitor one’s own performance, commonly known as metacognition. 
Practically, the inability to detect impairment in a task of high psychomotor 
demand, such as driving, could have severe consequences. It is also common to 
expect benzodiazepine users to determine their own impairment, for example 
before choosing to drive or operate machinery. There have been some attempts to 
examine the self-rated, subjective impact of benzodiazepines on driving ability.  
Metacognition 
Metacognition is commonly described as ‘thinking about thinking’ (Flavell, 1971, 
1979). Whilst there is not complete agreement in the literature as to the specific 
nature of meta-cognition, most definitions seem to acknowledge the components 
of monitoring, and if necessary, changing one’s performance (Georghiades, 2004). 
As there is an established benzodiazepine related cognitive impairment, capacity to 
detect this deficit is important, and inability to do so may have serious outcomes 
(Kleykamp, Griffiths, & Mintzer, 2010).  
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Research indicates benzodiazepines impair metacognitive abilities. One commonly 
studied area of metacognition is metamemory (Flavell, 1971); that is, knowledge 
and awareness of one’s memory, particularly the capacity to self-assess and 
regulate (Mintzer, Kleykamp, & Griffiths, 2010). Impairment in metamemory has 
been noted in those administered lorazepam (Bacon et al., 1998; Izaute & Bacon, 
2004; Massin-Krauss, Bacon, & Danion, 2002) and triazolam (Kleykamp et al., 2010; 
Mintzer et al., 2010). There is also evidence that benzodiazepines impair capacity to 
judge performance on other psychomotor tasks, such as the Digit Symbol 
Substitution Task (Mintzer & Griffiths, 2003), the circular lights task (Roache, 
Cherek, Bennett, Schenkler, & Cowan, 1993), and reduce awareness of internal 
states such as sedation (Mintzer & Griffiths, 2003; Weingartner et al., 1995). These 
studies are all undertaken in benzodiazepine-naïve healthy individuals, and thus 
findings cannot be extended to those who use benzodiazepines regularly. 
Subjective Detection of Driving Impairment 
Verster, Volkerts & Verbaten (2002) used a double-blind cross over design, to 
administer alprazolam (1mg) or placebo to benzodiazepine-naïve healthy 
individuals; both subjective and objective measures of performance were collected. 
As expected, alprazolam was associated with a significant deficit on measures of 
driving performance, including standard deviation of lateral position (p<.0001), and 
standard deviation of speed (p<.0001). This corresponded with the subjective 
ratings of participants; when compared to controls, participants given 1mg of 
alprazolam rated themselves as having significantly reduced driving quality 
(p<.0001), alertness (p<.0001) and mental activation (p<.0001), with increased 
mental effort required to drive (p<.0001). These findings suggest that participants in 
this study were able to detect impairment to their driving ability. However, six out 
of the 20 participants actually fell asleep whilst trying to complete the driving task, 
which indicates the degree of impairment experienced. The study used 
benzodiazepine-naïve participants only, and it is likely that in regular 
benzodiazepine users, impairment would be more subtle, and thus may not be so 
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readily detected. To date, to the author’s knowledge, no studies comparing 
objective and subjective performance on ecological driving tasks in chronic 
benzodiazepine users exist.  
Self-Report Survey Research 
The Australian Drug Foundation completed an extensive online survey, and key 
stakeholder interviews to investigate the Australian community’s experience and 
understanding of driving in conjunction with alcohol, licit and illicit drug use 
(Mallick, Johnston, Goren, & Kennedy, 2007). In this random internet sample 
(n=6,801) there was a higher representation of females, highly educated people, 
and drug use, compared to general population data. In the last 12 months, 12.6% of 
participants reported they had driven whilst over the 0.05% blood alcohol 
concentration (BAC). Comparatively 4% of all respondents reported that in the past 
12 months, they had driven within 3 hours of benzodiazepine use. Likelihood of 
driving whilst acutely affected by a benzodiazepine increased proportionally with 
frequency of use. 
Survey respondents were questioned about whether they detected any impairment 
on driving ability. Most respondents reported that there was no subjective change 
to their driving ability within three hours of using a benzodiazepine (67.4%). 
Approximately a quarter of participants perceived an impairment to driving ability, 
with 21.5% reporting that it was ‘slightly worse’ and 4.1% reporting that it was ‘a lot 
worse’.  
Attitudes and perceptions surrounding drink and drug-driving were also examined. 
It was found that 89.3% (n=6,331) of respondents considered that driving with a 
BAC of 0.05 or more, was ‘very risky or dangerous’. In comparison, 61.6% (n=4,188) 
thought that driving under the influence of benzodiazepines was ‘very risky or 
dangerous’. Driving under the influence of benzodiazepines was considered 
significantly more likely to be considered “very risky” by non-benzodiazepine users 
(64.2%, n=5,910) compared to benzodiazepine users (44.4%, n=891). 
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Overall findings from this study do not bode well for regular benzodiazepine users. 
Regular users were much more likely to drive within three hours of using a 
benzodiazepine, and less likely to consider that it was very risky to do so. Most of 
the group reported there was no change to their driving ability. Regular 
benzodiazepine users are a group that should be highly aware of the risks 
associated with benzodiazepines, and take relevant precautions. Data from the 
Australian Drug Foundation survey suggests that this is not the case.  
Summary of Benzodiazepine and Driving Research 
The evidence from epidemiological driving studies shows a strong association 
between benzodiazepine use and driving accidents. Benzodiazepine users are also 
more likely to be responsible for accidents they are involved in. Summarising 
laboratory testing, including simulator studies, has been difficult due to 
methodological issues, however, benzodiazepines do impair cognitive functions 
associated with driving. Evidence from on-the-road driving tests has high ecological 
validity and suggests significant driving impairment is associated with hypnotic 
benzodiazepines, including the morning after a night time dose. The extent to which 
benzodiazepine impairment can be self-detected remains unclear; it is possible that 
more subtle impairment may be missed. Self-report data suggests that even those 
who regularly use benzodiazepines may underestimate the risks involved with 
driving under the influence of benzodiazepines. The benzodiazepine and driving 
literature is difficult to summarise due to the broad range of methodology used and 
the variation inherent within the class of benzodiazepine drugs. However, deficits 
are quite consistently shown across many different studies, and the consequences 
associated with even a small deficit in driving ability are potentially fatal.  
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CHAPTER 4: THE SAFETY INCIDENT CONTINUUM 
As has been illustrated, the importance of understanding the impact of 
benzodiazepine use on driving is significant given the potentially catastrophic 
impact of accidents. However, benzodiazepine users are likely to be susceptible to 
accidents across a range of daily activities. Whilst much of the previous research is 
dependent on data obtained in serious and often fatal accidents, a novel research 
approach by the Bristol Stress and Health studies, examined a range of incidents 
varying in severity (Smith, Johal, Wadsworth, Davey Smith, & Peters, 2000; 
Wadsworth, Moss, Simpson, & Smith, 2003, 2005; Wadsworth, Simpson, Moss, & 
Smith, 2003).  
The incident types examined in the Bristol Stress and Health studies were measured 
both within and outside of the workplace and were as follows; (1) major accidents 
that required medical attention (2) minor injuries not requiring medical attention 
and (3) cognitive failures, or minor slips or lapses in normal cognitive function. An 
initial comprehensive study, the Bristol Stress and Health at Work Study (Smith, 
Johal, Wadsworth, Smith & Peters, 2000) examined factors related to stress at work 
via a mail out survey to 17,000 people in the Bristol Electoral register. This original 
study led to a series of follow up studies that have become more focused on specific 
substances and their impacts.  
The most relevant of this group of studies was that by Wadsworth, Moss, Simpson, 
and Smith (2005) which focused on the impact of particular psychotropic 
medications. This study used a postal survey of a random community sample of 
7,979 people in the Cardiff and Merthyr Tydfil electoral registers. Of this group, 58% 
(n=4,620) were employed, 58% (n=4,601) were female, and there was an average 
age of 45.6 years. Logistic regression was used to test for associations between 
medication use, demographic factors, and the outcome variables. Incidents were 
reported at the following rates; major accidents (11%), road accidents (2%), minor 
injuries (14% - quite or very frequent minor injuries), and cognitive failures (18% - 
quite or very frequent cognitive failures). Benzodiazepines were significantly 
Chapter 4: The Safety Incident Continuum | 47 
 
 
 
associated with non-work injuries (OR 4.43, 95%CI 1.89-10.38). There were also 
trends towards associations between benzodiazepines and general injuries (OR 
2.17, 95%CI 0.89–5.32), work accidents (OR 1.36, 95%CI 0.13–14.58), and general 
accidents (OR 2.01, 95%CI 0.71–5.67). To clarify findings, comparisons were also 
made between participants who had low or high levels of other risk factors for each 
incident type (such as alcohol use or risk taking), and the presence or absence of a 
mental health condition. For those who had both a mental health condition and 
high levels of other risk factors, benzodiazepines significantly increased the risk of 
non-work injuries (OR 16.18, 95%CI 6.24-41.94) and cognitive failures (OR 18.09, 
95%CI 6.17-53.04). A final set of analyses, focusing only on the groups with high 
other risks, suggested that there was an independent association between 
benzodiazepine use and injury risk (OR 3.06, 95%CI 1.32-7.10), over and beyond the 
effect associated with having a mental health condition (OR 1.67, 95%CI 1.28-2.17). 
There was also an interaction effect between mental health status, and 
benzodiazepine use on cognitive failures (OR 3.66, 95%CI 1.26-10.66), which had a 
greater effect than the impact of mental health problems alone (OR 2.14, 95%CI 
1.69-2.70). The findings of the Wadsworth study indicate a detrimental effect on 
the safety of benzodiazepine users, but this did not occur across all incident types. 
To our knowledge, no other studies have investigated the association between 
psychotropic medication use, and accidents, injuries and cognitive failures within 
the one set of analyses. The main effects of benzodiazepines on each of these 
incident types will be reviewed below.    
Major Accidents 
Major accidents, as defined by Wadsworth, Moss, et al. (2003), are those accidents 
that are high enough in severity to require medical attention. Major accidents are 
the outcome most commonly measured in research, as inherent in their nature, 
they require presentation to medical services, and thus can be readily tracked. As 
traffic accidents have already been reviewed in an earlier section, only non-traffic 
accidents will be covered here.  
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An epidemiological study by Kurzthaler et al. (2005), examined the types of 
incidents that led to people under the influence of alcohol or benzodiazepines 
presenting to an emergency room. The sample was collected over a one year period 
and involved 1,611 people presenting to the emergency department in Innsbruck, 
Austria; 19.5% (n=314) of people tested positive for alcohol, 5.2% (n=85) for 
benzodiazepines, and 1.4% (n=23) were positive for both substances. In injured 
people, benzodiazepines were significantly more common in violence-related 
injuries (19.6%) than any other accident type; this was also the most common injury 
type for alcohol and alcohol/benzodiazepines in combination also. Following 
violence related injuries, rates of benzodiazepine detection occurred the next most 
commonly in traffic incidents (7.1%), followed by falls (5.5%), sport injuries (3.8%) 
and work place accidents (2.3%). Whilst this study only indicates correlation not 
causality, results do give some indication of the types of accidents associated with 
benzodiazepine use.  
Palmer, Harris, and Coggon (2008) undertook a systematic literature review of 
chronic health conditions and related medications, and workplace accident risk. A 
total of 38 relevant papers from 1966 to 2006 were reviewed. Criteria for exposure 
variables and outcomes were too varied to warrant a meta-analysis. Across the 
papers reviewed, the association between anxiolytics, hypnotics, or sedatives, and 
workplace accidents was mixed, though some significant positive associations were 
found. Voaklander et al. (2006) found that use of anxiolytics/hypnotics/sedatives in 
the past 30 days was associated with a three-fold increase in the risk of work-
related accidents in elderly farmers (OR 3.01, 95%CI 1.39-6.52). The studies of 
Wadsworth, Moss, et al. (2003) and the earlier described study of Wadsworth et al. 
(2005) used a similar methodology. The 2003 study was a preliminary investigation 
of the association between ‘sleeping tablets’ and anti-depressants, and accidents, 
injuries and cognitive failures. In a general postal survey of 3,111 individuals, there 
were significant associations between benzodiazepine use and accidents at work 
(adjusted OR=2.82, 95%CI 0.84-9.44) and outside of work (adjusted OR 1.75, 95%CI 
0.95-3.24). The limitation inherent in this review by Palmer et al. (2008) is that there 
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is no indication that the use of benzodiazepines coincided with the accident 
experience.  
Psychotropic medications are commonly linked with increased rates of falls, 
particularly in the elderly. Bloch et al. (2011) undertook a systematic literature 
review and meta-analysis of psychotropic medications in people aged 60 and above, 
and their experience of everyday falls. 177 relevant studies published between 1996 
and 2007 were reviewed (n=20,576). There were associations between psychotropic 
medication use and falls (OR 1.78, 95%CI 1.57-2.01) and benzodiazepine use and 
falls (OR 1.39, 95%CI 1.24-1.54). The overall study findings supported that of an 
earlier meta-analysis (Woolcott et al., 2009). The authors conclude that despite 
strong evidence of the relationship between psychotropic medications and falls, 
there has been little change in prescribing behaviour.  
Minor Injuries 
For the purpose of this thesis ‘minor injuries’ are considered to be minor non-
venous cuts and scrapes that do not require medical attention (Wadsworth, 
Simpson, et al., 2003). The extent and cost of major accidents is commonly captured 
by workplace reporting systems, and medical services; however, there is a relative 
scarcity of research examining minor injuries (Simpson, Wadsworth, Moss, & Smith, 
2005). Even in the general population, there is little information about rates of 
minor injuries. For example, Safe Work Australia, responsible for work health and 
safety, only publishes information about serious claims resulting in a worker’s 
compensation case. Despite this, minor injuries are important in their own right, 
and can have a serious impact on well-being.  
Wadsworth, Moss, et al. (2003) found initial associations between sleeping tablet 
use and minor injuries both at and outside of work, but these were explained by 
other demographic and lifestyle variables in a multivariate analysis. In a larger 
sample (Wadsworth et al., 2005), benzodiazepines were significantly associated 
with non-work injuries (OR 4.43, 95%CI 1.89-10.38), and for those with other risk 
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factors and a mental health condition, the association between benzodiazepines 
and non-work injuries increased considerably (OR 16.18, 95%CI 6.24-41.94) 
Cognitive Failures 
Wadsworth, Simpson, et al. (2003) defined cognitive failures as problems of 
memory (e.g. forgetting where you put things), attention (e.g. failures of 
concentration), or action (e.g. making an unintended action). Cognitive failure is a 
term that has been broadly used to encompass a range of errors, and represents a 
slip in normal functioning, rather than a failure occurring due to lack of ability 
(Broadbent, Cooper, Fitzgerald, & Parkes, 1982). For example, forgetting to 
complete a routine task at work that would normally be handled efficiently would 
be considered a cognitive failure, compared to being unable to complete a task due 
to lack of necessary skills (failure of ability). Whilst everyday cognitive failures for 
the most part have a relatively benign, albeit frustrating outcome, in some 
instances they may result in more serious incidents, for example forgetting to turn a 
heater off, or crossing an intersection at a red light. Research has established some 
serious behavioural consequences arising from cognitive failures, including absent-
minded shop lifting (Reason & Lucas, 1984), car accidents (Larson & Merritt, 1991), 
and other accidents (Larson, Alderton, Neideffer, & Underhill, 1997).  
Prospective memory and retrospective memory are processes prone to cognitive 
failures. Retrospective memory is involved with remembering previously learned 
information, and is historically a well-studied concept; many standard recall and 
recognition tasks are dependent on retrospective memory (Crawford, Henry, Ward, 
& Blake, 2006). Prospective memory frequently described as ‘remembering to 
remember’, is involved with memory for future intentions. Whilst prospective 
memory has only more recently received attention, it is vital for making future 
actions and plans, and is a critical feature for the completion of many everyday 
tasks (Ellis & Kvavilashvili, 2000). Whilst prospective memory and retrospective 
memory are distinct concepts, they interact in the day-to-day memory required to 
live independently (Crawford & Smith, 2003). For example the simple task of 
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needing to stop at a pharmacy and pick up medication, requires both prospective 
memory (remembering to stop) and retrospective memory (remembering what you 
need to buy).  
The impact of benzodiazepines on memory is highly researched; a general 
detrimental effect occurs, but the many types of memory processes are 
differentially affected by benzodiazepines (Barker et al., 2003; Rich, Svoboda, & 
Brown, 2006). The varying models of memory that are common in the literature 
make summarising the research difficult. A review by Buffett-Jerrott and Stewart 
(2002), indicates there are minimal benzodiazepine induced effects on short-term 
memory, with a more significant deficit in long-term memory. Within the construct 
of long-term memory, benzodiazepine use appears to impair explicit memory 
(conscious effortful memory, and participant is aware that testing is occurring), and 
have a time and dose dependent effect on implicit memory (outside of conscious 
awareness, and participant is not aware that testing will occur). Buffett-Jerrott and 
Stewart (2002) suggest that future memory studies need to focus on measures 
more applicable to everyday memory. 
The effect of benzodiazepines on retrospective memory has been well studied using 
recall and recognition tasks. Whilst benzodiazepines impair retrospective memory, 
this impairment only occurs for information learned after drug administration, 
which is often referred to as anterograde memory/amnesia (Barker et al., 2003). 
Benzodiazepines seem to impair the acquisition process of learning new 
information, by disrupting the ability to form new associations between events, and 
impairing the consolidation phase of new memories (Beracochea, 2006).  
Despite the enormous quantity of literature examining benzodiazepines and 
memory, the research focusing on prospective memory is scarce. An exploratory 
study by Rich et al. (2006), examined the effect of a single dose of diazepam 
compared to placebo, on retrospective and prospective memory, sustained 
attention, and subjective arousal. In this exploratory study, one naturalistic 
prospective memory task was hidden amongst several retrospective memory tasks. 
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The prospective memory task required participants, upon receiving a verbal cue, to 
request a personal belonging taken from them earlier. Retrospective memory tasks 
included word recall and digit span tasks. Results found expected deficits in 
retrospective memory tasks for the diazepam users. In the prospective memory 
tasks the diazepam group required more reminders to request their hidden 
belonging than the placebo group (d=0.65). Despite associations between 
prospective memory, retrospective memory, and arousal measures, the authors 
conclude that there are likely independent effects of diazepam on prospective 
memory. However, only one prospective memory task was used in this study, so 
generalisability cannot be assumed. At the time of this study, the authors were the 
first to examine the effect of benzodiazepines on prospective memory, and since 
that time there seems to be no substantial published studies looking at this area.  
Summary 
Experience of safety incidents can be understood as a continuum of outcome 
severity. Benzodiazepine use has been shown to be associated with three incident 
types: major accidents, minor injuries, and cognitive failures. Whilst major accidents 
are the incident with the most serious outcome, each of these incident types can 
impact on a person’s wellbeing. Understanding how chronic benzodiazepine use 
uniquely effects each of these incident types will help to clarify the full range of 
consequences of benzodiazepine use. 
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CHAPTER 5: THESIS INTRODUCTION AND RATIONALE 
Theoretical Summary and Rationale 
Benzodiazepines are a group of commonly prescribed medications that are used for 
a wide variety of reasons, such as preoperative anaesthesia, anxiety, sleep 
disorders, alcohol withdrawal, and epilepsy. As a class of drugs, benzodiazepines 
vary considerably in their potency, and the speed at which they are metabolised 
and eliminated from the body. The considerable variation in half-life and potency is 
an important consideration in the selection of which benzodiazepine will be chosen 
to treat a condition. However, it is also one of the main difficulties in reconciling 
benzodiazepine research; dose and type of benzodiazepine studied varies greatly, 
as do their psychomotor effects. The conversion to a diazepam equivalent dose in 
the current thesis, allows comparisons to be made across the varying types and 
dosages of benzodiazepines.  
It is well established that during short-term use of benzodiazepines, there are a 
range of side-effects with deleterious effects on safety, including sedation, 
confusion, dizziness, and memory problems. For these reasons, patients are 
commonly urged to use caution when first taking benzodiazepines, especially when 
undertaking cognitively demanding activities, such as driving. However, the ongoing 
risk associated with longer-term benzodiazepine use remains less researched. 
Meta-analyses have found ongoing benzodiazepine use negatively effects a range of 
cognitive areas, in both current users (Barker et al., 2004a), and those who have 
ceased use (Barker et al., 2004b). Making clear recommendations about long-term 
use of benzodiazepines is also complicated by the differential development of 
tolerance to particular aspects of these medications (Vinkers & Olivier, 2012). The 
relatively quick development of tolerance to many of the therapeutic effects, in 
combination with the potential for dependence, has led to clinical 
recommendations that suggest benzodiazepines are used at the lowest dose, for 
the shortest time period possible (National Health and Medical Research Council, 
1991; Royal Australian College of General Practitioners, 2000). 
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Despite recommendations limiting the use of benzodiazepines being in place for 
over 35 years, there is evidence that use remains widespread and often long-term. 
Whilst overall benzodiazepine prescription appears to have plateaued (Stephenson 
et al., 2013), over 7 million benzodiazepine scripts are written in Australia each year 
and research suggests that quantity per script may be increasing (Islam et al., 2013). 
Long-term use has also been shown to regularly occur, although in the past 5-10 
years this has not been re-reviewed. 
A review of the benzodiazepine literature reveals the populations studied are 
usually young, healthy, benzodiazepine-naïve males. This is a group that is clearly at 
odds with the average benzodiazepine user who is more likely to be an older, 
anxious female, using for an extended period of time (Neutel, 2005; Nordfjaern et 
al., 2014; Olfson et al., 2015). This thesis aims to move away from the typical 
benzodiazepine research that examines brief dosing regimens in healthy individuals. 
Instead, the aim is to examine benzodiazepine use as it naturally arises in the 
Australian community; with varying levels of chronicity, and occurring amongst a 
range of other confounding variables. 
A large body of the research to date has examined the relationship between 
benzodiazepines and driving safety. Driving is an everyday task with a large 
psychomotor requirement, and any adverse effects caused by benzodiazepines 
could have catastrophic consequences. The risk of driving after using 
benzodiazepines has been equated to a similar level of risk as driving with a blood 
alcohol concentration of 0.05-0.08% (Hels et al., 2011). Much of the research 
examining the association between benzodiazepines, and traffic and other 
accidents, has relied on data obtained from medical services. Conversely, research 
by Wadsworth and colleagues (Simpson et al., 2005; Wadsworth, Moss, et al., 2003; 
Wadsworth et al., 2005) recognised that there is more often a continuum of 
accident severity, including; cognitive slips or errors, minor injuries, and more major 
accidents requiring medical attention. This research aims to extend that completed 
Chapter 5: Thesis Introduction and Rationale | 56 
 
 
 
in the United Kingdom to an Australian context, by examining a full range of 
incident severities.  
It is also important to recognise that whilst benzodiazepines are commonly 
prescribed and used appropriately, they are also frequently used illicitly for 
intoxication purposes (Darke, Topp, & Ross, 2002; Fry & Bruno, 2002). People who 
inject drugs (PWID), commonly use benzodiazepines to reduce the symptoms of 
opiate withdrawal, for their sedative and hypnotic effects, or for the synergistic 
effects when combined with other depressants. PWID are known to be a risk-taking 
population (Stafford & Burns, 2014), with high mortality (Mathers et al., 2013). It is 
important to consider how benzodiazepines independently contribute to safety in 
PWID, beyond the impact of other drug use and other risk-increasing factors. 
Reviewing the research to date guides the direction for the current studies. Firstly, 
in 2014 there were almost 6.5 million scripts dispensed for a population of 24.5 
million (Department of Health, 2015), which demonstrates the pervasiveness of the 
use of benzodiazepines and the importance in understanding how benzodiazepine 
use effects the everyday safety of consumers. To fully understand safety 
consequences, it is necessary to focus not just on serious accidents, but to also 
examine the more minor incidents that may occur. Secondly, research must focus 
on the chronicity of benzodiazepine use as it occurs in the community, rather than 
focusing on naïve users, or only brief benzodiazepine dosing regimens. Finally, the 
impact of benzodiazepines is complicated by many lifestyle factors, such as other 
drug use, health factors, and the attitudes and beliefs of the consumer; research 
must examine benzodiazepines within the context of these other factors. 
Understanding the experiences and views of current benzodiazepine users will help 
to inform quantitative research.  
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Aim & Research Questions 
The aim of this research is to examine the objective and subjective associations 
between ongoing benzodiazepine use and safety. The research aims to explore the 
relationship between benzodiazepine use, and a continuum of different incident 
severities, in both a general, and high risk (people who inject drugs) population 
sample. Controlling for demographic, health, and drug use factors will allow the 
unique effects of benzodiazepines to be determined. This research also aims to 
conduct a qualitative exploration of the experiences and beliefs of current 
benzodiazepine users, in relation to their well-being and safety, which will 
complement the objective data obtained. 
Research questions 1.1 and 1.2: The Effect of Benzodiazepine use on Safety: 
 What are the associations between ongoing benzodiazepine use and 
various incident types including; 
I. Major accidents – non-traffic related accidents requiring medical 
attention 
II. Minor Injuries – non-traffic related, non-venous injuries that did 
not require medical attention 
III. Cognitive Failures – prospective or retrospective memory 
problems 
IV. Traffic accidents – in which damage to person or property 
occurred 
V. Close calls – where a traffic accident was narrowly avoided 
 Is benzodiazepine use associated with each of the incident types listed 
above in the same way, or are some incident types more susceptible to 
benzodiazepine use? 
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Research Question 2.1 and 2.2: Dose, duration and frequency of benzodiazepine 
use: 
 What association does chronicity of benzodiazepine use have with each 
incident type? 
 Is experience of incidents associated more strongly with dosage, or pattern 
(duration and frequency) of benzodiazepine use? 
Research Question 3.1 and 3.2: Benzodiazepine use in people who inject drugs 
(PWID): 
 Following on from research questions 1.1 and 1.2, in PWID, what are the 
associations between benzodiazepine use, and major accidents, minor 
injuries and cognitive failures? 
 What other alcohol or drug use is associated with major accidents, minor 
injuries, and cognitive failures in PWID? 
Research Question 4.1, 4.2 and 4.3: Subjective experience of benzodiazepine side-
effects:  
 What do regular consumers know about the side-effects of 
benzodiazepines? 
 From what sources is information about side-effects obtained? 
 What side-effects do consumers detect and does this change over time? 
Research Question 5.1, 5.2 and 5.3: Perception of impairment to driving ability: 
 Do benzodiazepine consumers detect any impairment to their driving ability 
when first using benzodiazepines? 
 Does any impairment change over time as benzodiazepine use progresses? 
 Do people take any precautions regarding benzodiazepine use and driving? 
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Research Question 6: General Worries and Concerns: 
 What are the general worries and concerns that regular benzodiazepine 
consumers experience (related to their benzodiazepine use) 
Research Design 
With the aim of answering these research questions, data were obtained from two 
surveys: 
Survey 1: The ‘Benzodiazepine, Health, and Driving’ survey was constructed with the 
specific aim of providing data for this research. The survey, shown in the appendix, 
was an online survey, examining a general population sample, recruited through a 
range of advertising sources. Participants reported their lifetime benzodiazepine 
use and their experience of varying types of safety incidents over the past 12 
months. Data was also collected for a range of potentially confounding factors such 
as demographic factors, other drug use, and mental and physical health status. Data 
obtained from this study is aimed at answering research questions 1, 2, 4, 5, and 6. 
Survey 2: With the aim of answering research question 3, data were taken from 
relevant sections of the Illicit Drug Reporting System (IDRS), an Australian drug 
monitoring system. This well-known, annual survey recruits individuals over 18 
years of age, who have injected an illicit drug in the preceding six months. Data was 
taken from the 2009 and 2010 completions of the IDRS, with 2010 data being 
excluded from those who had completed the survey in both years.  
Organisation 
Each of the three main research areas investigated in this thesis are discussed in the 
following three chapters.  
Chapter 6 examines the self-reported safety experience of chronic benzodiazepine 
users. The association between varying levels of benzodiazepine chronicity and a 
range of incident types was explored (Research Question 1 and 2). The survey 
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approach used in this study allowed benzodiazepine use to be explored within the 
context of other relevant variables. 
Chapter 7 retains the same area of focus as Chapter 6, but a more specific 
population group was studied; people who inject drugs (PWID). The aim of this 
study was to understand whether benzodiazepines uniquely contributed to risk of 
safety incidents in people who inject drugs (Research Question 3). 
Chapter 8 examines the personal experiences of regular benzodiazepine users. 
Specifically, the study focused on the safety and wellbeing of the respondents, and 
their experiences of benzodiazepine use (Research Question 4, 5, and 6).  
Chapter 9 comprises a general discussion and integration of the thesis. The chapter 
aims to explore how the subjective experiences of chronic benzodiazepine users 
informs, and corresponds with the more objective measures of incident experience. 
Suggestions are made as to how these findings can guide clinical practice. 
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CHAPTER 6: ACCIDENTS, INJURIES, AND COGNITIVE FAILURES IN CHRONIC 
BENZODIAZEPINE USERS 
 
Preface 
This chapter investigates chronic benzodiazepine use in the general population 
(Study 1). The focus of this chapter is to examine the association between safety 
incidents (Research Question 1) and benzodiazepine use of varying chronicity 
(Research Question 2). The association between benzodiazepine use and more 
serious accidents is well studied. However, Study 1 and 2 aimed to extend on 
research by Wadsworth and colleagues, by examining a full range of incidents, 
including cognitive failures, minor injuries, and accidents requiring medical 
attention. Data for the current chapter and Chapter 8 was obtained through the use 
of an online survey. By using a sample from the Australian general population the 
impact of regular benzodiazepine use can be explored as it naturally occurs, rather 
than a carefully crafted experimental drug regimen. Unlike much of the research 
that examines healthy, benzodiazepine-naïve individuals, this allowed 
benzodiazepines to be studied in the context of other confounding variables such as 
health factors and drug-use.  
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ABSTRACT 
Background 
Benzodiazepines are recommended to be used for short-term treatment, usually for 
less than four weeks, due to the high risk of dependence and psychomotor effects. 
Despite this, there is evidence that within Australia, benzodiazepines are still 
prescribed more frequently than clinical guidelines would recommend. The chronic 
use of benzodiazepines is relatively less studied compared to the acute effects. This 
paper aimed to investigate the associations between chronic benzodiazepine use 
and safety incidents. A continuum of incident types was examined including; major 
accidents, minor injuries, and cognitive failures.  
Method 
Data was collected from 129 participants using an online survey that ran from 2013-
2015. Participants were required to; be over 18 years of age, be an Australian 
resident, have used a benzodiazepine during the last 12 months, and have a current 
driver’s license. Data was collected for the safety incident outcome variables, and 
other confounding factors.  
Results  
From the reported benzodiazepine use, three categories of benzodiazepine 
chronicity were established; short-term (length of use ≤ year; daily/occasional 
frequency), intermittent (length of use > year; occasional frequency) and chronic 
(length of use > year; daily frequency). Even in the short-term user group, use 
spanned on average almost six months – far beyond the recommended four-week 
period. Compared to the general population, rates of accidents were elevated in the 
sample. Intermittent users were at significantly decreased risk of general accidents 
(Univariate OR= 0.32, 95%CI 0.11-0.94, p=0.037), retrospective memory problems 
(Univariate OR=0.16, 95%CI 0.06-0.71, p=0.007), and prospective memory problems 
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(Univariate OR= 0.21, 95%CI 0.04-0.60, p=0.012), compared to chronic, daily, 
consumers.  
Conclusion 
This study of benzodiazepine consumers in the general community identified 
chronic and risky patterns of benzodiazepine use. Chronic users were at a higher 
risk of safety incidents, suggesting that tolerance to potentially dangerous side-
effects does not occur. Benzodiazepine use that is chronic in frequency, duration, 
and dosage must remain a target for harm minimisation. 
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INTRODUCTION 
Benzodiazepines are a diverse class of drugs employed to treat many conditions, 
through their hypnotic, anxiolytic, anticonvulsive, and muscle relaxant properties. 
The short-term efficacy of benzodiazepines has led to their escalating use 
worldwide. However, concerns about the consequences associated with continued 
use have generated research and debate. The recent pharmaceutical rescheduling 
of alprazolam in Australia, to require tighter restrictions on prescription, storage, 
and dispensing, points to the magnitude of this issue (Department of Health, 2013). 
The effect of initial benzodiazepine use is well-established; with new users 
cautioned about psychomotor effects including drowsiness, decreased 
concentration, and motor impairment (Barker, Jackson, Greenwood, & Crowe, 
2003). The risk of side-effects, addictive potential, and reduced efficacy with 
sustained use (Ashton, 1995; Voshaar, Couvee, Van Balkom, Mulder, & Zitman, 
2006) has led to clinical guidelines that recommend benzodiazepines are used at 
the lowest dose, and for the shortest time period possible (National Health and 
Medical Research Council, 1991; Royal Australian College of General Practitioners, 
2000). Recommended use is suggested to be no more than four weeks, and longer 
term therapy is endorsed only when there is a clear rationale, when use is 
intermittent, and when other first line treatments have not been successful (Royal 
Australian College of General Practitioners, 2015b). 
Despite these restrictive recommendations, there is evidence that clinical practice 
differs. Examination of benzodiazepine dispensing in Australia from 1992-2011 
found that nearly 7 million benzodiazepine prescriptions were given through PBS, 
RPBS, and private scripts each year (Islam, Conigrave, Day, Nguyen, & Haber, 2013). 
Whilst more recently there has been some plateau in script numbers, usage remains 
at a high level and a shift towards private scripts is associated with the quantity per 
script increasing (Islam et al., 2013). Additionally, duration of use is often longer 
than clinically recommended. For example, an Australian longitudinal study of 337 
people aged over 75 years, examined participants at 3- and 4.5- years post intake 
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and found 16.6% of participants were using benzodiazepines at all three time points 
(Jorm, Grayson, Creasey, Waite, & Broe, 2000). Similarly, in 2006 a study of 
Tasmanian residential aged care facilities found that 62.4% of those reviewed 
(n=1,307) were also taking the same dose of benzodiazepines 12 months later 
(Westbury, Beld, Jackson, & Peterson, 2010). Rates of benzodiazepine use are 
increased because benzodiazepines are used not just for prescribed purposes, but 
are commonly diverted and used for intoxication (Australian Institute of Health and 
Welfare, 2011). In addition to this, it is also suggested “Australia is likely to have a 
large, but relatively hidden, population who unintentionally misuse 
benzodiazepines” (Royal Australian College of General Practitioners, 2015b: p.6). 
It is widely assumed that long-term users of medications become less sensitive to 
the effects of that medication, due to the development of tolerance. However, 
tolerance to benzodiazepines does not occur in a straightforward manner (Vinkers 
& Olivier, 2012). Tolerance to the hypnotic and anti-convulsant effects occurs 
quickly, whereas tolerance to the anxiolytic and amnestic effects occurs more 
slowly, if at all (Vinkers & Olivier, 2012). This means that research findings from 
studies of acute or brief dosing, cannot be extrapolated to chronic users. It cannot 
be assumed that regular benzodiazepine users are no longer at risk of cognitive and 
psychomotor impairment.  
Laboratory research has established there are cognitive deficits associated with 
long-term benzodiazepine use. A meta-analysis by Barker and colleagues (Barker, 
Greenwood, Jackson, & Crowe, 2004a) examined 13 studies that investigated 
chronic benzodiazepine users. Benzodiazepine use varied between 1-34 years, with 
a mean duration of 9.9 years usage. In 11 out of the 13 studies a control group was 
used, including people classified as; non-anxious, anxious, and previous 
benzodiazepine users. Twelve cognitive domains were studied; sensory processing, 
psychomotor speed, nonverbal memory, visuospatial, attention/concentration, 
speed of processing, general intelligence, working memory, problem-solving, verbal 
memory, motor control/performance and verbal reasoning. Current benzodiazepine 
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users were significantly impaired across all domains, compared to controls, with 
moderate to large effect sizes found (mean weighted effect size =-0.74, SD=0.25), 
and no 95% confidence interval spanned zero, suggesting the effects were 
statistically significant.  
A large body of benzodiazepine research has focused on driving ability. Given the 
known psychomotor impairment associated with benzodiazepines, including 
decreased attention, coordination, memory and wakefulness (Barker et al., 2003), it 
is important to understand the impact of benzodiazepines on this common, but high 
risk activity. Recent Australian guidelines conclude the literature on 
benzodiazepines and driving suggests a dose-proportionate risk of accidents, even 
with longer-term, stable dosing (Royal Australian College of General Practitioners, 
2015b). A recent meta-analysis found that benzodiazepine users were 60-80% more 
likely to be involved in traffic accidents (for case-control studies: 59%, pooled OR 
1.59; 95%CI 1.10-2.31, and for cohort studies: 81% pooled incidence rate ratio 1.81; 
95%CI 1.35-2.43), and importantly were 40% more likely to be ‘responsible’ for the 
accident (pooled OR 1.41; 95%CI 1.03, 1.94) (Dassanayake, Michie, Carter, & Jones, 
2011). The relative risk of driving after using benzodiazepines has been equated to 
driving with a blood alcohol concentration of 0.05-0.08% (Hels et al., 2011).  
Limitations with the Australian driving research to date is that much of it is 
laboratory based and thus lacks face-validity, or it examines the effects of once-off, 
or short-term benzodiazepine use. Furthermore, accident rates are commonly 
obtained from those apprehended for impaired driving, or presenting to medical 
services. As such, it is likely that lower level driving incidents are not accurately 
identified. These ‘near misses’, may include occasions of late braking, missing traffic 
signals, poorly timed lane changes and so on. There is a significant gap in the 
research looking at the association between traffic incidents of different severities, 
in long-term, Australian benzodiazepine users. 
Whilst driving is one task of particularly high cognitive demand, benzodiazepine 
users are likely to be at an increased risk of accidents in many aspects of their lives. 
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Research by Wadsworth, Moss, Simpson, and Smith (2005) explored the impact of 
psychotropic medication use on incidents of varying severities, using a randomised 
general population postal survey in the United Kingdom (n=7979). This group 
examined the safety of psychotropic medication users across a range of incident 
types both at, and outside of work, including; cognitive failures (everyday cognitive 
slips or errors), minor injuries not requiring medical attention, and major accidents 
requiring medical attention. Significant associations were found between 
benzodiazepine use and non-work injuries, with benzodiazepine users almost four 
and a half times more likely to experience a non-work injury, than non-medication 
users (OR 4.43, 95%CI 1.89-10.38). To further clarify findings, participants were 
classified by mental health status, and according to low or high presence of other 
risk factors associated with the incident type, such as physical health, age, and risk-
taking. In the presence of high risk factors, and a mental health condition, 
benzodiazepine use markedly increased the risk of non-work injuries (OR 16.18, 
95%CI 6.24-41.94) and cognitive failures (OR 18.09, 95%CI 6.17-53.04), compared to 
those not using any medication. The increased danger for those with high levels of 
other risk factors points to the importance of examining benzodiazepine use in the 
context of other lifestyle factors.  
Lower severity incidents, such as minor injuries and cognitive failures, are less 
frequently studied, firstly because their outcomes are usually less critical, and 
secondly because they are not naturally recorded through presentation to medical 
services. However, repeated lower severity incidents are likely to have their own 
effect on a person’s well-being. It is also suggested that an elevated number of 
cognitive failures may compound risk of higher severity incidents, depending on the 
context in which they occur (Simpson, Wadsworth, Moss, & Smith, 2005). For 
example, a cognitive failure whilst driving, such as a lapse in concentration, could 
lead to a much more serious accident. Examining a full range of incidents, allows a 
thorough investigation of the effects of benzodiazepines on safety. 
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Cognitive failures are defined as problems of memory, attention, or action; these 
failures are commonly occurring and usually benign, but can have serious 
consequences (Wallace, Kass, & Stanny, 2002). Cognitive failures normally reflect an 
error in typical functioning rather than a lack of ability (Wallace et al., 2002). 
Prospective memory errors (forgetting to perform a future event) and retrospective 
memory errors (forgetting previously learned information) are examples of 
cognitive failures. Retrospective and prospective memories interact in the everyday 
memory required to live independently (Crawford & Smith, 2003). For example, 
remembering to stop and buy groceries requires both prospective memory 
(remembering to stop) and retrospective memory (recalling what you needed to 
buy). A general detrimental effect of benzodiazepines on memory is well-
established, but distinct memory processes are differentially affected by 
benzodiazepines (Barker et al., 2003; Rich, Svoboda, & Brown, 2006). Experimental 
studies are indicative of a dose- and time- dependent effect of acute use of 
benzodiazepines on retrospective and prospective memory (Barker et al., 2003; Rich 
et al., 2006). However, there have been few studies examining the relationship 
between chronic benzodiazepine use, and retrospective and prospective memory 
failures.  
Despite the extent of the benzodiazepine literature, gaps remain in the research to 
date. Many studies look at young, healthy, benzodiazepine-naïve, males - a group 
far removed from the typical benzodiazepine using population. The current study 
examined a sample of Australian benzodiazepine consumers, with varying chronicity 
of use. The study design allowed the influence of other lifestyle characteristics, such 
as health, medications, and demographic factors to be examined. The aim of this 
study was to examine the impact of chronic benzodiazepine use on a range of 
incident types including cognitive failures, minor injuries, and major accidents, in 
both driving and general contexts.  
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METHOD 
Participants and Procedure 
Data was collected through an online survey run from 2013-2015. The survey was 
marketed to Australian residents through advertising in doctor’s surgeries, 
pharmacies, hospitals, and targeted social media. On completion of the survey, 
participants could choose to enter a prize pool for 1 of 3 $500 vouchers. 251 
participants initiated the survey with 122 participants excluded from the analysis 
(leaving a total pool of 129 participants). Unfortunately, high numbers of 
participants provided no data relevant to the outcome variables, before exiting the 
survey, and thus had to be excluded from the analysis. Initial survey questions 
excluded those who were under 18 years of age, had not used a benzodiazepine in 
the last 12 months, or who did not agree to informed consent statements. The 
survey took approximately 30 minutes to complete, and non-relevant sections were 
excluded based on initial screening questions, reducing the total time required. 
Major survey sections included questions on: demographic information, 
benzodiazepine use, licence and driving, road accidents, perceptions of 
benzodiazepines, general accidents, memory, alcohol and other drug use, health, 
and other medication use (antidepressants, antipsychotics, painkillers, and other 
psychotropic medications). Ethical approval was granted by the Tasmanian Social 
Sciences Human Research Ethics Committee (approval number H0012343). 
Outcome variables 
Data was collected on a range of different incident severities; outcome variables 
and relevant survey questions are listed below (Table 1). 
For traffic accidents, traffic close calls, and general accidents, the number of 
incidents experienced was recorded, and for each incident type, those reporting 
more than one incident were compared with those who reported none. Minor 
injuries were rated on a five-point frequency scale, with frequency of occurrence 
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ranging from ‘not at all’ through to ‘very frequently’. Those rating their experience 
of minor injuries as ‘quite’ or ‘very’ frequent, were classified as frequently 
experiencing minor injuries, and were compared to those who reported 
experiencing them less frequently. These questions were taken from the survey 
used by Wadsworth and colleagues (Wadsworth et al., 2005; Smith, Johal, 
Wadsworth, Davey Smith, & Peters, 2000). 
Table 1. Analysis Outcome Variables and associated Survey Question 
 
 
 
 
 
 
 
 
 
 
 
Day-to-day cognitive failures were assessed using the Prospective and Retrospective 
Memory Questionnaire (PRMQ: Smith, Della Sala, Logie, & Maylor, 2000). The 
PRMQ has 16 items, split equally between those measuring prospective memory 
problems (e.g., Do you decide to do something in a few minutes time and then 
forget to do it?) and retrospective memory problems (e.g., Do you forget something 
that you were told a few minutes before?). Problems experienced in the last 6 
months are rated on a 5-point scale ranging from ‘never’, to ‘very often’. Higher 
Outcome variable Survey Question(s) 
Driving Accident: Ever When you have been driving, how many road 
crashes have you ever been involved in? 
Driving Accident: 12 
months 
In the last 12 months when you have been 
driving, how many road crashes have you had? 
Driving Close Call: 12 
months 
In the last 12 months when you have been 
driving, how many close calls have you had (i.e. 
incidents that almost resulted in a crash but did 
not)? 
General Accident: 12 
months 
Thinking about the last 12 months, how 
many accidents have you had that required 
medical attention from someone else (e.g. a first 
aider, GP, nurse, or hospital doctor)? 
Minor Injury: 12 months In the last 12 months how frequently have you 
had minor injuries (e.g. cuts and bruises) that did 
not require medical attention from anyone else? 
Minor Injury: 1 month In the last month how frequently have you had 
minor injuries (e.g. cuts and bruises) that did not 
require medical attention from anyone else? 
Cognitive Failures Prospective Retrospective Memory 
Questionnaire (Crawford & Smith, 2003) 
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scores are indicative of memory problems. Confirmatory Factor Analysis of the 
PRMQ items indicates best fit for a three-factor model, with a general memory 
factor and two orthogonal factors; prospective and retrospective memory 
(Crawford & Smith, 2003; Rönnlund, Mäntylä, & Nilsson, 2008). Crawford and Smith 
(2003) provide normative data based on a general adult UK population (m=38.88, 
SD=9.15), and using Cronbach’s alpha there is strong internal consistency for the 
PRMQ (prospective scale α=0.84, retrospective scale α=0.80 and total scale α=0.89). 
Problem scores were defined as a score more than one standard deviation above 
the UK general population mean (prospective memory, scores ≥25.09; retrospective 
memory, scores ≥23.67).  
Measures 
The predictor variables were chosen due to their known association with decreased 
safety and/or their potentially confounding nature (Table 2). Each of these variables 
were used as a categorical variable, with cut-off scores chosen to denote ‘at risk’ 
versus ‘low-risk’ groups. This then allowed for the demarcation of a level at which 
an incident variable occurred, rather than simply providing information on the 
relationships between variables, as would have happened if the variables were 
treated in a continuous manner. All variables were binary with the exception of 
education level and benzodiazepine chronicity which had three levels to allow for 
greater clarification.  
The Short-Form Health Surveys are a group of scales providing a general measure of 
self-rated health. Whilst the SF-36 has been extensively tested and used within 
Australia, a briefer form, the SF-12 version 1 (Ware, Kosinski, & Keller, 1995) was 
chosen for brevity. The SF-12 rates 8 domains of health, across the last 4 weeks; 
physical functioning, role functioning related to physical problems, bodily pain, 
general health, vitality, social functioning, role functioning related to emotional 
problems, and mental health. These domains then combine to form a physical 
component summary (PCS) score and mental component summary (MCS) score. For 
each scale, scores range between 0-100, with higher scores equating to better 
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health. Norms from a South Australian population study were chosen as the most 
up-to-date and representative Australian norms (Avery, Dal Grande, & Taylor, 
2004). Those scoring more than 2 standard deviations below the mean were 
identified as the at risk group (physical component summary score ≤28.62 and 
mental component summary score ≤34.79). 
The Kessler Psychological Distress Scale (K-10: Kessler & Mroczek, 1994) is a 10-item 
questionnaire providing a global indication of anxiety and depression symptoms. 
Symptoms experienced over the past four weeks are rated on a 5 point scale 
ranging from ‘none of the time’ to ‘all of the time’. Whilst different cut-off scores 
are used within Australia, the convention set by the Australian Bureau of Statistics 
(2003) was followed, with total scores equal to or above 22, taken as an indication 
of high psychological distress. Andrews and Slade (2001) found that the K-10 
appropriately identified those classified by the Composite International Diagnostic 
Interview v2.0, as having any DSM-IV or ICD-10 anxiety or affective diagnosis (at a 
score of 22; sensitivity=0.55, specificity=0.95). 
Alcohol use was assessed using the AUDIT-C; a shortened version of the well-
established Alcohol Use Disorders Identification Test (Saunders, Aasland, Babor, de 
la Fuente, & Grant, 1993). The AUDIT-C is scored on a scale of 0-12, with each 
question scored between 0 and 4. Different cut-off scores are recommended for 
men (Bush et al., 1998) and women (Bradley et al., 2003), with hazardous drinking 
identified through a score of 3 or more in women (sensitivity=0.66, specificity=0.94) 
and 4 or more in men (sensitivity=0.48, specificity=0.99).  
The Severity of Dependence Scale (Gossop et al., 1995) was used to screen for 
benzodiazepine dependence. The SDS is a short 5-item scale that can be used to 
measure the degree of dependence on different types of drugs. Each SDS item is 
concerned with a psychological component of dependence. The diagnostic 
capability of the SDS was established in a sample of 100 regular benzodiazepine 
users (de Las Cuevas, Sanz, De Las Fuente, Padilla, & Berenguer, 2000). A score 
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above 6 corresponded with benzodiazepine dependence, as determined by the 
Composite International Diagnostic Interview (specificity=94.2%, sensitivity=97.9%). 
The use of cannabis or other illicit drugs in the past 12 months was recorded, and 
non-users were compared to those who had any level of use. Likewise major 
categories of prescribed medications were enquired about (including 
antidepressants, antipsychotics, opioids, other psychotropic medications, other 
painkillers, and over-the-counter codeine use), with those who had taken these 
medications in the past 12 months, compared to those who had not. Medications 
examined in the ‘other psychotropic category’ included; acamprosate, buspirone, 
buproprion, clonidine, doxylamine, disulfiram, lithium, melatonin, naltrexone, 
varenicline, zolpicolone, and zolpidem. 
To clarify benzodiazepine use, participants were questioned on the duration and 
frequency of their use. This information was then used to guide a post-hoc 
development of three different categories of benzodiazepine chronicity. In the 
survey participants were asked to indicate which answer best reflected their 
pattern of benzodiazepine use: use daily for – less than a month, greater than a 
month, or greater than a year; or use occasionally for – less than a month, greater 
than a month, or greater than a year. At the point of analysis this self-identified 
pattern was verified with information from other survey questions, including; start 
and finish date of using benzodiazepines, total days using benzodiazepines, and 
number of days in last month using benzodiazepines. In order to have sufficient 
numbers in each chronicity group, a pragmatic decision was made to combine some 
of these self-identified patterns of use into three groups with distinct patterns of 
chronicity. The three chronicity groups developed were as follows; short-term users 
(those who had been using daily or occasionally for less than one year), intermittent 
users (those who had used occasionally, for a period greater than one year) and 
chronic users (those who had used daily for a period greater than one year). The 
development of the chronicity groups was guided by the following considerations; 
(1) allocating sufficient participant numbers to each group, (2) promoting 
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homogeneity within each group and (3) allowing comparisons to be made across 
key elements of interest, namely the different effects of duration and frequency of 
use. An additional benzodiazepine variable was created focusing on monthly 
dosage. Reported doses for all benzodiazepine types were re-calculated to an 
equivalent diazepam dose (Drug and Alcohol Services South Australia, 2014); based 
on a defined daily dose of 10mg (World Health Organisation, 2011), a cut-off score 
of 300mg diazepam equivalent/month was used. 
Table 2. Rationale for Inclusion of Predictor Variables. 
Factor Categorisation 
(at risk, low risk)a 
Included because of previous association with: 
Age  30 years plus, 0-30 years Accidents (Bureau of Infrastructure, 2014; Simpson 
et al., 2005; Wadsworth, Simpson, et al., 2003) 
Injuries (Simpson et al., 2005; Wadsworth, Moss, et 
al., 2003; Wadsworth, Simpson, et al., 2003) 
Cognitive failures (Simpson et al., 2005; Wadsworth, 
Simpson, et al., 2003),  
Sex Male, Female Accidents (Bureau of Infrastructure, 2014; Simpson 
et al., 2005) 
Injuries (Pointer, 2013) 
Cognitive failures (Simpson et al., 2005),  
Highest level of 
Education  
< Grade 10, Grades 11-
12b or TAFE/trade, 
University Degree 
Accidents (Cubbin & Smith, 2002) 
Injuries (Cubbin & Smith, 2002) 
Cognitive failures (Wadsworth, Simpson, et al., 
2003; Weinborn, Woods, O'Toole, Kellogg, & Moyle, 
2011),  
Income 
(weekly)c 
≤$600/week, 
>$600/week 
Accidents (Cubbin & Smith, 2002) 
Injuries (Cubbin & Smith, 2002; Simpson et al., 
2005), 
Cognitive failures (Simpson et al., 2005; Wadsworth, 
Moss, et al., 2003; Wadsworth, Simpson, et al., 
2003),  
 
 
Employment 
Status 
Not employed, Part or 
Full-time employment 
Accidents (Australian Bureau of Statistics, 2011) 
Injuries (Simpson et al., 2005; Wadsworth, Simpson, 
et al., 2003) 
Cognitive failures (Simpson et al., 2005; Wadsworth, 
Simpson, et al., 2003),  
Relationship 
Status 
Non-partnered, 
Partnered  
Accidents (Wadsworth, Moss, et al., 2003) 
Injuries (Wadsworth, Moss, et al., 2003)  
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Factor Categorisation 
(at risk, low risk)a 
Included because of previous association with: 
Physical health 
problems  
SF8-PCSd cut-off ≤2SD 
population; ≤ 28.62, 
>28.63 
and 
Chronic health condition 
reported e, Nil chronic 
health condition 
Accidents (Simpson et al., 2005) 
Injuries (Simpson et al., 2005; Wadsworth, Moss, et 
al., 2003) 
Cognitive failures (Simpson et al., 2005; Wadsworth, 
Moss, et al., 2003) 
Mental health 
problems  
SF8-MCSf cut-off ≤2SD 
population; ≤  34.79, 
>34.80 
and 
Kessler-10g score;  
22-50,0-21  
Accidents (Hilton & Whiteford, 2010; Simpson et al., 
2005) 
Injuries (Simpson et al., 2005; Wadsworth, Moss, et 
al., 2003; Wadsworth, Simpson, et al., 2003) 
Cognitive failures (Simpson et al., 2005; Wadsworth, 
Moss, et al., 2003; Wadsworth, Simpson, et al., 
2003)  
Alcohol 
Consumption 
 
Risky drinking /AUDITh 
score; 
Women: 3-12,0-2 
Men: 4-12, 0-3 
Accidents (Bureau of Infrastructure, 2014; Movig et 
al., 2004; Simpson et al., 2005) 
Injuries (Burger, Lichtenstein, Hays, & Decker, 1990) 
Cognitive failures (Griffiths et al., 2012; Heffernan, 
Moss, & Ling, 2002) 
Any cannabis 
use 
Used in past 12 months, 
Nil use 
Accidents (Kelly, Darke, & Ross, 2004; Wadsworth, 
Moss, Simpson, & Smith, 2006) 
Injuries (Barrio et al., 2012; Wadsworth et al., 2006) 
Cognitive failures (Bartholomew, Holroyd, & 
Heffernan, 2010; Matthews & Bruno, 2011; 
Montgomery, Seddon, Fisk, Murphy, & Jansari, 
2012) 
Other Illicit 
Drug Use (E.g. 
Speed or 
Ecstasy) 
Used in past 12 months, 
Nil use 
Accidents (Kelly et al., 2004; Raes et al., 2008) 
Cognitive failures (Iudicello et al., 2011; Rendell, 
Mazur, & Henry, 2009) 
Antidepressant 
Use 
Used in past 12 months, 
Nil use 
Accidents (Chang et al., 2012; Wadsworth, Moss, et 
al., 2003; Wadsworth et al., 2005) 
Injuries (Wadsworth, Moss, et al., 2003; Wadsworth 
et al., 2005) 
Cognitive failures (Wadsworth, Moss, et al., 2003; 
Wadsworth et al., 2005) 
Possible Sedation (Australian Medicines Handbook, 
2015) 
Antipsychotic 
Use 
Used in past 12 months, 
Nil use 
Cognitive failures (Horia et al., 2006) 
Possible Sedation (Australian Medicines Handbook, 
2015) 
Opioid Use Used in past 12 months, 
Nil use 
Accidents (Hulse, English, Milne, & Holman, 1999; 
Kelly et al., 2004; Raes et al., 2008) 
Injuries (Majdzadeh et al., 2009) 
Cognitive failures (Terrett et al., 2014)  
Sedation (Australian Medicines Handbook, 2015) 
Other 
Psychotropic 
Usei 
Used in past 12 months, 
Nil use 
Accidents (Chang et al., 2012; Gustavsen et al., 
2008) 
Sedation (Australian Medicines Handbook, 2015) 
Over-the-
counter 
Codeine Use 
Used in past 12 months, 
Nil use 
Sedation (Australian Medicines Handbook, 2015) 
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Factor Categorisation 
(at risk, low risk)a 
Included because of previous association with: 
Other 
Painkillers 
Used in past 12 months, 
Nil use 
Sedation (Australian Medicines Handbook, 2015) 
Benzodiazepine 
Use 
Chronicity of use; Chronic 
use, Intermittent use, 
Short-term use  
and 
Monthly Dose; Equivalent 
diazepam dose; >301mg, 
0-300mg 
Accidents (Chang et al., 2012; Kelly et al., 2004; 
Movig et al., 2004) 
Injuries (Wadsworth et al., 2005) 
Cognitive failures (Barker, Greenwood, Jackson, & 
Crowe, 2004b; Rich et al., 2006; Wadsworth et al., 
2005) 
aPredictor variables were used a categorical variables, and were separated into ‘at risk’ and ‘low risk’ 
groups, based on findings and cut-off scores from previous literature. In the regression analyses, the 
‘low risk’ categories were the baseline group, and the ‘at risk’ categories were the comparison group. 
bIn Australia, Grade 11 students are normally 16-17 years of age, and are typically in their twelfth 
year of education. cThis weekly cut-off was chosen as it was the income range provided in the 
questionnaire most representative of the June 2014 poverty line for a single working adult of 
$509.53; if the income for a family unit is less than the applicable poverty line, they are considered 
to be in poverty (Melbourne Institute of Applied Economic and Social Research, 2014). This amount 
does not take into account the presence of other dependent family members. dShort-Form Health 
Survey-8 – Physical Component Score (Ware, Kosinski, & Keller, 1995). eThe following chronic 
conditions were specified: chronic pain, sleep apnoea, neurological conditions, chronic lung disease, 
depression, anxiety, substance dependence, another mental health condition, any other chronic 
condition. fShort-Form Health Survey-8 – Mental Component Score (Ware, Kosinski, & Keller, 1995) 
gKessler Psychological Distress Scale (K-10: Kessler & Mroczek, 1994). hAlcohol Use Disorders 
Identification Test (Saunders, Aasland, Babor, de la Fuente, & Grant, 1993. iOther psychotropic 
medications included: acamprosate, buspirone, buproprion, clonidine, doxylamine, disulfiram, 
lithium, melatonin, naltrexone, varenicline, zolpicolone, and zolpidem. 
Analysis 
Using SPSS (Version 22) univariate logistic regression was conducted to examine 
associations between various demographic, health factor, and drug use predictor 
variables, and the dependent measures; driving accidents (ever, 12 months), driving 
close calls, general accidents, minor injuries (12 months, one month), prospective 
memory problems, and retrospective memory problems. The predictor variables 
were categorical, divided into ‘at risk’ or ‘low risk’ classifications. For each variable 
the ‘low risk’ group was used as the baseline group in the analysis, and the ‘at risk’ 
group was used as the comparison group. Therefore, an odds ratio of >1, means 
that the outcome variable is more likely to occur in the comparison group 
compared to the baseline group. The exceptions to this classification system were 
the ‘education’ and ‘benzodiazepine chronicity’ variables which were used as 
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categorical three-level predictors, in order to capture the variation within the 
variable. The benzodiazepine chronicity variable was coded so that the baseline 
group was the category of key interest – the chronic users. This means that for this 
variable an odds ratio of <1 means that the safety incident was more likely to occur 
in the chronic user group. Due to the large number of predictor variables, the 
chance of Type I errors was high. Given that the current sample size was small, the 
decision was made to also run a bootstrapping analysis. Bootstrapping is a general 
resampling procedure and was used to aid in interpretation of results.  
To understand the unique effects of benzodiazepine use, a multivariate logistic 
regression analysis was run, using a hierarchical stepwise model. Due to high 
multicollinearity the following variables were excluded from the multivariate 
analysis; education, income, SF-12 mental component score, other painkiller use, 
and any chronic condition. Model 1 included the benzodiazepine chronicity variable 
only. Model 2 added demographic factors (age, sex, employment, partnered). 
Model 3 added health factor variables (SF-12 physical component score, Kessler-10) 
and Model 4 added the remaining drug use variables (AUDIT-C, cannabis use, other 
illicit drug use, antidepressant use, antipsychotic use, opioid use, other psychotropic 
use, over-the-counter codeine use and monthly benzodiazepine dose). This series of 
stepwise models allowed the exploration of both the unique effects of 
benzodiazepine on the outcome variables, and the effects in context of other key 
correlated variables. Due to a relatively low sample size, power in this study was 
affected. In order to aid identification of effects, results with a significance of <0.1, 
are reported on.  
RESULTS 
Sample Characteristics 
The mean age of participants (n=129) was 38.15 years (SD=13.47), with an age 
range from 18-72 years. Slightly over half of the participants were female (n=71; 
55%). The sample was quite highly educated with almost half having completed or 
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were completing a University degree (n=64, 55.2%), whilst almost a third (n=32, 
27.6%) had completed year 11 or 12, or a TAFE /trade course. Only 17.2% of the 
sample had completed less than year 10. The sample was evenly split between 
those in work (part or full-time) compared to those who were unemployed (n=64, 
50.0%). The most common income bracket reported by 19.3% of participants was 
$250-399/week ($13,000-20,799/year). While reported income ranged between a 
‘negative income’ up to a highest income bracket of $2000 or more/week, slightly 
over half the sample (n=61, 51.3%) fell below the poverty line (<$600/week). 
The average K-10 score within the sample was 24.48 (SD=9.59). Half scored above 
the K-10 cut-off score, suggesting high levels of psychological distress (n=51, 52%). 
Similarly, the average SF-12 mental component score was 37.27 (SD=13.43), with 
half scoring more than two standard deviations below the population mean (n=51, 
50%). Physical health, as measured by the SF-12 physical component score, was 
close to the general population mean, with an average score of 45.81 (SD=12.39); 
only a small percentage of participants scored more than two standard deviations 
below the population mean on the PCS (n=11, 10.8%). 
Use of medication in the sample was high. In addition to benzodiazepines, over a 
third of the group had used at least one antidepressant in the past 12 months 
(35.7%), with the most common preparations being sertraline and escitalopram. 
Antipsychotics were used by 14% of the sample; most commonly used were 
quetiapine (10.9%) and olanzapine (3.1%). Almost a quarter of the participants 
reported using opioids (24%), most commonly prescription-only codeine (16.3%). 
Similar proportions had used other types of psychotropic medications (22.5%), with 
the active ingredients most commonly used being doxylamine (7%) and zolpidem 
(8.5%).  
Most of the sample reported using benzodiazepines for sleep only (n=59, 45.7%) or 
anxiety only (n=54, 41.9%), with only a small group reporting use for other or 
multiple reasons (n=16, 12.4%). Using the Severity of Dependence Scale (Gossop et 
al., 1995) to screen for benzodiazepine dependence revealed that most of the 
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participants (n=80, 68.4%) scored between 0-6 (i.e. below problem level), with 
31.6% (n=37) of the sample scoring above 7, thus indicating possible 
benzodiazepine dependence (de Las Cuevas et al., 2000). 
The benzodiazepine chronicity categories were developed according to participant’s 
self-reported pattern of use; short-term, intermittent, and chronic. Table 3 explores 
the variation between each category of chronicity on key variables. Short-term 
users, self-identified as having used benzodiazepines for less than one year were, as 
expected, the group with the shortest duration of use in the sample. Despite this, 
on average, their duration of use was far beyond the recommended four-week 
period. On average they used benzodiazepines half the days in a month, and their 
total monthly dose was comparable to 10mg of diazepam per day. Intermittent 
users showed a similar pattern to the short-term users, regarding days used per 
month and total dose per month, but as expected their average duration of use was 
significantly longer, at 6.5 years. Chronic benzodiazepine users, however, were a 
vastly different group; their average use was over 8 years. Although, this number 
may have been inflated by the use of multiple benzodiazepines, and there may have 
been periods of non-use during this time. In the chronic users, the average ‘total 
days used per month’ was greater than 30; as this figure was additive across 
different preparations, this indicates the use of multiple benzodiazepines 
simultaneously. The average total dose per month used by the chronic group was 
over 900mg (diazepam equivalent). Whilst a monthly dose of this size could feasibly 
be achieved by a standard 10mg three times a day for anxiety, current clinical 
guidelines would not support this high level of use for the long periods identified by 
this group. Univariate results are presented in Tables 4, 5, and 6, and Multivariate 
results in Tables 7, 8, and 9.
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Table 3. Analysis of Variance for Key variables of interest across each Benzodiazepine Chronicity Category 
 
 
Short-term 
Use (SD)a  
N=24 
Intermittent 
Use (SD)  
N=55 
Chronic Use 
(SD)  
N=50 
ANOVA Significant comparisonsb 
Reason for Benzodiazepine Use 
Sleep only n=9 (37.5%) n=27 (49.1%) n=23 (46.0%) n/a  
Anxiety only n=12 (50%) n=20 (36.4%) n=22 (44%) n/a  
Other/multiple reasons n=3 (12.5%) n=8 (14.5%) n=5 (10%) n/a  
Benzodiazepine Use 
Mean Length of Use - daysc 168.8 (243.8) 2416.7 (3840.8) 3053.9 (3605.1) F(2,126)=6.05, p=.003 ST<Int, p=.020; ST<Chr p=.002 
Mean Total days used per 
month 
14.9 (17.7) 10.3 (13.9) 38.1d (45.6) F(2,115)=10.65, p<.001 ST<Chr, p=.013; Int<Chr, p<.001 
Mean Total Dose per monthe 229.5f (381.9) 231.6 (432.1) 919.3 (1816.4) F(2,115)=4.81, p=.010 Int<Chr, p=.013 
Other variables of interest 
Mean Age 30.9 (11.9) 39.1 (14.7) 40.5 (11.7) F(2,126)=4.64, p=.011 ST<Int, p=.031; ST<Chr, p=.010 
Mean AUDIT-Cg; Average Score 4.1 (3.6) 4.2 (3.2) 3.5 (3.5) F(2,102)=0.54, p=.587 - 
Mean Kessler-10h 27.1 (8.3) 21.5 (8.3) 27.8 (10.5) F(2,95)=5.35, p=.006 Int<Chr, p=.008 
Mean SF-12 MCSi 33.0 (11.9) 40.5 (13.1) 35.6 (14.0) F(2,99)=2.60, p=.079 - 
Mean SF-12 PCSj 47.4 (11.3) 47.6 (12.3) 43.1 (12.8) F(2,99)=1.54, p=.219 - 
Mean GP visits (past year) 9.1 (8.8)k 6.7 (5.2) 12.4 (8.4) F(2,107)=7.002, p=.001 Int<Chr, p=.001 
Mean Average score BZD SDSl 4.2 (4.1) 2.6 (3.3) 7.3 (4.4) F(2,114)=18.87, p<.001 ST<Chr, p=.008; Int<Chr, p=<.001 
Benzodiazepine chronicity categories: Short-term Use (using benzodiazepines daily or occasionally for less than one year), Intermittent Use (using benzodiazepines occasionally for greater than one year), Chronic Use (using benzodiazepines daily for greater than one year).  
aSD=Standard Deviation. bTukey’s method used for post-hoc tests. ST=short-term group. Int=intermittent group. Chr=Chronic group. cCalculated using start and finish dates for each benzodiazepine, therefore does not represent the number of days on which benzodiazepines have 
been consumed, but rather the period of time that benzodiazepines have been used for. Additionally, this total is additive across each benzodiazepine type used. dThis is a cumulative sum across all benzodiazepine types, therefore the mean of 38.13 for chronic users reflects the use 
of more than one benzodiazepine a day. eConverted to an equivalent diazepam dose in milligrams. fThis monthly amount is equivalent to 7.63mg a day, which is less than the 10mg defined daily dose. gKessler-10 (Kessler & Mroczek, 1994); total scores ≥22, were taken as an 
indication of high psychological distress. hDifferent cut-off scores are recommended for men (Bush et al., 1998) and women (Bradley et al., 2003), on the AUDIT-C with hazardous drinking identified through a score of 3 or more in women (sensitivity=0.66, specificity=0.94) and 4 or 
more in men (sensitivity=0.48, specificity=0.99). iMental Component Score; scores range between 0-100, with higher scores equating to better health. jPhysical Component Score: scores range between 0-100, with higher scores equating to better health kIn this group there was a 
participant who identified as having 300 GP visits in the past year. This extreme outlier was removed as it severely inflated the result for this short-term user group, and was most likely an error during survey completion. lBZD=benzodiazepine, SDS=Severity of Dependence Scale. A 
score above 6 corresponds with benzodiazepine dependence, as determined by the Composite International Diagnostic Interview (specificity=94.2%, sensitivity=97.9%).
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Traffic Incidents 
In the sample, 93.7% had driven a car, with 90.7% (n=107) having a full license (car, 
motorbike, taxi or heavy), and 7.6% of the sample having only a learners, 
provisional or restricted licence. A large proportion of the group (n=75, 65.2%) had 
held their longest licence for over 10 years. Half the sample (n=58, 50.9%) reported 
they usually drove every day of the week, with the average estimated distance 
driven each week being 206.27kms (SD=288.58; range 3-2000kms). Most of the 
sample reported that they had never lost their licence due to a traffic offence (n=90, 
81.8%), nor had lost any demerit points in the last 12 months (n=83, 74.8%).  
Road Traffic Accident – Ever 
Half of the sample reported experiencing at least one road traffic accident, whilst 
the driver, in their lifetime (50.87%; 95%CI 41.82-59.87). The intermittent 
benzodiazepine use group were twice as likely to report ever experiencing an 
accident, compared to daily chronic users. People with a chronic health condition 
were almost three times more likely to have ever experienced an accident. Those 
who were below the poverty line, and/or unemployed were less likely to report 
ever experiencing a road traffic accident, which may be a reflection of time spent on 
the road and peak hour driving. People who had completed year 11 & 12 or a 
TAFE/trade course, were half as likely to ever experience a traffic accident 
compared to those who had gone to university. In the multivariate analysis 
examining lifetime experience of traffic accidents, only 34.8% of the variance was 
explained by the final model. This was not unexpected given that most of the 
predictor variables were focused on events occurring in the last 12 months or less, 
in comparison to the outcome variable which assessed lifetime traffic accident 
occurrences. Despite this, the significance of benzodiazepine use increased as more 
factors were added in, and in the final model, the intermittent user group were 
more than four times more likely than the chronic user group to report ever 
experiencing a traffic accident. In model 4 there was a negative association with 
being unemployed, use of other psychotropics, and ever experiencing a traffic 
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accident. Those who had used antipsychotics were five times more likely to have 
ever experienced a traffic accident. 
Road Traffic Accident – 12 months  
In this sample 14.91% reported experiencing a traffic accident whilst the driver, in 
the last 12 months (95%CI 9.52-22.59). Univariate analysis revealed a significant 
effect of benzodiazepine dosage. People using greater than 300mg diazepam 
equivalent/month of benzodiazepines were up to three times more likely to report 
a traffic accident in the last 12 months. Those reporting a traffic accident in the last 
12 months were also significantly more likely to be under 30 years of age, to report 
other illicit drug use, to use other painkillers, or be unpartnered. In the multivariate 
analysis, 61.8% of the variance was explained by model 4, and the only significant 
predictor was the use of other psychotropics, which was negatively associated with 
the risk of an accident in the past 12 months.  
Traffic Near Misses.  
Near miss traffic incidents were reported by 38.60% of the sample (95%CI 30.17-
47.77). Univariate analysis showed associations between those who were under 30 
years of age, unpartnered, those reporting mental health problems, high 
psychological distress, cannabis use and illicit drug use, and an increased incidence 
of traffic near misses. The final multivariate model explained 61.2% of the total 
variance. Significant predictors in this final model included being female, under 30 
years, unemployed, or unpartnered. 
Non-traffic General Incidents: 
General Accidents.  
General accidents were experienced by 22.94% of the sample (95%CI 16.05-31.67). 
Percentages described in the next section, refer to the percentage of the sample 
reporting each experience. The most common type of non-traffic accident, reported 
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by 7.8% of the sample, was a ‘slip, trip or fall on the same level’, with the area of 
the body most commonly reported to be injured being the hands (9.3%), followed 
by the head (7%). The types of damage most commonly reported was bruising 
(10.9%), followed by lacerations (open cuts and wounds; 10.1%). Most accidents 
were then treated at the Emergency department (11.6%) or by the GP (10.1%). 
Chronic daily benzodiazepine use, was associated with significantly higher rates of 
general accidents, compared to those the intermittent user group. Other variables 
significantly associated with increased risk of general accidents included being 
under 30 years of age, being unpartnered, having mental health problems, or high 
psychological distress, illicit drug use, and use of over-the-counter codeine, or 
prescribed painkillers. Notably the use of antipsychotics was associated with a 
seven fold greater risk of accidents. The final multivariate model explained 68.7% of 
the variance in the sample. Chronic use of benzodiazepines remained a significant 
predictor throughout each model. In the final model, being under 30 years, being 
unpartnered, using antipsychotics, or over-the-counter codeine, were significant 
predictors of increased general accidents. The use of other psychotropic medication 
was inversely associated with general accidents.  
Frequent Minor Injuries – 12 months 
In this sample, 16.07% had experienced frequent minor injuries over the last 12 
months (95%CI 10.41-23.98). There were few significant predictors in the univariate 
analysis; significant associations were found between being younger, unpartnered, 
having mental health problems, the use of other psychotropics, and having frequent 
minor injuries. The only significant predictor in the multivariate analysis, was being 
under 30 years of age, with 50.2% of the variance explained by the final model.  
Frequent Minor Injuries – One month 
Only 8.18% (95%CI 4.36-14.82) of the sample experienced frequent minor injuries in 
the last month. Univariate analysis revealed those who were under 30 years of age, 
or used other psychotropic medications were at a significant risk of minor injuries 
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over the past month. There was a notable 7 times greater risk of recent minor 
injuries for those reporting psychological distress. The multivariate analysis was not 
able to be run due to the small number of participants reporting problems over the 
last month. 
Cognitive Failures 
Cognitive failures were assessed using the Prospective Retrospective Memory 
Questionnaire (Smith, Della Sala, Logie, & Maylor, 2000), which allows two scores to 
be calculated measuring prospective memory and retrospective memory.  
Prospective Memory Problems 
In this group 19.61% experienced prospective memory problems; defined as scoring 
≥1SD above the population mean (95%CI 13.07-28.35). Chronic daily 
benzodiazepine use, was associated with a significantly increased risk of prospective 
memory problems compared to those who used long-term but only intermittently. 
Taking more than 300mg diazepam equivalent of benzodiazepines per month was 
also associated with prospective memory problems. Reporting poor mental health 
was significantly associated with almost a 14 times greater risk, and psychological 
distress, with a 6 times greater risk, of prospective memory problems. Other 
significant predictors in the univariate model included being under 30 years, being 
female, and using antidepressants, or antipsychotics. Surprisingly, there was an 
inverse association between using over-the-counter codeine and prospective 
memory problems. In the multivariate analysis, the final model explained 59.3% of 
the variance. Chronic benzodiazepine use remained a significant predictor in all but 
the final model. Being over 31 years old, and the use of over-the-counter codeine 
remained negatively associated with prospective memory problems in the final 
model.  
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Retrospective Memory Problems.  
Retrospective memory problems (scores ≥1SD above the population mean) were 
reported by 22.47% of this sample (95%CI 15.04-22.47). Chronic benzodiazepine use 
was associated with a significantly increased risk of retrospective memory problems 
compared to intermittent use. Other associated predictors in the univariate analysis 
included being female, unemployed, having mental health problems, high 
psychological distress, or using antipsychotics. In the multivariate analysis, 75% of 
the variance was explained by the final model, and chronic benzodiazepine use 
remained associated with a higher risk of retrospective memory problems. Being 
female, unemployed, and using opioids were associated predictors in the final 
model. 
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Table 4. Univariate Logistic Regression Predicting Likelihood of Traffic Incidents 
*Table Interpretation: The variables listed are the comparison group. This means that the percentages reported are the percentages in the comparison group that either did or did not experience an event. Regarding the odds ratio (OR), an OR>1 means that the event (e.g. accident) was more likely in the comparison group, an OR<1 means it was more likely in the baseline 
group. For example, as reported above, of those who had not experienced a traffic accident in the last 12 months, 20.2% had used ‘other illicit drugs’, for those who had experienced an accident, 46.2% had used ‘other illicit drugs’. Those who had used ‘other illicit drugs’ were 3.38 times more like to experience an accident than those who had not. aSF-12 Physical Component 
Score, bSF-12 Mental Component Score, cKessler-10, dAlcohol Use Disorders Identification Test-C, eOver-the-counter, fIn the benzodiazepine chronicity category, the chronic benzodiazepine group was used as the reference category and the intermittent and short-term groups were compared to this. gA monthly benzodiazepine (BZD) dose cut-off score of 300mg (diazepam 
equivalent) was used. This is equivalent to the defined daily dose of 10mg/day (World Health Organisation, 2011) being used daily for a month. 
Predictor Variables 
Comparison Groups 
Road Traffic Accident – Ever  
(Have ever had an accident, whilst the driver) 
n=114 
Road Traffic Accident – last 12 months 
(Have had accident in last 12 months, whilst the driver) 
n=114 
Traffic Near misses – last 12 months 
(A traffic incident almost resulting in a crash, whilst the driver) 
n=114 
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Demographic characteristics                
Age: ≥31 years  66.1 58.6 0.73 (0.412) 0.435 0.34-1.56 67.0 35.3 0.27 (0.017) 0.010 0.09-0.79 81.4 31.8 0.11 (<0.001) 0.001 0.04-0.26 
Male 39.3 44.8 1.26 (0.549) 0.562 0.60-2.65 43.3 35.3 0.71 (0.539) 0.512 0.24-2.09 47.1 34.1 0.58 (0.171) 0.171 0.27-1.27 
Education:   (0.249)     (0.710)     (0.610)    
 - University (baseline group) 50.0 64.7    56.7 61.5    54.5 62.2    
- Year 11/12 or Tafe/trade 30.8 17.6 0.44 (0.098) 0.522 0.17-1.16 25.6 15.4 0.55 (0.477) 0.754 0.11-2.82 24.2 24.3 0.88 (0.797) 0.309 0.33-2.32 
- < Year 10 19.2 17.6 0.71 (0.516) 0.440 0.25-2.00 17.8 23.1 1.20 (0.808) 0.288 0.28-5.05 21.2 13.5 0.56 (0.320) 0.500 0.18-1.76 
Income (<$13,000) 58.0 40.0 0.48 (0.067) 0.067 0.22-1.05 50.0 40.0 0.67 (0.475) 0.463 0.22-2.03 45.5 53.8 1.40 (0.406) 0.449 0.63-3.10 
Unemployed 61.8 36.2 0.35 (0.007) 0.007 0.16-0.75 51.0 35.3 0.52 (0.236) 0.229 0.18-1.53 47.1 51.2 1.18 (0.678) 0.699 0.55-2.51 
Unpartnered 51.9 62.5 1.54 (0.268) 0.271 0.72-3.32 53.8 76.5 2.79 (0.093) 0.062 0.84-9.19 44.8 78.0 4.39 (0.001) 0.001 1.81-10.60 
Health factors                
Physical health Problems: PCSa 8.9 11.8 1.37 (0.646) 0.629 0.36-5.19 12.0 0.0 0.00 (0.999) 0.001 - 31.1 5.7 0.40 (0.266) 0.127 0.08-2.01 
Mental health Problems: MCSb 40.0 54.9 1.83 (0.146) 0.152 0.81-4.12 45.8 61.5 1.90 (0.296) 0.283 0.57-6.28 41.0 60.0 2.16 (0.075) 0.067 0.93-5.04 
Psychological Distress: K-10c 47.8 52.1 1.19 (0.680) 0.690 0.53-2.66 47.6 66.7 2.21 (0.225) 0.192 0.62-7.90 41.7 64.7 2.57 (0.034) 0.030 1.08-6.13 
Chronic Health Conditions 67.9 86.2 2.96 (0.023) 0.020 1.16-7.53 78.4 70.6 0.66 (0.484) 0.495 0.21-2.09 80.0 72.7 0.67 (0.369) 0.376 0.28-1.62 
Drug use                
Risky drinking: AUDIT-Cd 57.4 54.7 0.90 (0.784) 0.808 0.41-1.98 54.7 64.3 1.49 (0.503) 0.499 0.46-4.83 50.8 64.9 1.79 (0.173) 0.181 0.78-4.13 
Cannabis use 34.0 28.6 0.78 (0.564) 0.559 0.33-1.84 29.8 41.7 1.69 (0.409) 0.384 0.49-5.82 23.3 44.4 2.63 (0.033) 0.041 1.08-6.35 
Other Illicit Drug Use  21.3 26.0 1.30 (0.585) 0.589 0.51-3.34 20.2 46.2 3.38 (0.049) 0.034 1.00-11.37 16.7 35.1 2.71 (0.041) 0.033 1.04-7.06 
Antidepressant Use 37.5 39.7 1.10 (0.813) 0.808 0.52-2.33 36.1 52.9 1.99 (0.193) 0.188 0.71-5.63 35.7 43.2 1.37 (0.426) 0.434 0.63-1.37 
Antipsychotic Use 10.7 19.0 1.95 (0.222) 0.209 0.67-6.69 14.4 17.6 1.27 (0.732) 0.694 0.32-5.00 12.9 18.2 1.51 (0.439) 0.431 0.53-4.25 
Opioid Use 19.6 31.0 1.84 (0.166) 0.163 0.78-4.36 22.7 41.2 2.39 (0.113) 0.110 0.81-7.00 27.1 22.7 0.79 (0.599) 0.602 0.33-1.90 
Other Psychotropic Use 25.0 20.7 0.78 (0.584) 0.592 0.33-1.88 22.7 23.5 1.05 (0.939) 0.933 0.31-3.54 21.4 25.0 1.22 (0.658) 0.658 0.50-2.98 
OTCe Codeine Use 53.2 60.0 1.32 (0.499) 0.496 0.59-2.95 55.3 66.7 1.62 (0.460) 0.441 0.45-5.78 52.5 63.9 1.60 (0.274) 0.275 0.69-3.74 
Prescribed painkillers 27.7 38.0 1.60 (0.281) 0.287 0.68-3.78 29.4 58.3 3.36 (0.055) 0.030 0.97-11.60 31.1 36.1 1.25 (0.616) 0.640 0.52-2.98 
Monthly BZD Dose: >300mgg 34.0 33.3 0.97 (0.943) 0.943 0.43-2.19 29.5 56.3 3.07 (0.044) 0.032 1.03-9.11 32.8 35.0 1.10 (0.818) 0.820 0.48-2.54 
Benzodiazepine Chronicity:f    (0.107)     (0.406)     (0.293)   
 - Chronic Use (baseline group) 41.1 31.0    35.1 41.2    40.0 29.5    
- Intermittent Use 35.7 55.2 2.04 (0.092) 0.078 0.89-4.70 44.3 52.9 1.02 (0.976) 0.970 0.34-3.01 45.7 45.5 1.35 (0.500) 0.502 0.59-3.19 
- Short-term 23.2 13.8 0.79 (0.661) 0.661 0.27-2.30 20.6 5.9 0.24 (0.200) 0.104 0.03-2.12 14.3 25.0 2.37 (0.117) 0.117 0.81-6.98 
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Table 5. Univariate Logistic Regression Predicting Likelihood of General Incidents  
*Table Interpretation: The variables listed are the comparison group. This means that the percentages reported are the percentages in the comparison group that either did or did not experience an event. Regarding the odds ratio (OR), an OR>1 means that the event (e.g. accident) was more likely in the comparison group, an OR<1 means it was more likely in the baseline 
group. For example, as reported above, of those who had not experienced a general accident in the last 12 months, 44.3% had ‘mental health problems’, for those who had experienced an accident, 66.7% had ‘mental health problems’. Those who had ‘mental health problems’ were 2.51 times more like to experience an accident than those who did not. aSF-12 Physical 
Component Score, bSF-12 Mental Component Score, cKessler-10, dAlcohol Use Disorders Identification Test-C, eOver-the-counter, fIn the benzodiazepine chronicity category, the chronic benzodiazepine group was used as the reference category and the intermittent and short-term groups were compared to this. gA monthly benzodiazepine (BZD) dose cut-off score of 300mg 
(diazepam equivalent) was used. This is equivalent to the defined daily dose of 10mg/day (World Health Organisation, 2011) being used daily for a month. 
 
General  Accident - 12 months 
(Accident requiring medical attention in last 12 months) 
n=109 
Minor Injuries – 12 months 
(At least one minor injury in last 12 months) 
n=112 
Minor Injuries – 1 month 
(At least one minor injury in last 1 month) 
n=110 
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Demographic characteristics                
Age: ≥31 years  69.0 44.0 0.35 (0.025) 0.022 0.14-0.88 69.1 38.9 0.28 (0.018) 0.010 0.10-0.81 67.3 22.2 0.14 (0.017) 0.005 0.03-0.70 
Male 40.5 56.0 1.87 (0.173) 0.171 0.76-4.61 43.6 44.4 1.03 (0.948) 0.949 0.38-2.851 41.6 55.6 1.76 (0.422) 0.407 0.45-6.93 
Education:   (0.661)     (0.423)     (0.869)   
 - University (baseline group) 52.6 61.9    55.7 50.0    54.7 60.0    
- Year 11/12 or Tafe/trade 30.8 28.6 0.79 (0.669) 0.268 0.27-2.35 27.3 42.9 1.75 (0.359) 0.213 0.53-5.78 30.5 20.0 0.60 (0.662) 0.506 0.06-6.01 
- < Year 10 16.7 9.5 0.49 (0.380) 0.475 0.10-2.44 17.0 7.1 0.47 (0.492) 0.118 0.05-4.10 14.7 20.0 1.24 (0.858) 0.158 0.12-12.84 
Income (<$13,000) 44.9 60.9 1.91 (0.181) 0.206 0.74-4.94 47.7 44.4 0.88 (0.803) 0.827 0.32-2.44 47.3 55.6 1.39 (0.638) 0.666 0.35-5.51 
Unemployed 47.0 48.0 1.04 (0.929) 0.927 0.43-2.55 49.5 33.3 0.51 (0.215) 0.216 0.18-1.48 46.0 55.6 1.47 (0.584) 0.563 0.37-5.79 
Unpartnered 54.4 76.0 2.65 (0.061) 0.036 0.96-7.35 55.6 76.5 2.60 (0.117) 0.079 0.79-8.59 57.3 77.8 2.61 (0.247) 0.137 0.52-13.22 
Health factors                
Physical health Problems: PCSa 12.7 4.8 0.35 (0.324) 0.157 0.04-2.86 11.8 5.9 0.47 (0.485) 0.231 0.06-3.93 11.8 0.0 - - - 
Mental health Problems: MCSb 44.3 66.7 2.51 (0.074) 0.070 0.91-6.90 44.7 76.5 4.02 (0.023) 0.018 1.21-13.34 46.2 100.0 - - - 
Psychological Distress: K-10c 44.9 77.8 4.30 (0.017) 0.009 1.30-14.24 48.8 68.8 2.31 (0.151) 0.135 0.74-7.24 49.4 87.5 7.16 (0.071) 0.048 0.85-60.61 
Chronic Health Conditions 88.1 76.0 0.43 (0.141) 0.131 0.14-1.33 86.2 72.2 0.42 (0.149) 0.141 0.13-1.37 85.1 77.8 0.61 (0.561) 0.428 0.12-3.23 
Drug use                
Risky drinking: AUDIT-Cd 54.3 68.2 1.80 (0.247) 0.230 0.66-4.89 56.3 55.6 0.97 (0.952) 0.943 0.35-2.69 55.8 55.6 0.99 (0.989) 0.961 0.25-3.92 
Cannabis use 28.2 45.5 2.12 (0.130) 0.128 0.80-5.62 30.6 35.3 1.24 (0.703) 0.716 0.41-3.71 31.2 25.0 0.74 (0.717) 0.592 0.14-3.87 
Other Illicit Drug Use  20.3 40.9 2.73 (0.052) 0.039 0.99-7.50 22.1 35.3 1.93 (0.251) 0.236 0.63-5.88 23.4 25.0 1.09 (0.919) 0.780 0.21-5.80 
Antidepressant Use 40.5 44.0 1.16 (0.754) 0.778 0.47-2.85 41.5 38.9 0.90 (0.837) 0.828 0.32-2.52 41.6 44.4 1.12 (0.868) 0.842 0.29-4.44 
Antipsychotic Use 8.3 40.0 7.33 (<0.001) 0.001 2.41-22.32 13.8 27.8 2.40 (0.149) 0.125 0.73-7.85 14.9 33.3 2.87 (0.166) 0.110 0.65-12.73 
Opioid Use 26.2 36.0 1.59 (0.342) 0.344 0.61-4.10 26.6 33.3 1.38 (0.559) 0.609 0.47-4.07 27.7 33.3 1.30 (0.721) 0.692 0.31-5.57 
Other Psychotropic Use 23.8 32.0 1.51 (0.412) 0.425 0.57-4.01 23.3 44.4 2.78 (0.056) 0.038 0.97-7.94 23.8 55.6 4.01 (0.051) 0.030 1.00-16.14 
OTCe Codeine Use 51.9 72.7 2.47 (0.087) 0.085 0.88-6.97 55.8 52.9 0.89 (0.828) 0.831 0.31-2.53 57.4 37.5 0.44 (0.286) 0.208 0.10-1.97 
Prescribed painkillers 29.1 54.5 2.92 (0.030) 0.030 1.11-7.70 32.6 41.2 1.45 (0.495) 0.508 0.50-4.21 35.1 25.0 0.62 (0.566) 0.437 0.12-3.23 
Monthly BZD Dose: >300mgg 32.1 45.8 1.79 (0.220) 0.217 0.71-4.56 35.6 29.4 0.75 (0.623) 0.608 0.24-2.33 34.0 37.5 1.16 (0.843) 0.794 0.26-5.18 
Benzodiazepine Chronicity:f    (0.083)     (0.887)     (0.915)   
 - Chronic Use (baseline group) 34.5 52.0    38.3 44.4    39.6 33.3    
- Intermittent Use 50.0 24.0 0.32 (0.037) 0.025 0.11-0.94 43.6 38.9 0.77 (0.641) 0.632 0.25-2.33 42.6 44.4 1.24 (0.786) 0.729 0.26-5.89 
- Short-term 15.5 24.0 1.03 (0.961) 0.962 0.32-3.31 18.1 16.7 0.79 (0.755) 0.698 0.19-3.38 17.8 22.2 1.48 (0.681) 0.555 0.23-9.65 
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Table 6. Univariate Logistic Regression Predicting Likelihood of Cognitive Failures 
 
Prospective Memory (PM) Problems  
(Remembering to remember – e.g. an appointment,  or to take 
medication) n=102 
Retrospective Memory (RM) Problems 
(Remembering what you want to remember – e.g. forgetting 
information) n=99 
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Demographic characteristics           
Age: ≥31 years  69.5 45.0 0.36 (0.044) 0.051 0.13-0.97 67.1 55.0 0.60 (0.315) 0.341 0.22-1.63 
Male 46.3 25.0 0.39 (0.090) 0.062 0.13-1.16 45.6 25.0 0.40 (0.102) 0.081 0.13-1.20 
Education:   (0.537)     (0.466)   
 - University (baseline group) 55.3 47.1    57.5 47.1    
- Year 11/12 or Tafe/trade 27.6 41.2 1.75 (0.337) 0.699 0.56-5.48 26.0 41.2 1.93 (0.261) 0.744 0.62-6.11 
- < Year 10 17.1 11.8 0.81 (0.802) 0.283 0.15-4.29 16.4 11.8 0.88 (0.876) 0.267 0.16-4.68 
Income (<$13,000) 46.1 47.4 1.05 (0.918) 0.910 0.39-2.89 44.6 55.6 1.55 (0.405) 0.393 0.55-4.38 
Unemployed 41.5 57.9 1.94 (0.199) 0.181 0.71-5.34 39.2 68.4 3.36 (0.026) 0.013 1.15-9.76 
Unpartnered 57.7 57.9 1.01 (0.987) 0.988 0.37-2.78 57.3 52.6 0.83 (0.712) 0.722 0.30-2.27 
Health factors           
Physical health Problems: PCSa 11.5 10.5 0.90 (0.901) 0.755 0.18-4.56 12.0 10.5 0.86 (0.858) 0.734 0.17-4.37 
Mental health Problems: MCSb 38.5 89.5 13.60 (0.001) 0.002 2.93-63.09 38.7 78.9 5.95 (0.004) 0.005 1.80-19.69 
Psychological Distress: K-10c 44.2 83.3 6.32 (0.006) 0.008 1.69-23.64 43.2 82.4 6.13 (0.008) 0.002 1.62-23.14 
Chronic Health Conditions 89.0 85.0 0.70 (0.618) 0.585 0.17-2.86 87.3 85.0 0.82 (0.782) 0.722 0.20-3.31 
Drug use           
Risky drinking: AUDIT-Cd 57.5 55.0 0.90 (0.840) 0.852 0.34-2.42 55.1 57.9 1.12 (0.828) 0.835 0.41-3.09 
Cannabis use 33.3 26.3 0.71 (0.558) 0.582 0.23-2.20 30.7 36.8 1.32 (0.607) 0.602 0.46-3.78 
Other Illicit Drug Use  25.3 21.1 0.79 (0.698) 0.692 0.23-2.65 23.7 26.3 1.15 (0.811) 0.825 0.36-3.63 
Antidepressant Use 37.8 65.0 3.06 (0.032) 0.017 1.10-8.49 38.0 55.0 2.00 (0.172) 0.171 0.74-5.38 
Antipsychotic Use 13.4 30.0 2.77 (0.082) 0.073 0.88-8.72 11.4 25.0 2.59 (0.128) 0.097 0.76-8.85 
Opioid Use 30.5 25.0 0.76 (0.630) 0.635 0.25-2.32 29.1 30.0 1.04 (0.938) 0.939 0.36-3.05 
Other Psychotropic Use 23.2 40.0 2.21 (0.132) 0.130 0.79-6.20 25.3 35.0 1.59 (0.387) 0.384 0.56-4.54 
OTCe Codeine Use 59.5 36.8 0.40 (0.080) 0.078 0.14-1.12 57.9 42.1 0.53 (0.220) 0.218 0.19-1.46 
Prescribed painkillers 34.2 36.8 1.12 (0.827) 0.825 0.40-3.18 31.6 47.4 1.95 (0.200) 0.220 0.70-5.42 
Monthly BZD Dose: >300mgg 27.3 47.4 2.40 (0.096) 0.094 0.86-6.73 30.7 31.6 1.04 (0.939) 0.936 0.35-3.09 
Benzodiazepine Chronicity:f    (0.041)     (0.020)   
 - Chronic Use (baseline group) 34.1 65..0    32.9 60.0    
- Intermittent Use 50.0 20.0 0.21 (0.012) 0.006 0.06-0.71 53.2 15 0.16 (0.007) 0.003 0.04-0.60 
- Short-term 15.9 15.0 0.50 (0.334) 0.279 0.12-2.05 13.9 25.0 0.99 (0.981) 0.987 0.28-3.47 
*Table Interpretation: The variables listed are the comparison group. This means that the percentages reported are the percentages in the comparison group that either did or did not experience an event. Regarding the odds ratio (OR), an OR>1 means that the event (e.g. accident) was more likely in the comparison group, an OR<1 means it was more likely 
in the baseline group. For example, as reported above, of those who had not experienced prospective memory problems, 38.5% had ‘mental health problems’, for those who had experienced a prospective memory problems, 89.5% had ‘mental health problems’. Those who had ‘mental health problems’ were 13 .6 times more like to experience a 
prospective memory problems than those who did not. aSF-12 Physical Component Score, bSF-12 Mental Component Score, cKessler-10, dAlcohol Use Disorders Identification Test-C, eOver-the-counter, fIn the benzodiazepine chronicity category, the chronic benzodiazepine group was used as the reference category and the intermittent and short-term groups 
were compared to this. gA monthly benzodiazepine (BZD) dose cut-off score of 300mg (diazepam equivalent) was used. This is equivalent to the defined daily dose of 10mg/day (World Health Organisation, 2011) being used daily for a month. 
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Table 7. Multivariate Logistic Regression Predicting Likelihood of Traffic Incidents  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Table Interpretation: An odds ratio (OR) >1 means that the event (e.g. accident) was more likely in the comparison group, an OR<1 means it was more likely in the baseline group. Model 1 included the benzodiazepine chronicity variable only. Model 2 
added the variables: age, sex, employment, partnered. Model 3 added the variables: SF-12 physical component score, Kessler-10. Model 4 added the variables: AUDIT-C, cannabis use, other illicit drug use, antidepressant use, antipsychotic use, opioid use, 
other psychotropic use, over-the-counter codeine use, and monthly benzodiazepine dose. The Nagelkerke R2 value indicates the amount of variance explained by the model. aSF-12 Physical Component Score, bKessler-10, cAlcohol Use Disorders 
Identification Test-C, dOver-the-counter, eA monthly benzodiazepine (BZD) dose cut-off score of 300mg (diazepam equivalent) was used. This is equivalent to the defined daily dose of 10mg/day (World Health Organisation, 2011) being used daily for a 
month.
Model 
Traffic Accident Ever 
(n=78) 
Traffic Accident – 12 months 
(n=78) 
Traffic Near Misses  
(n=78) 
 Comparison Groups OR p  95%CI OR p  95%CI OR p  95%CI 
Step 1 R2=0.074 R2=0.112 R2=0.023 
Chronic Use (baseline group):    0.118   0.549   0.518  
- Intermittent Use 2.33 0.096 0.86-6.29 0.47 0.274 0.12-1.83 1.20 0.726 0.43-3.39 
- Short-term 0.71 0.632 0.17-2.90 0.00 0.999 - 2.22 0.256 0.56-8.81 
Step 2 R2=0.185 R2=0.253 R2=0.445 
Chronic Use (baseline group):    0.217   0.356   0.858  
- Intermittent Use 2.06 0.179 0.72-5.90 0.33 0.151 0.08-1.49 0.98 0.973 0.27-3.55 
- Short-term 0.68 0.621 0.15-3.14 0.00 0.999 - 1.56 0.624 0.26-9.35 
Step 3 R2=0.240 R2=0.337 R2=0.480 
Chronic Use (baseline group):    0.091   0.554   0.955  
- Intermittent Use 2.72 0.084 0.87-8.47 0.42 0.277 0.09-2.02 1.19 0.804 0.31-4.59 
- Short-term 0.57 0.488 0.11-2.81 0.00 0.998 - 1.27 0.799 0.20-7.94 
Step 4 R2=0.348 R2=0.618 R2=0.612 
Chronic Use (baseline group):    0.052   0.919   0.760  
- Intermittent Use 4.24 0.037 1.09-16.48 2.03 0.681 0.03-3.35 0.51 0.464 0.09-3.07 
- Short-term 0.81 0.829 0.12-5.62 0.00 0.998 - 0.57 0.669 0.04-7.66 
Age: ≥31 years 0.53 0.341 0.14-1.96 0.32 0.341 0.07-60.15 0.12 0.012 0.02-0.63 
Male 1.59 0.502 0.41-6.20 0.29 0.502 0.01-11.09 0.01 0.003 0.00-0.22 
Unemployed 0.12 0.003 0.03-0.49 5.39 0.421 0.09-325.79 6.12 0.081 0.80-46.86 
Unpartnered 1.63 0.434 0.48-5.56 41.25 0.121 0.38-4531.29 11.14 0.011 1.75-70.77 
Physical health Problems: PCSa 1.38 0.760 0.17-10.99 0.00 0.998 - 0.75 0.829 0.06-9.91 
Psychological Distress: K-10b 2.49 0.210 0.60-10.40 0.07 0.254 0.00-7.02 2.98 0.218 0.52-16.95 
Risky drinking (AUDIT-C)c 0.48 0.289 0.13-1.85 0.65 0.780 0.03-13.34 4.56 0.136 0.62-33.59 
Cannabis use 0.81 0.802 0.15-4.31 0.04 0.199 0.00-5.66 3.34 0.326 0.30-37.02 
Other Illicit Drug Use  0.86 0.886 0.11-6.56 113.80 0.158 0.16-80779.52 7.17 0.151 0.49-105.67 
Antidepressant Use 1.20 0.778 0.33-4.37 88.15 0.105 0.39-19901.85 1.71 0.527 0.33-8.98 
Antipsychotic Use 5.37 0.057 0.95-30.20 6.07 0.350 0.14-265.19 0.98 0.980 0.15-6.36 
Opioid Use 1.47 0.598 0.35-6.22 82.03 0.133 0.26-25710.51 0.38 0.318 0.06-2.53 
Other Psychotropic Use 0.17 0.037 0.03-0.90 0.01 0.023 0.00-0.54 3.59 0.187 0.54-24.07 
OTCd Codeine Use 1.71 0.395 0.50-5.85 0.16 0.263 0.01-3.92 0.68 0.674 0.11-4.15 
Monthly BZD Dose: >300mge 1.08 0.919 0.23-5.07 4.18 0.410 0.14-126.05 0.19 0.169 0.02-2.02 
Chapter 6: Accidents, Injuries, and Cognitive Failures in Chronic Benzodiazepine Users | 104 
 
 
 
Table 8. Multivariate Logistic Regression Predicting Likelihood of General Incidents  
Model 
Comparison Groups 
General Accident 
(n=80) 
Frequent Injury_12m 
(n=82) 
OR p  95%CI OR p  95%CI 
Step 1 R2=0.082 R
2=0.012 
Chronic Use (baseline group):    0.150   0.737  
- Intermittent Use 0.29 0.059 0.08-1.05 1.01 0.985 0.28-3.69 
- Short-term 0.92 0.912 0.20-4.26 1.80 0.476 0.36-9.08 
Step 2 R2=0.318 R
2=0.277 
Chronic Use (baseline group):    0.065   0.850  
- Intermittent Use 0.16 0.019 0.04-0.74 0.77 0.723 0.18-3.28 
- Short-term 0.39 0.319 0.06-2.48 1.270 0.804 0.19-8.42 
Step 3 R2=0.381 R
2=0.366 
Chronic Use (baseline group):    0.106   0.994  
- Intermittent Use 0.18 0.039 0.03-0.91 1.05 0.948 0.23-4.91 
- Short-term 0.26 0.197 0.03-2.03 0.942 0.955 0.12-7.43 
Step 4 R2=0.687 R
2=0.502 
Chronic Use (baseline group):    0.121   0.787  
- Intermittent Use 0.01 0.046 0.00-0.933 0.47 0.489 0.05-4.03 
- Short-term 0.05 0.271 0.00-10.34 0.57 0.721 0.03-12.81 
Age: ≥31 years 0.00 0.049 0.00-0.97 0.10 0.048 0.01-0.98 
Male 1.63 0.719 0.12-22.86 0.19 0.123 0.02-1.57 
Unemployed 1.64 0.688 0.15-18.41 0.23 0.150 0.03-1.70 
Unpartnered 45.18 0.077 0.66-3084.31 6.95 0.115 0.62-77.54 
Physical health Problems: 
PCSa 
0.20 0.494 0.00-21.03 0.00 0.999 - 
Psychological Distress: K-10b 3.55 0.499 0.09-139.52 2.58 0.423 0.25-26.37 
Risky drinking (AUDIT-C)c 0.18 0.355 0.00-7.94 0.51 0.507 0.07-3.79 
Cannabis use 0.04 0.147 0.00-3.19 0.35 0.573 0.01-14.01 
Other Illicit Drug Use  55.22 0.149 0.24-12828.60 5.71 0.413 0.09-371.53 
Antidepressant Use 1.36 0.813 0.11-17.29 0.46 0.398 0.08-2.801 
Antipsychotic Use 554.46 0.011 4.19-73392.64 6.70 0.111 0.64-69.75 
Opioid Use 6.632 0.224 0.31-140.37 0.64 0.698 0.07-6.18 
Other Psychotropic Use 0.01 0.055 0.00-1.12 2.35 0.383 0.35-15.91 
OTCd Codeine Use 9.48 0.097 0.66-135.19 0.69 0.662 0.13-3.71 
Monthly BZD Dose: >300mge 0.16 0.252 0.01-3.779 0.56 0.630 0.05-5.97 
*Table Interpretation: The predictor variables listed are the comparison group. This means that the percentages 
reported are the percentages in the comparison group that either did or did not experience an event. Regarding the 
odds ratio (OR), an OR>1 means that the event (e.g. accident) was more likely in the comparison group, an OR<1 
means it was more likely in the baseline group. The Nagelkerke R2 value indicates the amount of variance explained 
by the model. aSF-12 Physical Component Score, bKessler-10, cAlcohol Use Disorders Identification Test-C, dOver-the-
counter, eA monthly benzodiazepine (BZD) dose cut-off score of 300mg (diazepam equivalent) was used. This is 
equivalent to the defined daily dose of 10mg/day (World Health Organisation, 2011) being used daily for a month. 
Note: Due to the small number of frequent minor injuries occurring in the last one month, there was overfit in the 
data and the model would not appropriately converge, therefore this data is not reported here. 
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Table 9. Multivariate Logistic Regression Predicting Likelihood of Cognitive 
Failures 
*Table Interpretation: The predictor variables listed are the comparison group. This means that the percentages 
reported are the percentages in the comparison group that either did or did not experience an event. Regarding the 
odds ratio (OR), an OR>1 means that the event (e.g. accident) was more likely in the comparison group, an OR<1 
means it was more likely in the baseline group. The Nagelkerke R2 value indicates the amount of variance explained 
by the model. aSF-12 Physical Component Score, bKessler-10, cAlcohol Use Disorders Identification Test-C, dOver-the-
counter, eA monthly benzodiazepine (BZD) dose cut-off score of 300mg (diazepam equivalent) was used. This is 
equivalent to the defined daily dose of 10mg/day (World Health Organisation, 2011) being used daily for a month. 
 
  
Model 
Comparison Groups 
Prospective Memory Problems 
(n=79) 
Retrospective Memory Problems 
(n=76) 
OR p  95%CI OR p  95%CI 
Step 1 R2=0.121 R
2=0.246 
Chronic Use (baseline group):    0.074   0.033  
- Intermittent Use 0.20 0.024 0.05-0.81 0.07 0.014 0.01-0.58 
- Short-term 0.83 0.804 0.18-3.78 1.33 0.698 0.31-5.72 
Step 2 R2=0.319 R
2=0.468 
Chronic Use (baseline group):    0.066   0.036  
- Intermittent Use 0.15 0.020 0.03-0.74 0.06 0.014 0.01-0.56 
- Short-term 0.38 0.315 0.06-2.51 1.21 0.845 0.17-8.47 
Step 3 R2=0.402 R
2=0.525 
Chronic Use (baseline group):    0.134   0.083  
- Intermittent Use 0.18 0.055 0.03-1.04 0.06 0.033 0.01-0.80 
- Short-term 0.24 0.196 0.03-2.09 1.002 0.998 0.13-8.02 
Step 4 R2=0.593 R
2=0.750 
Chronic Use (baseline group):    0.396   0.229  
- Intermittent Use 0.20 0.178 0.02-2.08 0.01 0.091 0.00-2.54 
- Short-term 0.44 0.619 0.02-11.53 0.03 0.347 0.00-42.28 
Age: ≥31 years 0.04 0.026 0.01-0.69 0.22 0.358 0.01-5.53 
Male 0.21 0.131 0.03-1.60 0.00 0.098 0.00-3.55 
Unemployed 7.05 0.123 0.59-84.52 298.21 0.041 1.26-70801.71 
Unpartnered 0.33 0.277 0.05-2.42 0.15 0.344 0.00-7.78 
Physical health Problems: PCSa 0.34 0.564 0.01-13.51 2.06 0.807 0.01-689.22 
Psychological Distress: K-10b 4.35 0.228 0.40-47.64 13.63 0.105 0.58-319.21 
Risky drinking (AUDIT-C)c 1.88 0.571 0.21-16.57 59.62 0.245 0.06-58755.97 
Cannabis use 0.26 0.425 0.01-7.01 0.70 0.921 0.00-741.49 
Other Illicit Drug Use  0.55 0.735 0.02-17.82 34.68 0.454 0.00-370397.75 
Antidepressant Use 1.00 0.999 0.14-7.17 0.04 0.217 0.00-7.04 
Antipsychotic Use 6.23 0.135 0.56-68.87 6.11 0.487 0.04-1001.82 
Opioid Use 0.92 0.942 0.09-9.53 30.22 0.095 0.55-1648.71 
Other Psychotropic Use 2.92 0.334 0.33-25.56 0.42 0.669 0.01-23.09 
OTCd Codeine Use 0.11 0.028 0.02-0.79 0.01 0.124 0.00-3.22 
Monthly BZD Dose: >300mge 4.02 0.282 0.32-50.68 0.09 0.437 0.00-42.37 
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DISCUSSION 
The patterns of benzodiazepine consumption found in this study are indicative of 
prolonged and frequent use. Chronic benzodiazepine use was associated with an 
increased risk of general accidents, and retrospective and prospective memory 
problems. Those who used most days for a year or more, experienced more of 
these problems, than those who used only sporadically over a similar time period. 
This may indicate that tolerance does not develop in chronic users as is often 
expected. Those who had a high monthly dose of benzodiazepines reported 
increased traffic accidents in the last 12 months.  
The typical patterns of benzodiazepine use identified by many of this sample are far 
in excess of the clinical guidelines that recommend a time- and dose-limited 
approach. The short-term user group in this study were the most benzodiazepine-
naïve participants. Whilst average dosage in the short-term group was within the 
defined daily dose (World Health Organisation, 2011), their average length of use 
spanned almost six months. The focus group of this study, the chronic users, had 
even higher levels of benzodiazepine use. Average length of use spanned almost 
nine years, and the average monthly dosage was 900mg diazepam equivalent – 
which is three times the monthly dose calculated using a defined daily dose. Use of 
more than one benzodiazepine was also common. 
Incident rates in this sample were compared to the rates found in other general 
population research. Comparable research in the UK (Wadsworth et al., 2005) used 
a postal survey (n=7979) to examine psychotropic medication use in the general 
population, and found 11% of the population reported a general accident (excluding 
traffic accidents). In the current study, general accidents were reported by 22.94%, 
a significantly larger proportion of the population (χ2(1n=8108)=17.03, p<0.001). 
Experience of frequent minor injuries did not differ significantly between the 
populations, with rates of 14% in the UK, and 16% in the current study 
(χ2(1n=8108)=0.30, p=0.587). In this study, chronic users were three times more likely 
to experience a general accident requiring medical attention, in the last 12 months, 
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than intermittent users, and this finding remained in the multivariate results. This is 
a serious impact on the safety of this group. 
Regarding traffic incidents whilst the driver, 50.87% of study participants had 
experienced an accident at any time in their life, and 14.91%, had experienced at 
least one in the last 12 months. ‘Close calls’ whilst driving were reported by 38.60% 
of the group. There is little available population data about rates of traffic incidents 
available for comparison. Most data is that collected from fatalities, or those 
requiring police or medical services, and does not capture more minor non-reported 
incidents. There was an association between lifetime experience of traffic accidents, 
and intermittent benzodiazepine use; this was the only variable for which the 
intermittent users were at higher risk than the daily users. However, there are 
limitations inherent in this comparison, as the predictor variables do not occur over 
this same ‘lifetime’ time frame. Those on a monthly dose of greater than 300mg 
(diazepam equivalent) were three times more likely to report having a traffic 
accident in the last 12 months, compared to those using less than 300mg (although 
this effect did not remain in the multivariate analysis). This finding supports the 
premise of using the lowest dose possible in order to reduce side-effects. 
Expected cognitive performance was estimated for the Prospective Retrospective 
Memory Questionnaire using a large sample (n=551; Crawford & Smith, 2003). 
Assuming a standard distribution, approximately 16% of the general population is 
expected to score greater than one standard deviation above the mean. 
Proportions of the sample scoring greater than one standard deviation above the 
mean in this benzodiazepine sample were higher, but not significantly so, for both 
prospective memory (19.61%; χ2 (1n=680) =0.74, p=0.390) and retrospective memory 
(22.47%; χ2 (1n=680) =2.63, p=0.105). In this group, chronic benzodiazepine use and a 
high monthly dose were significantly associated with prospective memory problems 
in the univariate analysis, but this finding disappeared in the multivariate analysis, 
after controlling for demographic, health and drug use variables. Daily chronic users 
were at a higher risk of retrospective memory problems than occasional users, in 
both the univariate and multivariate analyses. Whilst the association between 
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memory deficits and benzodiazepine use is well established in the literature, this is 
the first study, to our knowledge, that has examined the relationship between 
prospective memory problems and chronic benzodiazepine use.  
With the exception of lifetime traffic accidents, the chronic user group had an 
increased experience of incidents compared to the intermittent users. No significant 
differences were found between the short-term user group and the chronic group. 
The short-term group included all participants who identified they had used 
benzodiazepines for less than a year, and use was evenly split between daily (n=13, 
54.2%) or occasional consumption (n=11, 45.8%). For those in the short-term and 
intermittent user groups who are occasional users of benzodiazepines, there may 
be some susceptibility to the acute effects of benzodiazepines each time they 
recommence use. However, as evidenced by the findings in this study, the chronic 
users experienced the greatest deficit. This is consistent with the literature 
suggesting tolerance to the effects of benzodiazepines does not develop equally, 
and for some functions may not occur at all (Vinkers & Olivier, 2012). This study 
suggests that psychomotor deficits build as the duration and frequency of 
benzodiazepine use increases, and does not lessen through the development of 
tolerance to particular features of benzodiazepines. 
There were also other predictors that emerged regularly in the analyses. Due to the 
exacerbated effects of benzodiazepines on older adults (Barker et al., 2004a), the 
older age group was expected to be at greatest risk of incidents. However, stronger 
associations were found between most incident types and being in the younger age 
group (average age=25.19 years, SD=3.81), compared to being in the older adult 
group (average age=45.57 years, SD=11.18). It is possible that the association with 
incidents may change if a group of much older adults, for example with an average 
age of 70, were included. Being female, unemployed, and the use of various 
sedating medications appeared to have independent effects on increasing risk of 
incidents. Overall, there are some complexities to the pattern of predictors in this 
study. Larger participant numbers may have allowed these trends to become more 
obvious. The influence of these extraneous variables on the results support the 
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methodology used in this study which controls for a range of other demographic, 
health, and drug use factors. 
Unfortunately despite varied methods of participant recruitment, data obtained 
were less than expected, which affected the power of the study. It is unclear why 
the response rate for this survey remained low, despite various different methods 
of recruitment. It is thought that the low completion rate may be in part due to the 
lengthy survey. The small sample size meant the individual effects of different 
active ingredients could not be explored as planned. It remains an ongoing 
limitation in the literature to date that most studies do not differentiate between 
benzodiazepine types, despite the varied differences in potency and half-life 
between the individual preparations. The use of diazepam equivalent doses goes 
some way towards resolving this. The fact that effects have remained, despite this 
small sample size, points to the severity of the effects of these medications and the 
magnitude of the issue in the general population.  
The use of a survey in this study involves a reliance on self-report, meaning incident 
reports may be prone to forgetfulness and under-reporting. Research suggests that 
more significant accidents are usually successfully recalled within a 12 month 
period; however, recall of more minor injuries may be diminished over a period 
greater than three months (Harel et al., 1994; Moshiro, Heuch, Astrom, Setel, & 
Kvale, 2005). It is possible there may be some type of recall bias occurring for the 
minor incidents, in which they are neither critical enough in severity nor frequent 
enough in occurrence to be accurately recalled. However, reported rates were 
similar to those found in other comparable populations, suggesting that either 
there has not been persistent under-reporting occurring in this sample, or that 
there is consistent recall bias with these types of studies. Another potential issue 
with the reporting of minor injuries is that the related survey questions were non-
definitive and left the decision of what constituted a minor injury and how 
frequently they occurred, to the judgement of respondents. Comparatively major 
accidents were more clearly defined by the requirement of medical attention. 
Nevertheless, minor injuries have the potential to have a cumulative impact on a 
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person’s wellbeing, and are worthy of further study. Future research could focus on 
more specific prompts regarding minor injuries, and use real-time technology, such 
as a Phone App to  capture individual’s experiences as they occur.  
Accountable prescribing is described as “the use of medicines with proven 
effectiveness and the avoidance of medicines when they do not help or cause 
harm” (Morden, Schwartz, Fisher, & Woloshin 2013; Royal Australian College of 
General Practitioners, 2015a: p.18). Whether the benzodiazepine use within this 
sample aligns with these principles is unclear. For example, almost half the group 
stated they use benzodiazepines to treat anxiety, yet average Kessler-10 (Kessler & 
Mroczek, 1994) scores were indicative that high anxiety and affective symptoms 
remain. Similarly, the SF-12 mental component score (Ware et al., 1995), which 
indicates the effect of mental health on social and emotional functioning was on 
average close to 2 standard deviations below the mean, suggesting a lower than 
average wellbeing. Prescribers need to continually balance the ongoing clinical 
efficacy, with the potential negative effects, such as the detrimental impact on 
safety identified in this study. Given that most of the sample identified that they 
were using benzodiazepines for sleep only (n=59, 45.7%) or anxiety only (n=54, 
41.9%), it is expected that there should be other medications and therapies that 
would be preferable first-line treatments, due to their higher efficacy and lower risk 
of side-effects, particularly for ongoing use (Baldwin et al., 2013; National Institute 
for Health and Care Excellence, 2014).  
There are several clinical recommendations that arise from this study. Results 
support the premise that complete tolerance does not occur in chronic users. For 
prescribers, this means that even long-term benzodiazepine users should be 
regularly cautioned about detrimental safety effects. Awareness of ongoing risks to 
safety, and the subsequent actions required to mitigate risk, for example refraining 
from driving, may provide motivation for patients to cease use. An association was 
found between higher doses of benzodiazepines, and increased accidents. This 
evidence can be used as a ‘selling point’ to patients about the benefits of a 
reduction in dose. Finally, it is apparent that there must be some method for 
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identifying long-term benzodiazepine users, and providing them with alternative 
solutions for managing their concerns, whether this is a pharmacological or 
psychological treatment. 
Current clinical guidelines suggest that benzodiazepines should be used at the 
lowest effective dose for the shortest time period possible, with use for longer than 
four weeks rarely warranted (Royal Australian College of General Practitioners, 
2015b). The first clinical guideline suggesting this limited use of benzodiazepines 
was implemented in the UK in the 1980s (Committee on the Review of Medicines, 
1980), and since then many international guidelines have followed. However, over 
35 years on, patterns of benzodiazepine use found in the current study are far from 
that recommended. Many individuals had use spanning several years, high daily 
doses, and used multiple benzodiazepine types. It is highly unlikely that such high 
levels of use are justified in the vast majority of this group. It could be readily 
assumed that the chronic benzodiazepine users in this study, who have had many 
years of ongoing use, would be less susceptible to the impairing effects of 
benzodiazepines. However, results suggest that full tolerance does not develop to 
incident risk, with chronic users at a greater risk of general accidents, and 
prospective and retrospective memory problems, compared to those who use only 
intermittently. The association between chronic benzodiazepine use and accidents 
remained, even after controlling for other demographic, health and drug use 
variables, which indicates the strength of this association. Data from this study 
suggests the effects of benzodiazepines on safety cannot be ignored. There must be 
continual assessments made as to whether the ongoing use of benzodiazepines is 
indicated, with careful consideration given to costs and benefits. Both prescribers 
and patients must be provided with adequate skills to cease benzodiazepine use, 
and to find alternative solutions.  
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CHAPTER 7: THE UNIQUE IMPACT OF BENZODIAZEPINES ON THE SAFETY OF 
PEOPLE WHO INJECT DRUGS 
 
Preface 
Study 1 examined the association between chronic benzodiazepine use and 
accidents in the general population. It was found that benzodiazepine use in the 
sample investigated was ongoing and regular, and there was a higher rate of safety 
incidents experienced by the most chronic user group. The focus of this chapter is 
similar to that of Study 1, in that it examines the association between 
benzodiazepine use and experience of accidents; comparable methodology and 
data analysis was used. However, Study 2 specifically examines this association 
within a high-risk population – people who inject drugs (PWID). PWID are already a 
high risk group, due to both their typical population demographics, and common 
risk-taking behaviours. Study 2 aimed to understand whether benzodiazepines 
uniquely contributed to risk of safety incidents in people who inject drugs (Research 
Question 3). Data for this study comes from the Tasmanian Illicit Drug Reporting 
System (IDRS), and was collected during 2009 and 2010. The author acknowledges 
the work of those involved in the IDRS in collecting and collating the data. It is 
hoped that the results will improve the understanding of the risks faced by those 
who are polydrug users, and contribute to harm minimisation knowledge. 
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ABSTRACT 
Objective 
The use of benzodiazepines in people who inject drugs (PWID) is usually counter 
indicated, due to the high risk of dependence, respiratory depression, and other 
adverse events. Despite this it is known that PWID commonly use benzodiazepines, 
both for their own and synergistic effects, and for managing withdrawal from other 
substances. The current study aimed to examine whether benzodiazepines 
independently contributed to risk of safety incidents in PWID. Specifically three 
incident types were examined; cognitive failures, minor injuries, and accidents 
requiring medical attention.  
Method 
170 participants were interviewed through the Illicit Drug Reporting System. Data 
was collected in Hobart, Tasmania, in 2009 and 2010. Participants were required to 
be over 18 years of age, and to have injected drugs within the last six months.  
Results 
After controlling for other confounding variables, moderate-to-regular 
benzodiazepine use independently contributed to an increased risk of retrospective 
memory problems (Multivariate OR 8.21, 95%CI 1.03-65.41, p=0.047), and major 
accidents (Multivariate OR 3.88, 95%CI 1.20-12.50, p=0.023). 
Conclusion 
Reported rates of safety incidents were elevated in this sample compared to the 
general population. Despite the extensive injecting drug use in this group, 
benzodiazepine use had an independent and detrimental effect on the safety of the 
cohort. This suggests that benzodiazepines cannot be ignored as a target for harm 
minimisation in this group.   
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INTRODUCTION 
There is a large body of evidence supporting a relationship between 
benzodiazepines, commonly used for sleep and anxiety, and psychomotor 
impairment. There are significant cognitive effects during early benzodiazepine use, 
such as sedation, memory problems, and motor impairment (Buffett-Jerrott & 
Stewart, 2002. De Visser et al., 2002). Long-term benzodiazepine users also show a 
generalised deficit across a broad range of cognitive areas (Barker, Greenwood, 
Jackson, & Crowe, 2004a, 2004b, 2005). As a class, prescribing of benzodiazepines 
in Australia appears to have stabilised (Stephenson, Karange, & McGregor, 2013); 
however, around 7 million scripts are still written every year and research suggests 
that quantity per script may be increasing (Islam, Conigrave, Day, Nguyen, & Haber, 
2013). 
The effects of long-term benzodiazepine use on cognition, has been investigated in 
a meta-analysis of 13 studies (Barkeret al., 2004a). The benzodiazepine user group 
had benzodiazepine use varying between 1-34 years, with a mean duration of 9.9 
years. In 11 out of the 13 studies a control group was used, including people 
classified as; non-anxious, anxious, and previous benzodiazepine users. The current 
benzodiazepine users were significantly impaired across all 12 cognitive domains 
studied (cognitive domains: sensory processing, psychomotor speed, nonverbal 
memory, visuospatial, attention/concentration, speed of processing, general 
intelligence, working memory, problem-solving, verbal memory, motor 
control/performance and verbal reasoning). Moderate to large effect sizes were 
found for all cognitive domains; the mean weighted effect size was -0.74 (SD±0.25) 
and no 95% confidence interval spanned zero, meaning results are statistically 
significant.  
These well-established laboratory findings are substantiated by the high rates of 
benzodiazepine users in road (Dassanayake, Michie, Carter, & Jones, 2011; Kelly, 
Darke, & Ross, 2004), work (Wadsworth, Moss, Simpson, & Smith, 2005) and other 
accidents (Stenbacka, Jansson, Leifman, & Romelsjö, 2002). A review of 
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epidemiological traffic data by Kelly, Darke, and Ross (2004) found that following 
cannabis, benzodiazepines were the most commonly detected drug in drivers 
involved in an accident and apprehended for impaired driving. A recent meta-
analysis (Dassanayake et al., 2011) found that people who used benzodiazepines 
were 60-80% more likely to be involved in accidents (for case-control studies: 59%, 
pooled OR 1.59; 95%CI 1.10-2.31, and for cohort studies: 81% pooled incidence rate 
ratio 1.81; 95%CI 1.35-2.43), and importantly were 40% more likely to be 
‘responsible’ for the accident (pooled OR 1.41; 95%CI 1.03, 1.94). 
In a randomised general population postal survey in the United Kingdom, 
Wadsworth, Moss, Simpson and Smith (2005), investigated the effects of 
psychotropic medication use on respondents’ experience with major accidents, 
minor injuries and cognitive failures (minor everyday cognitive slips or errors). Initial 
analysis found a significant association between benzodiazepine use and non-work 
injuries, with benzodiazepine users almost four and a half times more likely to 
experience a non-work injury (OR 4.43, 95%CI 1.89-10.38). To further clarify 
findings, participants were classified by mental health status and according to low 
or high presence of other risk factors associated with the incident type, such as 
physical health, age, and risk-taking. In the presence of high risk factors, and a 
mental health condition, benzodiazepine use markedly increased the risk of non-
work injuries (OR 16.18, 95%CI 6.24-41.94) and cognitive failures (OR 18.09, 95%CI 
6.17-53.04). This approach by Wadsworth and colleagues is unique in its exploration 
of a range of incident severities, previously research has focused mostly on 
accidents requiring medical attention. 
Cognitive failure is a broad term used to define problems of memory, attention, or 
action. Cognitive failures are common and usually benign, but can have serious 
consequences (Wallace, Kass, & Stanny, 2002). They normally reflect a failure of 
typical functioning rather than a lack of ability (Wallace et al., 2002). Prospective 
memory (remembering to perform a future event) and retrospective memory 
(remembering previously learned information) are processes prone to cognitive 
failures. Whilst these types of memory are distinct concepts, they interact in the 
Chapter 7: The Unique Impact of Benzodiazepines on the Safety of PWID | 123 
 
 
 
everyday memory required to live independently (Crawford & Smith, 2003). For 
example the simple task of planning to call a colleague, requires both prospective 
memory (remembering to call at the appropriate time) and retrospective memory 
(remembering what you needed to discuss).  
The impact of benzodiazepines on memory is highly researched; whilst a general 
detrimental effect occurs, the many types of memory processes are differentially 
affected by benzodiazepines (Barker, Jackson, Greenwood, & Crowe, 2003; Rich, 
Svoboda, & Brown, 2006). Retrospective and prospective memory impairment has 
been established in self-report and lab-based objective measures in users of alcohol 
(Griffiths et al., 2012), nicotine (Heffernan et al., 2005), cannabis (Bartholomew, 
Holroyd, & Heffernan, 2010; Montgomery, Seddon, Fisk, Murphy, & Jansari, 2012), 
ecstasy (Rendell, Gray, Henry, & Tolan, 2007), cocaine (Hadjiefhyvoulou, Fisk, 
Montgomery, & Bridges, 2011), methamphetamines (Rendell, Mazur, & Henry, 
2009) and opiate maintenance drugs: methadone, buprenorphine and suboxone 
(Terrett et al., 2014). Experimental studies examining retrospective memory 
through recall and recognition tasks, have established a dose- and time- dependent 
effect of acute use of benzodiazepines (Barker et al., 2003). An exploratory study, 
found that in healthy participants, a once-off weight-relative dose of diazepam 
impaired performance on both retrospective and prospective memory tasks (Rich et 
al., 2006). However, there have been few studies examining the relationship 
between ongoing benzodiazepine use and self-reported retrospective and 
prospective memory failures in the context of everyday life.  
When considering demographic factors alone, the injecting-drug population has 
attributes commonly associated with increased experience of accidents and injuries, 
including for example; male sex, young age, low income, low education, and 
psychological distress (Simpson, Wadsworth, Moss, & Smith, 2005). Risk-taking 
behaviour is also a common trend in people who inject drugs (PWID), an 
observation supported by the findings of the 2013 Illicit Drug Reporting System 
(IDRS). In this national sample of 887 PWID, significant proportions of the sample 
identified that they undertook risky behaviours such as; sharing needles (11%) and 
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other injecting equipment (24%), being involved in criminal activity in the last 
month (36%), and of the 42% of the sample who had driven within the last 6 
months, considerable numbers had driven under the influence of alcohol (18%) or 
an illicit drug (77%) (Stafford & Burns, 2014).  
The sample for the current study was formed from the 2009 and 2010 Tasmanian 
IDRS samples. As such, the relevant IDRS reports provide an indication of the 
pattern of benzodiazepine and other drug use that occurs in the current sample. In 
the cohort of the 2009 IDRS (N=100; de Graaff & Bruno, 2010), the mean reported 
age of first injection was 18.9 years (SD=4.6, range 12-33). Regarding the 2009 
cohort’s drug of choice, 33% reported they preferred heroin, whilst 21% preferred 
methamphetamine. Consistent with this preference, 73% stated an opioid was the 
drug they had most often injected in the preceding month. Most (95%) of the 2009 
IDRS sample had used benzodiazepines at some point in their lives; 51% of the 
sample had ever injected benzodiazepines, and 25% had injected in the six months 
prior to interview. Similar numbers in the cohort reported ever having been 
prescribed a benzodiazepine (78%, n=78), compared to lifetime use of illicit 
benzodiazepines (83%, n=83). Importantly, there was a large amount of overlap in 
the use of licit and illicit benzodiazepines. Out of those who had recently used 
benzodiazepines: 44% reported illicit benzodiazepine use only (n=34), 15% reported 
licit use only (n=12), and 41% had recently used benzodiazepines accessed both 
licitly and illicitly (n=32). The most common self-reported reasons for using 
benzodiazepines was self-treatment (48%, n=30), and intoxication purposes (37%, 
n=23). Overall, these findings suggest that PWID tend to use benzodiazepines in a 
risky manner; benzodiazepines are used regularly, and commonly in conjunction 
with other sedatives, and they are often injected, accessed from illicit sources, and 
used for non-clinical reasons. The safety of PWID is complicated due to 
demographic characteristics associated with adverse events, hazardous behaviour, 
and poly-drug use. It is assumed that the combined impact of these factors would 
make PWID very vulnerable to a range of incident types, including everyday 
cognitive failures, minor injuries, and major accidents requiring medical attention. 
Chapter 7: The Unique Impact of Benzodiazepines on the Safety of PWID | 125 
 
 
 
The aim of this study was to determine whether, within this complex context, 
benzodiazepines contribute any additional risk to PWID. 
METHOD 
Participants and Procedure 
Data was collected as part of the Illicit Drug Reporting System, an Australian drug 
monitoring system. A total of 170 participants were recruited through a purposive 
sampling strategy in Hobart, Tasmania in June 2009 and 2010. Inclusion criteria 
required that participants be at least 18 years old, and had injected drugs at least 
monthly in the preceding six months. Trained staff conducted interviews with 
participants lasting 30-60 minutes in a range of public locations. Demographic 
characteristics, drug use, and health were assessed. Respondents provided written 
informed consent and were reimbursed AUD$40. For those who had completed the 
study in both years, 2010 data was omitted. Full methodological detail and findings 
are available elsewhere (de Graaff & Bruno, 2010; de Graaff & Bruno, 2011). Ethical 
approval was granted by the University of New South Wales and the Tasmanian 
Social Sciences Human Research Ethics Committee (approval H0007853 for the 
Tasmanian committee). 
Outcome variables 
Self-reported experiences of safety incidents were classified as major accidents or 
minor injuries. The number of major accidents experienced in the last 12 months 
was recorded; these being accidents that required medical attention, not resulting 
from assault. Those reporting one or more accidents were compared with those 
reporting none. Minor injuries, experienced in the last 12 months, included non-
venous cuts and bruises that did not require medical attention. These were rated on 
a five-point frequency scale, ranging from ‘Not at all’ through to ‘Very frequently’. 
Those rating their experience of minor injuries as ‘quite’ or ‘very’ frequent, were 
compared to those who reported less frequent minor injuries. These questions 
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were replicated from the survey used by Wadsworth and colleagues (Wadsworth et 
al., 2005; Wadsworth, Simpson, Moss, & Smith, 2003). 
Day-to-day cognitive failures were assessed using the Prospective and Retrospective 
Memory Questionnaire (PRMQ: Smith, Della Sala, Logie, & Maylor, 2000). The 
PRMQ has 16 items, split equally between those measuring prospective memory 
problems (e.g., Do you decide to do something in a few minutes time and then 
forget to do it?) and retrospective memory problems (e.g., Do you forget something 
that you were told a few minutes before?). Problems experienced in the last 6 
months are rated on a 5 point scale ranging from ‘never’, to ‘very often’. Higher 
scores are more indicative of memory problems. Confirmatory Factor Analysis of 
the PRMQ items indicates best fit for a three-factor model, with a general memory 
factor, and two orthogonal factors – prospective and retrospective memory 
(Crawford & Smith, 2003; Rönnlund, Mäntylä, & Nilsson, 2008). Crawford and Smith 
(2003) provide normative data based on a general adult UK population (m=38.88, 
SD=9.15), and using Cronbach’s alpha indicated strong internal consistency for the 
PRMQ (prospective scale α=0.84, retrospective scale α=0.80 and total scale α=0.89). 
Problem scores were defined as a score ≥2SDs above the general population mean 
(approximately2.3% of the population). Problem scores for each measure were 
defined as follows: prospective memory ≥30, retrospective memory ≥28.65. 
Measures 
The predictor variables were chosen due to their known association with decreased 
safety and/or their potentially confounding nature (Table 1). Each of these variables 
were used as a categorical variable, with cut-off scores chosen to denote ‘problem’ 
versus ‘non-problem’ groups. This then allowed for the demarcation of a level at 
which an incident variable occurred, rather than simply providing information on 
the relationships between variables, as would have happened if the variables were 
treated in a continuous manner. For all drug types, use within the last 6 months was 
recorded, with daily users compared to those who used less than daily. The 
exception to this was amphetamines; due to low levels of daily use within the 
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population, comparisons were made between weekly and less than weekly users. 
To clarify findings, an additional graded benzodiazepine variable was included 
comparing those who used; less than weekly (low use), 1-6 times per week 
(moderate use), and most days each week (regular use).   
The Kessler Psychological Distress Scale (K-10) is a 10-item questionnaire providing 
a global indication of anxiety and depression symptoms (Kessler & Mroczek, 1994). 
Symptoms experienced over the past four weeks are rated on a 5 point scale 
ranging from ‘none of the time’ to ‘all of the time’. Whilst different cut-off scores 
are used within Australia, the convention set by the Australian Bureau of Statistics 
(2003) was followed, with total scores equal to or above 22, taken as an indication 
of high psychological distress. Andrews and Slade (Andrews & Slade, 2001) found 
that the K-10 appropriately identified those classified by the Composite 
International Diagnostic Interview v2.0, as having any DSM-IV or ICD-10 anxiety or 
affective diagnosis (at a score of 22; sensitivity=0.55, specificity=0.95). 
The Personal Wellbeing Index (PWI) is designed to provide a subjective measure of 
quality of life (International Wellbeing Group, 2013). This scale is based on the 
premise that each person has a genetically determined ‘set-point’ for well-being 
that is internally maintained (Cummins et al., 2011). The PWI rates this set point on 
a standardised 0-100 point scale. Data for the average Australian wellbeing is 
collected regularly; there is minimal variation in the PWI score across each occasion 
of data collected (Cummins et al., 2011). The PWI has seven items each assessing a 
broad personal life domain, including – health, personal relationships, safety, 
standard of living, achieving, community connectedness, and future security. 
Ratings are made on a 10-point scale ranging from ‘no satisfaction at all’ through to 
‘completely satisfied’. It is suggested that a ‘normal’ range can be calculated based 
on 2 standard deviations either side of the mean (Cummins et al., 2011). In 2011, 
data was collected from 2000 randomly selected adults in a geographically 
representative Australian sample (Cummins et al., 2011). Based on this data 
(m=75.46, SD=12.87), the current study defines low quality of life as scores less than 
49.72 (greater than 2SD below the mean). 
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The Short-Form Health Surveys are a group scales providing a general measure of 
self-rated health. Whilst the SF-36 has been extensively tested and used within 
Australia, the briefer form, the SF-8 was chosen for brevity, and was re-scaled to fit 
SF-36 norms. The SF-8 measures 8 domains, across the last four weeks; physical 
functioning, role functioning related to physical problems, bodily pain, general 
health, vitality, social functioning, role functioning related to emotional problems 
and mental health. These domains then combine to form a physical component 
summary score and mental component summary score. For each scale, scores range 
between 0-100, with higher scores equating to better health. Norms from a South 
Australian population study were chosen as the most up-to-date and representative 
Australian norms (Avery, Dal Grande, & Taylor, 2004). Those scoring less than two 
standard deviations below the mean were identified as the problem group, cut-off 
scores were as follows; physical component summary score ≤28.62 (norms; 
m=48.99, SD=10.18) and mental component summary score ≤34.79 (norms; 
m=52.38, SD=8.79). 
In addition to the distinction made between people who consumed alcohol daily, or 
less than daily, problematic alcohol use was assessed using the Alcohol Use 
Disorders Identification Test (AUDIT; Babor, Higgins-Biddle, Saunders, & Monteiro, 
2001). The AUDIT is a 10-item questionnaire developed to identify risky or harmful 
drinking, as well as alcohol dependence. The AUDIT has demonstrated excellent 
psychometric characteristics, and has been validated in large multi-nation studies 
(de Meneses-Gaya, Zuardi, Loureiro, & Crippa, 2009). Scores range from 0-40, with 
higher scores indicative of more problematic alcohol use. Scores of 16 and above 
represent high levels of alcohol problems.  
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Table 1. Rationale for inclusion of Predictor variables 
Factor: Categorisation: 
(at risk, low risk)a 
Included because of previous association 
with: 
Age  0-30 years, 30 
years plus 
Accidents (Bureau of Infrastructure, 2014; 
Simpson et al., 2005; Wadsworth, 
Simpson, et al., 2003) 
Injuries (Simpson et al., 2005; Wadsworth, 
Moss, Simpson, & Smith, 2003; 
Wadsworth, Simpson, et al., 2003) 
Cognitive failures (Simpson et al., 2005; 
Wadsworth, Simpson, et al., 2003),  
Sex Male, female Accidents (Bureau of Infrastructure, 2014; 
Simpson et al., 2005) 
Injuries (Pointer, 2013) 
Cognitive failures (Simpson et al., 2005),  
Education  Grades 1-10, 
Grades 11-12b 
Accidents (Cubbin & Smith, 2002) 
Injuries (Cubbin & Smith, 2002) 
Cognitive failures (Wadsworth, Simpson, 
et al., 2003; Weinborn, Woods, O’Toole, 
Kellogg, & Moyle, 2011),  
Income 
(weekly)c 
≤$504, >$505  Accidents (Cubbin & Smith, 2002) 
Injuries (Cubbin & Smith, 2002; Simpson 
et al., 2005), 
Cognitive failures (Simpson et al., 2005; 
Wadsworth, Moss, et al., 2003; 
Wadsworth, Simpson, et al., 2003),  
Employment 
Status 
Not employed, 
Employed 
Accidents (Australian Bureau of Statistics, 
2011) 
Injuries (Simpson et al., 2005; Wadsworth, 
Simpson, et al., 2003) 
Cognitive failures (Simpson et al., 2005; 
Wadsworth, Simpson, et al., 2003),  
Relationship 
Status 
Partnered, Non-
partnered 
Accidents (Wadsworth, Moss, et al., 2003) 
Injuries (Wadsworth, Moss, et al., 2003)  
Physical health 
problems  
SF-8 Physical 
Component 
Scored cut-off  
≤2SD population; 
≤ 28.62, >28.63 
Accidents (Simpson et al., 2005) 
Injuries (Simpson et al., 2005; Wadsworth, 
Moss, et al., 2003) 
Cognitive failures (Simpson et al., 2005; 
Wadsworth, Moss, et al., 2003) 
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Factor: Categorisation: 
(at risk, low risk)a 
Included because of previous association 
with: 
Mental health 
problems  
SF8 Mental 
Component 
Scoree cut-off 
≤2SD population; 
≤34.79, >34.80 
and  
Kessler-10f score 
22-50, 0-21 
Accidents (Hilton & Whiteford, 2010; 
Simpson et al., 2005) 
Injuries (Simpson et al., 2005; Wadsworth, 
Moss, et al., 2003; Wadsworth, Simpson, 
et al., 2003) 
Cognitive failures (Simpson et al., 2005; 
Wadsworth, Moss, et al., 2003; 
Wadsworth, Simpson, et al., 2003)  
Quality of Life PWIg cut-off ≤2SD 
population; 
Scores ≤ 49.72, > 
49.73 
Accidents (Cummins et al., 2011) 
Injuries (Cummins et al., 2011) 
Injecting drug use (Dietze et al., 2010) 
Alcohol 
Consumption 
 
Daily Alcohol: 
Used 180 + times, 
Used 0-179 times 
(within 6 month 
period) 
and 
Risky 
drinking/AUDITh 
score: 16-40, 0-15 
Accidents (Bureau of Infrastructure, 2014; 
Movig et al., 2004; Simpson et al., 2005) 
Injuries (Burger, Lichtenstein, Hays, & 
Decker, 1990) 
Cognitive failures (Griffiths et al., 2012; 
Heffernan, Moss, & Ling, 2002) 
Daily cannabis 
use 
Used 180 + times, 
Used 0-179 times 
(within 6 month 
period) 
Accidents (Kelly et al., 2004; Wadsworth, 
Moss, Simpson, & Smith, 2006) 
Injuries (Barrio et al., 2012; Wadsworth et 
al., 2006) 
Cognitive failures (Bartholomew et al., 
2010; Matthews & Bruno, 2011; 
Montgomery et al., 2012) 
Daily 
benzodiazepine 
use  
Used 180 + times, 
Used 0-179 times 
(within 6 month 
period) 
 
Accidents (Kelly et al., 2004; Movig et al., 
2004) 
Injuries (Wadsworth et al., 2005) 
Cognitive failures (Barker, Greenwood, 
Jackson, & Crowe, 2004b; Rich et al., 
2006; Wadsworth et al., 2005) 
 
Graded 
Benzodiazepine 
use  
Regular: Used 
144-180, 
Moderate: Used 
24-143  times, 
Low: Used 0-23 
times (within 6 
month period) 
Accidents (Kelly et al., 2004; Movig et al., 
2004) 
Injuries (Wadsworth et al., 2005) 
Cognitive failures (Barker, Greenwood, 
Jackson, & Crowe, 2004b; Rich et al., 
2006; Wadsworth et al., 2005) 
 
Chapter 7: The Unique Impact of Benzodiazepines on the Safety of PWID | 131 
 
 
 
Factor: Categorisation: 
(at risk, low risk)a 
Included because of previous association 
with: 
Daily opioid 
use 
Used 180 + times, 
Used 0-179 times 
(within 6 month 
period) 
Accidents (Hulse, English, Milne, & 
Holman, 1999; Kelly et al., 2004; Raes et 
al., 2008) 
Injuries (Majdzadeh et al., 2009) 
Cognitive failures (Terrett et al., 2014) 
Weekly 
Amphetamine 
Use 
Used 24-80 times, 
Used 0-23 
times(within 6 
month period) 
Accidents (Kelly et al., 2004; Raes et al., 
2008) 
Cognitive failures (Ludicello et al., 2011; 
Rendell et al., 2009) 
Daily tobacco 
use 
Used 180 + times, 
Used 0-179 times 
(within 6 month 
period) 
Accidents (Wadsworth, Simpson, et al., 
2003) 
Injuries (Collins & Lapsley, 2008; 
Wadsworth, Simpson, et al., 2003) 
Cognitive failures (Heffernan et al., 2005; 
Simpson et al., 2005)  
Daily injection Injected 180 + 
times, Injected 0-
179 times (within 
6 month period) 
Dependence & drug related harms (Loxley 
et al., 2004) 
aPredictor variables were used a categorical variables, and were separated into ‘at risk’ and ‘low risk’ 
groups, based on findings and cut-off scores from previous literature. In the regression analyses, the 
‘low risk’ categories were the baseline group, and the ‘at risk’ categories were the comparison group. 
bIn Australia, Grade 11 students are normally 16-17 years of age, and are typically in their twelfth 
year of education. cThis weekly amount represents the poverty line for a single working adult. If the 
income for a family unit is less than the applicable poverty line, they are considered to be in poverty 
(Melbourne Institute of Applied Economic and Social Research, 2014). This amount does not take 
into account the presence of other dependent family members. dShort-Form Health Survey-8 – 
Physical Component Score (Ware, Kosinski, & Keller, 1995) eShort-Form Health Survey-8 – Mental 
Component Score (Ware, Kosinski, & Keller, 1995) fKessler Psychological Distress Scale (K-10: Kessler 
& Mroczek, 1994). gPersonal Wellbeing Index (International Wellbeing Group, 2013). hAlcohol Use 
Disorders Identification Test (Saunders, Aasland, Babor, de la Fuente, & Grant, 1993).  
Analysis 
Using SPSS (Version 22) univariate logistic regression was conducted to examine 
associations between demographic, substance use, and health related predictor 
variables, and the dependent measures; major accidents, frequent minor injuries, 
prospective memory problems, and retrospective memory problems. The predictor 
variables were categorical, divided into ‘at risk’ or ‘low risk’ classifications. For each 
variable the ‘low risk’ group was used as the baseline group in the analysis, and the 
‘at risk’ group was used as the comparison group. Therefore, an odds ratio of >1, 
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means that the outcome variable is more likely to occur in the comparison group 
compared to the baseline group. Given that the current sample size is small, the 
decision was made to also run a bootstrapping analysis. Bootstrapping is a general 
resampling procedure and was used to aid in interpretation of results. A 
multivariate model was then run, and to avoid multicollinearity the following 
variables were excluded; income, SF-8 Mental component, risky drinking (AUDIT), 
and daily benzodiazepine use. All other variables listed in Table 1 were included in 
the analysis. Data from this analysis is reported in the multivariate results. A final 
stepwise analysis was run in order to determine the individual contribution of 
benzodiazepine use to safety. Model 1 included demographic predictors only (age, 
sex, education, employment, partnered, physical health problems, psychological 
distress, and quality of life), Model 2 added drug use variables, excluding 
benzodiazepines (daily alcohol, daily cannabis, daily opioid, daily tobacco, weekly 
amphetamine, and daily injecting) and Model 3 added the graded benzodiazepine 
variable (low, moderate, and regular use).  
RESULTS 
Sample Characteristics 
Participants (n=170) had a mean age of 33.91 years (SD=9.05, range 19-60) and 
59.4% (95%CI 52.0-66.8) were males. Mean grade of school completion was grade 
10 (SD=1.53, range grades 4-12), with slightly less than half (45.9%, 95%CI 38.4-
53.4) completing further qualifications, and the majority being unemployed (74.7%, 
95%CI 68.2-81.2). Respondents typically injected on multiple occasions per week 
(57.6%, 95%CI 50.2-65.0), with about one-third injecting daily (34.6%, 95%CI 27.5-
41.8), despite this over half were not in substitution treatment (55.9%, 95%CI 48.4-
63.4). 
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Logistic Regression 
Results from the univariate analysis are shown in Tables 2 and 3, from the 
multivariate analysis in Table 4 and 5, and Table 6 presents the Nagelkerke R2 
values.  
Major Accidents 
A considerable 18% (95%CI 12.8-24.7) of this sample had experienced at least one 
accident requiring medical attention in the last 12 months. The only significant 
predictors of major accidents were physical health problems and regular 
benzodiazepine use (at least 6 times a week). There was a trend towards increased 
accidents for daily cannabis users. In the multivariate analysis, benzodiazepine use 
most days and daily opioid use were the only significant predictors of accidents. As 
shown by the stepwise analysis, benzodiazepines contributed independently to 
5.4% of the variance in the model. 
Minor Injuries 
Minor injuries were experienced by 24.8% (95%CI 18.8-32.1%) of the sample. Those 
with low quality of life were almost three times more likely to report frequent 
minor injuries; this was the only significant association. There were trends close to 
significance for those who were unpartnered and used cannabis daily. After 
controlling for other factors in the multivariate model, the only predictor 
approaching significance was daily cannabis use. 
Prospective Memory 
Prospective memory problems were found in 22.2% (95%CI 16.4-29.2) of the 
sample. There were associations between prospective memory problems and 
regular benzodiazepine use, physical health problems, psychological distress, low 
quality of life, daily alcohol use, daily cannabis use, daily injecting, being female, and 
being partnered. After controlling for other variables in the multivariate model, 
those with physical health problems were almost 25 times more likely to experience 
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a prospective memory problem. Surprisingly, those with prospective memory 
problems were also significantly more likely to be employed, or have a partner. 
Daily cannabis use and weekly amphetamine use were also significant predictors of 
prospective memory problems. Stepwise analysis showed that benzodiazepine use 
did not contribute independently to the risk of prospective memory problems. 
Retrospective Memory 
In this group, 10.8% (95%CI 6.8-16.6) reported retrospective memory problems. The 
univariate analysis revealed those experiencing retrospective memory problems 
were significantly more likely to be female, report problems with physical and 
mental health, psychological distress, and low quality of life, and to consume 
alcohol daily, inject daily, and use benzodiazepines most days in a week. In the 
multivariate analysis those reporting low quality of life were almost 6 times more 
likely to experience retrospective memory problems. People reporting intermediate 
benzodiazepine use (using 1-6 times a week) were 8 times more likely to experience 
retrospective memory problems. There were effects approaching significance for 
those who used benzodiazepines almost every day (OR 6.67, 95%CI 0.98-45.46, 
p=0.053), for daily alcohol use, and daily injecting. In the stepwise analysis, 
benzodiazepine use independently contributed to 5.9% of the variance in 
retrospective memory. 
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Table 2. Univariate Logistic Regression Predicting Likelihood of Accidents and Injuries 
*Table Interpretation: The predictor variables listed are the comparison group. The percentages reported are the percentages of the comparison group that either did or did not experience an event. Regarding the odds ratio (OR), an OR>1 means that the event 
(e.g. accident) was more likely in the comparison group, an OR<1 means it was more likely in the baseline group. For example, as reported above, of those who had not experienced a major accident in the last 12 months, 6.9% had ‘physical health problems’, for 
those who had experienced an accident, 17.9% had ‘physical health problems’. Those who had ‘physical health problems’ were 2.95 times more like to experience an accident than those who did not. For the benzodiazepine chronicity variable, the ‘low use’ 
category was the baseline group. aSF-8 Physical Component Score, bSF-8 Mental Component Score, cKessler-10, dAlcohol Use Disorders Identification Test-C, ePersonal Wellbeing Index 
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Demographic characteristics            
Age (<30) 41.7 41.4 0.99 (0.977) 0.972 0.44-2.24  39.7 47.5 1.38 (0.385) 0.402 0.67-2.83 
Male 60.6 58.6 0.92 (0.843) 0.847 0.41-2.09  58.7 65.0 1.31 (0.479) 0.500 0.62-2.75 
Education (≤Year 10) 67.4 75.9 1.52 (0.376) 0.399 0.60-3.83  66.9 75.0 1.48 (0.341) 0.353 0.66-3.33 
Income (<$13,000) 93.1 96.6 2.07 (0.500) 0.241 0.25-16.98  93.4 94.9 1.31 (0.74) 0.642 0.27-6.44 
Unemployed 15.2 17.2 1.17 (0.779) 0.777 0.40-3.42  14.9 17.5 1.21 (0.692) 0.702 0.47-3.16 
Unpartnered 43.9 44.8 1.04 (0.930) 0.922 0.46-2.33  39.7 57.5 2.06 (0.051) 0.062 1.00-4.25 
Health factors            
Physical health problems: SF8 PCSa  6.9 17.9 2.95 (0.073) 0.001 0.91-9.60  6.7 15.0 2.45 (0.119) 0.120 0.79-7.55 
Mental health problems: SF8 MCSb 41.2 42.9 1.07 (0.873) 0.897 0.47-2.44  39.5 47.5 1.39 (0.375) 0.368 0.67-2.85 
Psychological Distress: K-10c 60.8 58.6 0.91 (0.829) 0.833 0.40-2.08  58.6 65.8 1.36 (0.434) 0.429 0.63-2.92 
Risky drinking: AUDITd 23.6 33.3 1.62 (0.294) 0.272 0.66-3.99  23.2 31.6 1.53 (0.308) 0.324 0.68-3.44 
Quality of Life: PWIe 28.8 37.9 1.51 (0.335) 0.334 0.65-3.5  24.8 47.5 2.74 (0.008) 0.008 1.30-5.78 
Drug use over past 6 months            
Daily alcohol 7.6 13.8 1.95 (0.289) 0.254 0.57-6.72  6.6 15.0 2.49 (0.112) 0.104 0.81-7.68 
Daily cannabis use 45.5 65.5 2.28 (0.054) 0.056 0.99-5.28  44.6 62.5 2.07 (0.052) 0.067 0.99-4.31 
Daily benzodiazepine use  23.5 41.4 2.30 (0.052) 0.060 0.99-5.36  26.4 27.5 1.055 (0.896) 0.895 0.47-2.36 
Benzodiazepine use  
- Low (Used 0-23 times) 
- Moderate (Used 24-143 times) 
- Regular (Used 144-180 times) 
 
53.0 
22.7 
24.2 
 
34.5 
20.7 
44.8 
(0.079) 
 
1.40 (0.548) 
2.85 (0.027) 
 
 
0.566 
0.021 
 
 
0.47-4.20 
1.13-7.17 
  
51.2 
21.5 
27.3 
 
45.0 
25.0 
30.0 
(0.787) 
 
1.33 (0.540) 
1.25 (0.601) 
 
 
0.549 
0.614 
 
 
0.54-3.25 
0.54-2.91 
Daily opioid use 58.3 44.8 0.58 (0.188) 0.183 0.26-1.30  54.5 60.0 1.25 (0.547) 0.541 0.61-2.59 
Daily tobacco use 92.4 93.1 1.11 (0.900) 0.761 0.23-5.34  92.6 92.5 0.99 (0.990) 0.940 0.26-3.86 
Weekly amphetamine Use 36.4 34.5 0.92 (0.849) 0.829 0.40-2.14  33.9 42.5 1.44 (0.326) 0.349 0.69-3.00 
Daily injection 33.6 44.8 1.61 (0.255) 0.265 0.71-3.64  32.5 45.0 1.70 (0.155) 0.148 0.82-3.53 
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Table 3. Univariate Logistic Regression Predicting Likelihood of Cognitive Failures 
 
 
 
 
 
 
 
 
 
 
 
 
*Table Interpretation: The predictor variables listed are the comparison group. The percentages reported are the percentages of the comparison group that either did or did not experience an event. Regarding the odds ratio (OR), an OR>1 
means that the event (e.g. accident) was more likely in the comparison group, an OR<1 means it was more likely in the baseline group. For example, as reported above, of those who had not experienced a prospective memory problem in 
the last 12 months, 30.3% injected daily, for those who had experienced an accident, 54.3% had injected daily. Those who injected daily were 2.73 times more like to experience a prospective memory problem than those who did not. For 
the benzodiazepine chronicity variable, the ‘low use’ category was the baseline group aSF-8 Physical Component Score, bSF-8 Mental Component Score, cKessler-10, dAlcohol Use Disorders Identification Test-C, ePersonal Wellbeing Index.
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Demographic characteristics            
Age (<30) 39.8 45.7 1.27 (0.534) 0.547 0.60-2.71  41.1 41.2 1.00 (0.997) 0.998 0.36-2.79 
Male 65.0 40.0 0.36 (0.009) 0.008 0.17-0.78  62.4 35.3 0.33 (0.038) 0.033 0.12-0.94 
Education (≤Year 10) 69.1 74.3 1.29 (0.555) 0.540 0.55-3.02  68.8 82.4 2.12 (0.257) 0.183 0.58-7.74 
Income (<$13,000) 93.4 97.1 2.39 (0.420) 0.211 0.29-19.76  93.6 100.0 - (0.999) 0.001 - 
Unemployed 17.9 5.7 0.28 (0.095) 0.056 0.06-1.25  15.6 11.8 0.72 (0.678) 0.559 0.15-3.38 
Unpartnered 48.0 28.6 0.43 (0.044) 0.034 0.19-.98  44.7 35.3 0.68 (0.463) 0.470 0.24-1.93 
Health factors            
Physical health problems: SF8 PCSa  5.0 22.9 5.68 (0.003) 0.001 1.82-17.73  7.2 23.5 3.97 (0.037) 0.019 1.09-14.45 
Mental health problems: SF8 MCSb 38.8 51.4 1.67 (0.186) 0.195 0.78-3.55  37.4 76.5 5.43 (0.005) 0.004 1.68-17.56 
Psychological Distress: K-10c 55.6 82.4 3.73 (0.007) 0.003 1.44-9.69  57.8 93.8 10.96 (0.022) 0.020 1.41-85.39 
Risky drinking: AUDITd 24.3 29.4 1.30 (0.552) 0.559 0.55-3.03  23.5 41.2 2.28 (0.123) 0.113 0.80-6.49 
Quality of Life: PWIe 26.8 45.7 2.30 (0.036) 0.030 1.06-4.99  27.0 64.7 4.97 (0.003) 0.001 1.72-14.37 
Drug use over past 6 months            
Daily alcohol 5.7 17.1 3.43 (0.038) 0.022 1.07-10.98  6.4 23.5 4.51 (0.024) 0.007 1.22-16.70 
Daily cannabis use 44.7 71.4 3.09 (0.007) 0.006 1.37-6.98  48.9 64.7 1.91 (0.225) 0.241 0.67-5.46 
Daily benzodiazepine use  23.6 40.0 2.16 (0.057) 0.067 0.98-4.78  24.1 52.9 3.54 (0.016) 0.007 1.27-9.89 
Benzodiazepine use  
- Low (Used 0-23 times) 
- Moderate (Used 24-143 times) 
- Regular (Used 144-180 times) 
 
53.7  
 22.0 
24.4 
 
34.3 
22.9 
42.9 
(0.076) 
 
1.63 (0.339) 
2.75 (0.023) 
 
 
0.329 
0.018 
 
 
0.60-4.43 
1.15-6.59 
  
 53.2  
 21.3 
25.5 
 
17.6 
29.4 
52.9 
(0.031) 
 
4.17 (0.061) 
6.25 (0.009) 
 
 
0.022 
0.004 
 
 
0.94-18.54 
1.60-24.49 
Daily opioid use 55.3 60.0 1.21 (0.62) 0.651 0.57-2.61  56.0 58.8 1.12 (0.826) 0.826 0.40-3.11 
Daily tobacco use 91.1 97.1 3.34 (0.257) 0.130 0.42-26.80  92.2 94.1 1.35 (0.779) 0.418 0.16-11.19 
Weekly amphetamine Use 34.1 51.4 2.04 (0.066) 0.068 0.96-4.37  36.2 52.9 1.99 (0.184) 0.185 0.72-5.46 
Daily injection 30.3 54.3 2.73 (0.011) 0.008 1.26-5.89  32.1 64.7 3.87 (0.012) 0.010 1.35-11.13 
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Table 4. Multivariate Logistic Regression Predicting Likelihood of Accidents and Injuries 
 Major Accidents  
(Requiring medical attention) 
 Minor Injuries  
(Not requiring medical attention) 
Predictor Variables 
Comparison Groups 
No Accident  
% 
n=131 
Accident 
% 
n=29 
OR 
(significance) 
95%CI  No Minor 
Injury 
% 
n=130 
Minor 
Injury 
% 
n=40 
OR 
(significance) 
95%CI 
Age (<30) 41.7 41.4 0.79 (0.639) 0.30-2.11  39.7 47.5 1.20 (0.680) 0.51-2.84 
Male 60.6 58.6 1.22 (0.716) 0.42-3.49  58.7 65.0 1.17 (0.746) 0.46-2.98 
Education (≤Year 10) 67.4 75.9 1.59 (0.402) 0.54-4.66  66.9 75.0 1.46 (0.442) 0.55-3.88 
Unemployed 15.2 17.2 1.00 (0.996) 0.24-4.13  14.9 17.5 2.08 (0.227) 0.63-6.82 
Unpartnered 43.9 44.8 1.10 (0.847) 0.41-2.97  39.7 57.5 2.04 0.111) 0.85-4.92 
Physical health problems: SF8 PCSa 6.9 17.9 2.97 (0.141) 0.70-12.59  6.7 15.0 2.25 (0.246) 0.57-8.83 
Psychological Distress: K-10b 60.8 58.6 0.62 (0.382) 0.21-1.82  58.6 65.8 1.20 (0.725) 0.44-3.22 
Quality of Life: PWIc 28.8 37.9 1.13  (0.826) 0.38-3.33  24.8 47.5 1.89 (0.169) 0.76-4.68 
Daily alcohol 7.6 13.8 1.59 (0.557) 0.34-7.46  6.6 15.0 1.90 (0.364) 0.48-7.58 
Daily cannabis use 45.5 65.5 2.00 (0.157) 0.77-5.22  44.6 62.5 2.27 (0.058) 0.97-5.30 
Benzodiazepine use  
- Low (Used 0-23 times) 
- Moderate (Used 24-143 times) 
- Regular (Used 144-180 times) 
 
53.0 
22.7 
24.2 
 
34.5 
20.7 
44.8 
(0.072) 
 
2.44 (0.168) 
3.88 (0.023) 
 
 
0.69-8.71 
1.20-12.50 
  
51.2 
21.5 
27.3 
 
45.0 
25.0 
30.0 
(0.663) 
 
1.47 (0.478) 
0.87 (0.803) 
 
 
0.51-4.24 
0.30-2.56 
Daily opioid use 58.3  44.8  0.29 (0.020) 0.10-0.82  54.5 60.0 1.19 (0.712) 0.48-2.92 
Daily tobacco use 92.4 93.1 0.53 (0.483) 0.09-3.13  92.6 92.5 0.96 (0.964) 0.16-5.68 
Weekly amphetamine Use 36.4 34.5 0.78 (0.632) 0.28-2.15  33.9 42.5 1.31  (0.547) 0.55-3.14 
Daily injection 33.6 44.8 2.60 (0.069) 0.93-7.29  32.5 45.0 1.59 (0.312) 0.65-3.89 
*Table Interpretation: The predictor variables listed are the comparison group. The percentages reported are the percentages of the comparison group that either did or did not experience an event. Regarding the 
odds ratio (OR), an OR>1 means that the event (e.g. accident) was more likely in the comparison group, an OR<1 means it was more likely in the baseline group. For example, as reported above, of those who had not 
experienced a major accident in the last 12 months, 58.3% used opioids daily, for those who had experienced an accident, 44.8% had used opioids daily. Those who used opioids daily were only one-third as likely to 
experience an accident as those who did not. For the benzodiazepine chronicity variable, the ‘low use’ category was the baseline group. aSF-8 Physical Component Score, bKessler-10, cPersonal Wellbeing Index.  
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Table 5. Multivariate Logistic Regression Predicting Likelihood of Cognitive Failures 
*Table Interpretation: The predictor variables listed are the comparison group. The percentages reported are the percentages of the comparison group that either did or did not experience an event. Regarding the 
odds ratio (OR), an OR>1 means that the event (e.g. accident) was more likely in the comparison group, an OR<1 means it was more likely in the baseline group. For example, as reported above, of those who had not 
experienced a prospective memory problem in the last 12 months, 44.7% used cannabis daily, for those who had experienced an accident, 71.4% used cannabis daily. Those who used cannabis daily were 7.33 times 
more like to experience a prospective memory problem than those who did not. For the benzodiazepine chronicity variable, the ‘low use’ category was the baseline group. aSF-8 Physical Component Score, bKessler-
10, cPersonal Wellbeing Index.
 
 
Prospective memory problem  
(Remembering to remember – e.g. an appointment, medication) 
 Retrospective memory problem  
(Remembering what you want to remember – e.g. information) 
 No PM 
problem 
% 
n=122 
PM 
Problem 
% 
n=35 
OR 
(significance) 
95%CI  No RM  Problem 
% 
n=140 
RM 
Problem 
% 
n=17 
OR 
(significance) 
95%CI 
Age (<30) 39.8 45.7 1.65 (0.381) 0.54-5.06  41.1 41.2 0.43 (0.325) 0. 8-2.31 
Male 65.0 40.0 0.45 (0.181) 0.15-1.43  62.4 35.3 0.57 (0.487) 0.11-2.81 
Education (≤Year 10) 69.1 74.3 0.68 (0.514) 0.21-2.18  68.8 82.4 1.98 (0.465) 0.32-12.38
Unemployed 17.9 5.7 0.03 (0.007) 0.00-3.80  15.6 11.8 0.41 (0.538) 0.03-6.88 
Unpartnered 48.0 28.6 0.11 (0.002) 0.03-0.44  44.7 35.3 0.26 (0.119) 0.05-1.41 
Physical health problems: SF8 PCSa 5.0 22.9 24.67 (0.001) 4.05-150.07  7.2 23.5 4.79 (0.161) 0.54-42.79 
Psychological Distress: K-10b 55.6 82.4 2.64 (0.154) 0.70-9.98  57.8 93.8 3.59 (0.299) 0.32-39.93 
Quality of Life: PWIc 26.8 45.7 2.34 (0.177) 0.68-8.03  27.0 64.7 5.84 (0.031) 1.17-29.15 
Daily alcohol 5.7 17.1 3.83 (0.147) 0.62-23.63  6.4 23.5 9.32 (0.072) 0.82-106.40 
Daily cannabis use 44.7 71.4 7.33 (0.002) 2.06-26.07  48.9 64.7 1.45 (0.632) 0.32-6.56 
Benzodiazepine use  
- Low (Used 0-23 times) 
- Moderate (Used 24-143 times) 
- Regular (Used 144-180 times) 
 
53.7 
22.0 
24.4 
 
34.3 
22.9 
42.9 
(0.733) 
 
1.72 (0.486) 
1.58 (0.494) 
 
 
0.38-7.87 
0.42-5.90 
  
53.2 
21.3 
25.5 
 
17.6 
29.4 
52.9 
(0.094) 
 
8.21 (0.047) 
6.67 (0.053) 
 
 
1.03-65.41 
0.98-45.46 
Daily opioid use 55.3 60.0 0.87 (0.811) 0.27-2.83  56.0 58.8 0.29 (0.186) 0.05-1.8  
Daily tobacco use 91.1 97.1 1.53 (0.750) 0.11-21.37  92.2 94.1 0.21 (0.306) 0.01-4.17 
Weekly amphetamine Use 34.1 51.4 3.71 (0.035) 1.10-12.51  36.2 52.9 1.62 (0.546) 0.34-7.67 
Daily injection 30.3 54.3 2.43 (0.113) 0.81-7.26  32.1 64.7 4.52 (0.070) 0.88-23.11 
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Table 6. Nagelkerke R2 values for Stepwise analysis, for each Outcome variable 
 
 
 
 
aModel 1 Included demographic predictors only (age, sex, education, employment, 
partnered, physical health problems, psychological distress, and quality of life), 
bIncluded variables from Model 1 plus drug use variables, excluding 
benzodiazepines (daily alcohol, daily cannabis, daily opioid, daily tobacco, weekly 
amphetamine, and daily injecting).cIncluded variables from Models 1 and 2 plus the 
graded benzodiazepine variable (low, moderate, and regular use). 
 
DISCUSSION 
This study aimed to investigate the characteristics of injecting drug use associated 
with decreased safety. Results showed a variety of predictors were associated with 
the outcome measures, which is consistent with the premise that there are a range 
of risk factors impacting on the lives of injecting drug users. Even with the multitude 
of other hazardous factors and behaviours, moderate benzodiazepine use 
independently contributed to an increased risk of retrospective memory problems 
(OR 8.21, 95%CI 1.03-65.41, p=0.047), and regular benzodiazepine use was 
associated with major accidents (OR 3.88, 95%CI 1.20-12.50, p=0.023). 
It is commonly recommended that the prescription of benzodiazepines is best 
avoided in people who misuse other drugs. This is due to the high risk of adverse 
events that can occur when benzodiazepines are used in combination with other 
central nervous system depressants (such as alcohol or opioids), including sedation, 
respiratory depression, and death (Royal Australian College of General Practitioners, 
2015). Benzodiazepine use is associated with an increase in general harms linked 
with injecting drug use, including poorer physical and mental health (Darke, Hall, 
Ross, & Wodak, 1992; Darke et al., 2010). There is also evidence that people 
participating in opioid substitution therapy, who regularly or occasionally use 
 Accidents Injuries Prospective 
Memory 
Retrospective 
Memory 
Model 1a 0.036 0.120 0.312 0.286 
Model 2b 0.134 0.183 0.517 0.423 
Model 3c 0.188 0.190 0.521 0.482 
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benzodiazepines, have more adverse outcomes (Mental Health and Drug and 
Alcohol Office (MHDAO), 2006). It is not recommended that prescribers provide 
substitution benzodiazepine therapy for those who are using benzodiazepines 
illicitly (Royal Australian College of General Practitioners, 2015). Despite these 
recommendations, many of this sample are regular benzodiazepine users. That 
benzodiazepine use is so common in a population at high risk of negative outcomes, 
does emphasise the importance of greater control of benzodiazepine prescription. 
In this sample of people who inject drugs, reported rates of accidents, injuries, and 
prospective and retrospective memory problems occurred in significantly higher 
proportions compared to the general population. Comparable research in the UK 
(Wadsworth et al., 2005) found that in a random postal population study (n=7979), 
11% of respondents reported an accident (excluding traffic accidents), 
comparatively 18% of this sample had reported at least one accident 
(χ2(1n=8139)=7.34, p=0.006). Likewise when comparing minor injury rates, 14% of 
the UK general population sample experienced quite or very frequent injuries, 
compared to 25% of this injecting drug sample (χ2(1n=8140)=14.35, p<0.001). 
General population data were obtained for the PRMQ from a large sample (n=551) 
by Crawford and colleagues (2003). Assuming a standard distribution, prospective 
and retrospective memory problems are expected to occur in the general 
population at a rate of less than 2.3%. Rates in the PWID sample occurred at 
significantly higher levels for both prospective memory, with 22% experiencing 
problems (χ2(1n=709)=73.21, p<0.001), and retrospective memory with 11% 
reporting problems (χ2(1n=709)=20.80, p<0.001). Elevated rates of incidents are 
indicative of the hazardous lifestyle led by this group; the variables examined here 
go some way towards understanding this risk. 
Current findings indicate that this cohort experiences low levels of health and well-
being. For example, 30% of this injecting drug population reported a personal 
wellbeing index (PWI) score of more than two standard deviations below the mean 
(<49.73), indicating very low quality of life. Comparatively, in a general population 
survey of 34,804 people, only 4.4% fell below a score of 50 (Cummins et al., 2011). 
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This difference in proportions is statistically significant (χ2(1n=34,973)=241.20, 
p<0.001). Extensive research on the PWI suggests that a normal level of wellbeing, 
usually around 75 points, allows people to feel good about themselves, be 
motivated to conduct their lives, and optimistic (Cummins et al., 2011). It is 
suggested that most people are able to maintain their quality of life around this 
normal range, despite a variety of difficult life events. When levels do fall below this 
range, people are at risk of depression and low wellbeing. Inability to maintain 
homeostasis of wellbeing is influenced by genetic and environmental factors, but 
can also be strengthened by certain aspects, like personal relationships. Likewise, 
when examining psychological distress, 60% of the current group were classified in 
the ‘very high’ level of distress, which is significantly elevated 
(χ2(1n=20,661)=384.37, p<0.001) compared to a national rate of 10.8%, calculated 
from 20,500 people in the National Health Survey (Australian Bureau of Statistics, 
2012. Rating within this very high level of distress places individuals at a high risk of 
depression. That such a considerable proportion of this PWID cohort, are so 
markedly below the average range on these measures, is indicative of the high 
levels of stressful life events experienced, combined with a lack of protective 
factors, and is likely to have a substantial impact on their continued health and 
wellbeing. 
Much of the previous accident research has relied on data gained from presentation 
to medical services. A strength of the current study is that it follows the research of 
Wadsworth and colleagues (for example: Wadsworth, Moss, et al., 2003; 
Wadsworth et al., 2005) in examining safety incidents of a lower severity. Given that 
deficits in cognitive processes have been shown to predict propensity for accident 
involvement (Wallace & Vodanovich, 2003), it is extremely important that these 
lower level incidents continue to be involved in study designs. However with this 
comes a reliance on self-report data. Whilst the use of self-report is well-established 
in this population (Darke, 1998), it is necessary to find a time frame that allows for 
accurate recall, whilst providing sufficient time for exposure to accidents and 
injuries. Research suggests that an extended period of recall leads to 
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underestimation of minor injuries; however, reports of more significant injury are 
not affected within a 12 month period (Harel et al., 1994; Moshiro, Heuch, Astrom, 
Setel, & Kvale, 2005). Considering the 6-month time frame used in this study, and 
the fact that reported incident rates far exceed general population rates, it appears 
that incident recall has not been significantly affected in this study; a viable concern 
given the possibly cognitively compromised population studied. 
It is notable that even in the context of high severity injecting drug use, substances 
that may be considered a low treatment priority, such as alcohol and cannabis, have 
significant associations with safety. From a research consideration, this 
demonstrates the importance of screening and controlling for and including these 
substances in analyses. Regarding clinical practice, it shows the importance of harm 
minimising interventions that target all regular drug use, not just the substance that 
is deemed the most hazardous, or is the presenting issue. 
This research found that benzodiazepines independently contribute to an increased 
risk of incidents in a PWID cohort; a group for whom safety and well-being is 
already compromised. It is often argued that benzodiazepine users are most at risk 
during initial onset of use and side-effects decrease with time. However, with 28% 
of the cohort using at least daily for 6 months, they are clearly chronic users, and 
they still appear to be negatively affected by the use of benzodiazepines. From a 
clinical practice consideration, these findings support the importance of further 
regulating benzodiazepine prescription, and increasing treatment options for those 
living with drug and alcohol addictions.  
As expected, there are a range of predictors that influence the safety of people who 
inject drugs, including some that are commonly seen as more benign such as 
alcohol, cannabis, and prescribed benzodiazepines. The use of benzodiazepines in 
people who inject drugs is countraindicated. The findings of the current study show 
that there are additional and independent detrimental effects of benzodiazepines 
on safety in this cohort. More effective management of benzodiazepine use is an 
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important component of improving the remarkably low levels of self-rated well-
being, and high psychological distress found in this cohort. 
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CHAPTER 8: THE SUBJECTIVE EXPERIENCES OF CHRONIC BENZODIAZEPINE 
CONSUMERS 
 
Preface 
Study 1 and Study 2 examined the association between benzodiazepine use, other 
confounding variables, and experience of safety incidents. Reports of safety 
incidents were elevated in both the general population sample (Study 1) and a 
sample of people who inject drugs (Study 2). Comparatively, the focus of this 
chapter is to report on the subjective perceptions of a group of chronic 
benzodiazepine users (Study 3). Data for Study 1 and 3 were collected through the 
same online survey. Respondents were asked about their awareness and experience 
of side-effects (Research Question 4), perceived impairment to driving ability 
(Research Question 5), and general worries and concerns related to benzodiazepine 
use (Research Question 6). This chapter helps to inform the findings from Study 1 
and Study 2, by providing details about the consumer’s experience. 
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ABSTRACT 
Objective 
Benzodiazepines have been well-studied for many years; however, surprisingly few 
studies investigate the subjective experiences of regular benzodiazepine 
consumers. There is evidence that benzodiazepine use is often chronic, and that 
psychomotor impairment persists in these users. Therefore alongside this objective 
evidence, it is important to understand how chronic consumers understand, 
perceive, and monitor, their use of benzodiazepines.   
Method 
Data was collected from 129 participants using an online survey that ran from 2013-
2015. Participants were required to; be over 18 years of age, be an Australian 
resident, have used a benzodiazepine during the last 12 months, and have a current 
driver’s license. A range of demographic, and benzodiazepine use information was 
gathered, as well as information about subjective perceptions of benzodiazepine 
use. 
Results 
Duration, dose, and frequency of benzodiazepine use were in excess of standard 
clinical recommendations for the majority of this sample. Symptoms of 
dependence, in particular withdrawal symptoms, were reported as a barrier to 
reduction of benzodiazepine use. Overall, the respondents had poor knowledge of 
benzodiazepine side-effects, and reported that the education that they had 
received about benzodiazepines was minimal. Side-effects were regularly 
experienced by the group, and did not abate, particularly for the most chronic 
users. 
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Conclusion 
The attitudes of benzodiazepine users in this sample were mixed. For a small 
proportion, benzodiazepines were seen as positive, and no problems were had with 
dependence or escalation of use. Unfortunately for many, benzodiazepines were 
reported to no longer be effective, and were associated with negative effects and 
symptoms of dependence. A benzodiazepine contract, similar to that used in opioid 
treatment, is suggested as a strategy to manage ongoing high rates of 
benzodiazepine prescription.  
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INTRODUCTION 
Benzodiazepines are a highly effective psychoactive drug class, used to treat a 
variety of conditions including anxiety, sleep disorders, and epilepsy (Barker, 
Jackson, Greenwood, & Crowe, 2003). Concerns regarding negative side-effects and 
dependence, has led to more restrictive prescribing of benzodiazepines. However, 
current research suggests benzodiazepines remain widely prescribed worldwide 
(Islam, Conigrave, Day, Nguyen, & Haber, 2013). Experimental studies examining 
benzodiazepine use are extensive, but there has been a comparative absence of 
research examining the experiences and perceptions of regular benzodiazepine 
consumers (Barker, Greenwood, Jackson, & Crowe, 2004).  
Current clinical guidelines recommend that benzodiazepines should be avoided if 
possible, or if necessary used at the lowest possible dose and for the shortest time 
period feasible (National Health and Medical Research Council, 1991; Royal 
Australian College of General Practitioners, 2000). These guidelines have been 
established based on; the known rapid development of tolerance and subsequent 
reduced efficacy to the desired effects (Vinkers & Olivier, 2012), established 
cognitive and psychomotor deficits (Barker et al., 2003), and the growing body of 
evidence suggesting long-term harm associated with use, such as an increased risk 
of dementia (Billioti deGage et al., 2012). Alongside these recommendations, more 
restrictive practices have been established. For example, alprazolam has recently 
been rescheduled in Australia to a restricted S8 medication, which is the same level 
of restrictions as are required for strong opioids such as morphine and oxycodone 
(The Royal Australian College of General Practitioners, 2013).  
Whilst the guidelines directing prescription that have been released over the past 
35 years are evidence based and well-intentioned, there are no doubt, some 
unintended consequences of these directives, for those that are prescribed 
benzodiazepines. Understanding the consumer’s experience is essential for 
clinicians, and can help to guide interventions. For example, knowing the typical 
positive and negative factors that lead to consumers continuing benzodiazepine 
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use, could help to guide motivational interviewing techniques. Similarly, knowing 
the withdrawal symptoms that consumers usually find most difficult to manage, 
may pre-empt a conversation around techniques to manage these symptoms. 
Information about the subjective experiences of benzodiazepine users, will only 
help to enrich data gained from quantitative studies. 
The acute effects of benzodiazepine use are well-known, with new users commonly 
cautioned about drowsiness, memory loss, confusion, and psychomotor impairment 
(Barker et al., 2003). It is becoming increasingly accepted that many of these side-
effects continue even with long-term use (Barker et al., 2004). Particularly, research 
has focused on the impact of benzodiazepine use on driving, although much of the 
experimental research examines naïve benzodiazepine users; see Kelly, Darke, and 
Ross (2004) for a review of drugged driving research. As an error prone and 
potentially fatal activity, the interest in driving is not surprising; however, few 
studies examine the driving skills of benzodiazepine users from a subjective point of 
view. There is some evidence that benzodiazepine use impairs metacognition, one 
aspect of which is the ability to accurately judge one’s performance, and detect 
impairment (Bacon et al., 1998; Mintzer & Griffiths, 2003; Roache, Cherek, Bennett, 
Schenkler, & Cowan, 1993). Given the potential discrepancy between impairment 
and perception of such impairment, the importance of the subjective experience of 
benzodiazepine users becomes clear. Particularly so, as medication labels advise 
self-monitoring of impairment, for example the Australian medication Label 12 
states ‘if affected do not drive a motor vehicle or operate machinery’ (Sansom, 
2002).   
Similarly, it is also essential to recognise the positive reasons for which people use 
benzodiazepines. Benzodiazepines remain a useful treatment option due to their 
effectiveness and speed of onset, relatively good ability to be tolerated, capacity to 
be used ‘as needed’, and comparative safety in overdose (Starcevic, 2012). Evidence 
suggests benzodiazepines remain efficacious for several conditions, for example; in 
the short-term treatment of certain anxiety disorders, in the period before other 
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medications, such as antidepressants become effective, or for managing acute 
alcohol withdrawal (Baldwin et al., 2013). Compliance with treatment guidelines by 
keeping dosage short-term and intermittent, is likely to reduce problematic usage. 
Whilst there is a vast amount of literature on the negative effects of 
benzodiazepines, there is comparatively little documented about those who are 
able to use without problems of dependence. As Baldwin and colleagues (Baldwin 
et al., 2013; pg 971) conclude “benzodiazepines have a range of beneficial effects 
and a range of untoward effects, like all forms of pharmacological and psychological 
treatment”. Recognising this, and acknowledging the varying experiences of 
consumers is essential. 
As has been demonstrated, there are many ways in which benzodiazepine 
prescription can be optimised, but the risk of dependence and negative 
consequences persists. What remains unclear is just how well this information is 
disseminated to patients. Within Australia, the process of prescribing 
benzodiazepines, is left largely to the judgement of the individual prescriber, 
providing they adhere to government regulations. The level of information provided 
will depend in part on the characteristics of the health professional, such as their 
own or organisational preferences, time available, and communication skills. 
Without doubt, patient variables will also influence the level of information 
retained. It is well established that patient’s memory for information provided at 
the doctors is poor (Kessels, 2003). This is particularly the case when the patient is 
older or anxious, as is commonly the case with benzodiazepine users (Kessels, 
2003). Consequently, also of interest in this study is whether benzodiazepine users 
retain information pertinent to their safety. 
The main focus of this study is to conduct a qualitative exploration of the views of 
regular benzodiazepine users regarding safety and well-being. The aims of the study 
are as follows: 
 To investigate awareness and experience of benzodiazepine side-effects, 
specifically:  
Chapter 8: The Subjective Experiences of Chronic Benzodiazepines Consumers | 157 
 
 
 
o What do regular consumers know about the side-effects of 
benzodiazepines? 
o From what sources is information about side-effects obtained? 
o What side-effects do consumers detect and does this change over 
time? 
 To explore whether regular benzodiazepine consumers perceive any 
impairment to their driving ability: 
o Do benzodiazepine consumers detect any impairment to their driving 
ability when first using benzodiazepines? 
o Does any impairment change over time as benzodiazepine use 
progresses? 
o Do people take any precautions regarding benzodiazepine use and 
driving? 
 To conduct an exploration of the perceptions and viewpoints of 
benzodiazepine consumers with varying patterns of usage, and with a 
particular focus on their worries and concerns. 
This research will explore the perceptions of regular benzodiazepine users. The 
information gained in this study will assist professionals with understanding the 
experiences of benzodiazepine users, and in turn, inform clinical practice. 
METHOD 
Participants 
Data was collected through an online survey run from 2013-2015. The survey was 
marketed to Australian residents through advertising in doctor’s surgeries, 
pharmacies, hospitals, and targeted social media. On completion of the survey, 
participants could choose to enter a prize pool for 1 of 3 $500 vouchers. A total of 
251 participants initiated the survey, with 122 participants excluded from the 
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analysis due to incomplete data (n=129). This high exclusion rate occurred because 
there were many participants who had entered no data at all (n=37), or only 
demographic information (n=57), before exiting the survey. Initial survey questions 
excluded those who were under 18 years of age, had not used a benzodiazepine in 
the last 12 months, or who did not agree to informed consent statements. 
To clarify benzodiazepine use, participants were questioned on the duration and 
frequency of their use. This information was then used to guide a post-hoc 
development of three different categories of benzodiazepine chronicity. In the 
survey participants were asked to indicate which answer best reflected their 
pattern of benzodiazepine use: use daily for – less than a month, greater than a 
month, or greater than a year; or use occasionally for – less than a month, greater 
than a month, or greater than a year. At the point of analysis this self-identified 
pattern was verified with information from other survey questions, including; start 
and finish date of using benzodiazepines, total days using benzodiazepines, and 
number of days in last month using benzodiazepines. In order to have sufficient 
numbers in each chronicity group, a pragmatic decision was made to combine some 
of these self-identified patterns of use into three main patterns of chronicity. The 
three chronicity groups developed were as follows; short-term users (those who 
had been using daily or occasionally for less than one year), intermittent users 
(those who had used occasionally, for a period greater than one year) and chronic 
users (those who had used daily for a period greater than one year). The 
development of the chronicity groups was guided by the following considerations; 
(1) allocating sufficient participant numbers to each group, (2) promoting 
homogeneity within each group and (3) allowing comparisons to be made across 
key elements of interest, namely the different effects of duration and frequency of 
use.  
Procedure 
The survey took approximately 30 minutes to complete, and non-relevant sections 
were excluded based on initial screening questions, reducing the total time 
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required. Major survey sections included questions on: demographic information, 
benzodiazepine use, licence and driving, road accidents, perceptions of 
benzodiazepines, general accidents, memory, alcohol and other drug use, health, 
and other medication use (antidepressants, antipsychotics, painkillers, and other 
psychotropic medications). Ethical approval was granted by the Tasmanian Social 
Sciences Human Research Ethics Committee (approval number H0012343 - 
Benzodiazepines; Use, health and driving). 
Measures 
Side-Effects 
Survey questions focused on three aspects of side-effects; knowledge of side-
effects, sources of information, and side-effects experienced. As a test of user 
knowledge, respondents were asked to identify commonly occurring 
benzodiazepine side-effects. The question used in the survey was: Tick all of the 
symptoms listed below that you think could be a side-effect of taking 
benzodiazepines. There were a total of 10 answers to choose from, including seven 
commonly occurring benzodiazepine side-effects (drowsiness, sedation, light-
headedness, double vision, slurred speech, memory loss, and ataxia - difficulty with 
coordination). These symptoms were included as they were identified as the most 
commonly occurring side-effects in the Australian Medicines Handbook (Australian 
Medicines Handbook, 2015). Also included were three side-effects not usually 
associated with benzodiazepine use (nausea, indigestion, constipation), which were 
included to verify discrimination and accuracy of participant’s answers. 
To investigate the sources of information from which benzodiazepine users received 
information about side effects, the survey used the following question: When you 
first started using Benzodiazepines how did you learn about the possible negative 
side effects? There were eight answer options provided, and respondents could 
select all that applied (I was not aware of the side-effects, the Doctor told me, the 
Pharmacist told me, I read the information in the box, I saw a warning label on the 
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box, a friend/family member told me, the internet, and ‘other’). These answer 
options were chosen as they represent best practice (e.g. being told by doctor, 
and/or pharmacist), Australian legal requirements (e.g. warning labels and 
information in box), or common non-professional sources of information for 
consumers (e.g. family/friend and the internet). 
As an indication of side-effects encountered and change over time, respondents 
were asked about their experience on six key symptoms. Respondents were asked 
to indicate whether they had experienced a symptom, for example: Have you 
experienced any confusion that you feel is related to your benzodiazepine use? 
Respondents who answered ‘yes’ were further questioned about how this symptom 
had changed over time, for example: Since you began taking benzodiazepines has 
this confusion; stayed the same, worsened, improved. Side-effects investigated in 
this question, were the same as those used in the initial test of consumer 
knowledge. The exception to this was ‘sedation’ and ‘drowsiness’, which were 
combined into one category ‘daytime drowsiness’, in order to avoid those using 
benzodiazepines for night-time sedation reporting this as a side-effect. 
Driving Safety 
To examine the self-detected effects on driving, consumers were asked about the 
impact they felt benzodiazepines had on their driving ability, when they first started 
taking benzodiazepines (survey question: When you first started taking 
benzodiazepines [e.g. for the first month], how did you think they impacted on your 
driving ability?), and then at the current time (survey question: How do you think 
your use of benzodiazepines currently impacts on your driving ability?). Respondents 
were then asked to indicate any safety precautions they used (survey question: 
Whilst taking benzodiazepines have you taken any safety precautions in regards to 
driving?) Seven precautions were provided as answer options; I did not take any 
precautions, I stopped taking benzodiazepines, I did not drive at all, I did not drive 
immediately after I had taken a benzodiazepine, I drove more slowly, I took other 
things to counter any side-effects and ‘other’.  
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General perceptions and concerns 
To gain insight into the general concerns of regular benzodiazepine users, an open-
ended question was used to gather this information. Respondents were first asked 
about whether they worried about using benzodiazepines (survey question: Do you 
worry about using Benzodiazepines? Yes or No), and were then invited to elaborate 
on this answer if they wished. An open-ended question was also included at the end 
of the survey: We're really interested in the positive and negative effects that 
benzodiazepines have on people's lives. The questionnaire can't capture all of this, 
so if there are any other comments you would like to make, please let us know in the 
space below. This question was initially included to improve consumer satisfaction, 
but due to the quantity of information it revealed related to benzodiazepine use, 
answers to this question were merged with the data from the other open ended 
question. Information gained from these questions was organised into key themes. 
Statements from respondents reported in the results section are identified by the 
user group they were allocated to (St=short-term users, Int=intermittent Users, 
Ch=Chronic Users), and numbered according to the order in which the participant 
completed the survey. 
Related Variables 
The Short-Form Health Surveys are a group scales providing a general measure of 
self-rated health. Whilst the SF-36 has been extensively tested and used within 
Australia, a briefer form, the SF-12 version 1 (Ware, Kosinski, & Keller, 1995) was 
chosen for brevity, and was re-scaled to fit SF-36 norms. The SF-12 measures eight 
domains, across the last 4 weeks; physical functioning, role functioning related to 
physical problems, bodily pain, general health, vitality, social functioning, role 
functioning related to emotional problems and mental health. These domains then 
combine to form a physical component summary (PCS) score and mental 
component summary (MCS) score. For each scale, scores range between 0-100, 
with higher scores equating to better health. Norms from a South Australian 
population study were chosen as the most up-to-date and representative Australian 
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norms (Avery, Dal Grande, & Taylor, 2004). Those scoring less than 2SD below the 
mean were identified as the at risk group (physical component summary score 
≤28.62 and mental component summary score ≤34.79). 
The Kessler-10 is a 10-item questionnaire providing a global indication of anxiety 
and depression symptoms (Kessler & Mroczek, 1994). Symptoms experienced over 
the past 4 weeks are rated on a 5 point scale ranging from ‘none of the time’ to ‘all 
of the time’. Whilst different cut-off scores are used within Australia, the 
convention set by the Australian Bureau of Statistics was followed, with total scores 
equal to or above 22, taken as an indication of high psychological distress (2003). 
Andrews and Slade (Andrews & Slade, 2001) found that the K-10  appropriately 
identified those classified by the Composite International Diagnostic Interview v2.0, 
as having any DSM-IV or ICD-10 anxiety or affective diagnosis (at a score of 22; 
sensitivity=0.55, specificity=0.95). 
Alcohol use was assessed through the use of the AUDIT-C; a shortened version of 
the well-established AUDIT tool (Saunders, Aasland, Babor, de la Fuente, & Grant, 
1993). The AUDIT-C is scored on a scale of 0-12, with each question scored between 
0 and 4. Different cut-off scores are recommended for men (Bush et al., 1998) and 
women (Bradley et al., 2003), with hazardous drinking identified through a score of 
3 or more in women (sensitivity=0.66, specificity=0.94) and 4 or more in men 
(sensitivity=0.48, specificity=0.99).  
The Severity of Dependence Scale (Gossop et al., 1995) was used to screen for 
benzodiazepine dependence. The SDS is a short five-item scale that can be used to 
measure the degree of dependence on different types of drugs. Each SDS item is 
concerned with a psychological aspect of dependence. The diagnostic capability of 
the SDS in regards to benzodiazepines was established in a sample of 100 regular 
benzodiazepine users (de Las Cuevas, Sanz, De Las Fuente, Padilla, & Berenguer, 
2000); a score above six was used as an indication of benzodiazepine dependence 
(sensitivity=97.9%, specificity=94.2%). 
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Data Analysis 
Data about detection and change in side-effects, and driving related information 
was obtained through a series of closed-ended questions and summarised with 
descriptive statistics. Data from the open-ended questions was analysed using 
content analysis, which involves identifying and grouping themes and categories 
within data (Pope & Mays, 1995). Two multidisciplinary raters (Psychologist and 
Pharmacist) carefully and repeatedly studied the data from the open ended-
questions, and identified emerging themes within text segments. Themes reported 
in the results are those that occurred repeatedly across the data. Themes were not 
chosen beforehand, so this reduced the chance of preconceptions influencing the 
findings. Attention has been given to deviant case analysis (Kitzinger, 1995). Given 
that the sample sizes in the study were smaller than expected, and thus the 
resultant power of analyses would be low, the decision was made to focus on 
descriptive analysis.  
RESULTS 
A total of 129 subjects participated in this study, and results were examined across 
three categories of benzodiazepine chronicity (table 1).As expected the groups 
differed on benzodiazepine use with the chronic group having a higher average 
dosage and frequency of benzodiazepine use compared to the other groups. 
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Table 1. Analysis of Variance for Key Variables of interest Across Benzodiazepine Chronicity Categories 
Benzodiazepine chronicity categories: Short-term Use (using benzodiazepines daily or occasionally for less than one year), Intermittent Use (using benzodiazepines occasionally for greater than one year), 
Chronic Use (using benzodiazepines daily for greater than one year). aSD=Standard Deviation. bTukey’s method used for post-hoc tests. ST=short-term group. Int=intermittent group. Chr=Chronic group. 
cCalculated using start and finish dates for each benzodiazepine, therefore does not represent the number of days on which benzodiazepines have been consumed, but rather the period of time that 
benzodiazepines have been used for. Additionally, this total is additive across each benzodiazepine type used. dThis is a cumulative sum across all benzodiazepine types, therefore the mean of 38.13 for 
chronic users reflects the use of more than one benzodiazepine a day. eConverted to an equivalent diazepam dose in milligrams. fThis monthly amount is equivalent to 7.63mg a day, which is less than the 
10mg defined daily dose. gKessler-10 (Kessler & Mroczek, 1994); total scores ≥22, were taken as an indication of high psychological distress. hDifferent cut-off scores are recommended for men (Bush et al., 
1998) and women (Bradley et al., 2003), on the AUDIT-C with hazardous drinking identified through a score of 3 or more in women (sensitivity=0.66, specificity=0.94) and 4 or more in men (sensitivity=0.48, 
specificity=0.99). iMental Component Score; scores range between 0-100, with higher scores equating to better health. jPhysical Component Score: scores range between 0-100, with higher scores equating 
to better health kIn this group there was a participant who identified as having 300 GP visits in the past year. This extreme outlier was removed as it severely inflated the result for this short-term user group, 
and was most likely an error during survey completion. lBZD=benzodiazepine, SDS=Severity of Dependence Scale. A score above 6 corresponds with benzodiazepine dependence, as determined by the 
Composite International Diagnostic Interview (specificity=94.2%, sensitivity=97.9%).
 
 
Short-term 
Use (SD)a 
N=24 
Intermittent 
Use (SD) 
 N=55 
Chronic Use 
(SD)  
N=50 
ANOVA Significant comparisonsb 
Reason for Benzodiazepine Use 
Sleep only n=9 (37.5%) n=27 (49.1%) n=23 (46.0%) n/a  
Anxiety only n=12 (50%) n=20 (36.4%) n=22 (44%) n/a  
Other/multiple reasons n=3 (12.5%) n=8 (14.5%) n=5 (10%) n/a  
Benzodiazepine Use 
Mean Length of Use (days)c 168.8 (243.8) 2416.7 (3840.8) 3053.9 (3605.1) F(2,126)=6.05, p=.003 ST<Int, p=.020; ST<Chr p=.002 
Mean Total days used per month 14.9 (17.7) 10.3 (13.9) 38.1d (45.6) F(2,115)=10.65, p<.001 ST<Chr, p=.013; Int<Chr, p<.001 
Mean Total Dose per monthe 229.5f (381.9) 231.6 (432.1) 919.3 (1816.4) F(2,115)=4.81, p=.010 Int<Chr, p=.013 
Other variables of interest 
Mean Age 30.9 (11.9) 39.1 (14.7) 40.5 (11.7) F(2,126)=4.64, p=.011 ST<Int, p=.031; ST<Chr, p=.010 
Mean AUDIT-Cg; Average Score 4.1 (3.6) 4.2 (3.2) 3.5 (3.5) F(2,102)=0.54, p=.587 - 
Mean Kessler-10h 27.1 (8.3) 21.5 (8.3) 27.8 (10.5) F(2,95)=5.35, p=.006 Int<Chr, p=.008 
Mean SF-12 MCSi 33.0 (11.9) 40.5 (13.1) 35.6 (14.0) F(2,99)=2.60, p=.079 - 
Mean SF-12 PCSj 47.4 (11.3) 47.6 (12.3) 43.1 (12.8) F(2,99)=1.54, p=.219 - 
Mean GP visits (past year) 9.1 (8.8)k 6.7 (5.2) 12.4 (8.4) F(2,107)=7.002, p=.001 Int<Chr, p=.001 
Mean Average score BZD SDSl 4.2 (4.1) 2.6 (3.3) 7.3 (4.4) F(2,114)=18.87, p<.001 ST<Chr, p=.008; Int<Chr, p=<.001 
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Knowledge and Experience of Side-Effects 
Table 2 presents the results related to consumers’ experience of side-effects. A brief 
test of user knowledge regarding benzodiazepines side-effects revealed that very 
few respondents were able to correctly identify side-effects, with only 3 
respondents scoring all 10 answers correctly. 
Also of interest were the sources of information regarding the potentially negative 
side-effects of benzodiazepines (Table 2). The most commonly reported source of 
information across the groups was the information pamphlet provided within the 
box. Surprisingly low numbers of respondents reported they had received 
information from their Doctor or Pharmacist, and even fewer stated that they had 
seen a warning label on the box. Answers provided in an ‘other’ section included: 
“learning through own profession”, “trial and error”, and “I was not given sufficient 
information from my GP and I would have never taken Alprazolam if I had been”. 
Respondents were asked to identify side-effects that they had experienced from a 
commonly occurring list of symptoms. Overall the short-term and chronic user 
groups were more likely to report the occurrence of negative symptoms compared 
to the intermittent users (Table 2). Figure 1 represents the experience of change in 
these symptoms over time. Unfortunately for a large proportion of the sample, 
symptoms seemed to stay the same or worsen, suggesting that tolerance likely does 
not universally develop over time, particularly in respect to cognitive deficits. 
Reports of memory loss were particularly of note, with most of the group reporting 
no resolution in this symptom; only 30% of the short-term users reported memory 
loss had improved over time.  
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Table 2. Consumer reported Knowledge of Side-Effects, Sources of Information regarding 
Side-Effects, and Personal Experience of Side-Effects, across Benzodiazepine Chronicity 
 
  
Short-term 
Users (n=24) 
Intermittent 
Users (n=55) 
Chronic Users 
(n=50) 
Knowledge of Side-Effects  
Survey Question: “Tick all of the symptoms listed below that you think could be a side-
effect of taking benzodiazepines” 
Scored 0-5 answers correct 31.3% (n=5) 43.9% (n=18) 53.8% (n=21) 
Scored 6-9 answers correct 62.5% (n=10) 53.7% (n=22) 43.6% (n=17) 
Scored all answers correct 6.3% (n=1) 2.4% (n=1) 2.6% (n=1) 
Sources of information  
Survey Question: “When you first started using benzodiazepines, how did you learn 
about the possible negative side effects?” 
I was not aware of the side-effects 16.7% (n=4) 12.7% (n=7) 20.0% (n=10) 
The Doctor told me 25.0%  (n=6) 34.5% (n=19) 34.0% (n=17) 
The Pharmacist told me 16.7% (n=4) 21.8% (n=12) 20.0% (n=10) 
I read the information in the box 41.7 % (n=10) 34.5% (n=19) 36.0% (n=18) 
I saw a warning label on the box 12.5% (n=3) 16.4% (n=9) 14.0% (n=7) 
A friend/family member told me 12.5% (n=3) 1.8% (n=1) 4.0% (n=2) 
The internet 29.2% (n=7) 29.1% (n=16) 26.0% (n=13) 
Side-Effects experienced 
Survey Question: “Have you ever experienced any [insert symptom] that you feel is 
related to your benzodiazepine use?” 
Daytime drowsiness 57.9% (n=11) 40.8% (n=20) 59.1% (n=26) 
Poor concentration 47.4% (n=9) 24.5% (n=12) 54.5% (n=24) 
Light-headedness 44.4% (n=8) 18.8% (n=9) 28.6% (n=12) 
Memory Loss 55.6% (n=10) 16.3% (n=8) 54.5% (n=24) 
Slurred speech 44.4% (n=8) 15.2% (n=7) 38.1% (n=16) 
Confusion 35.3% (n=6) 8.2% (n=4) 37.5% (n=15) 
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Figure 1. Symptom Change Experienced since Initiation of Benzodiazepine Use 
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Impact on Driving 
Respondents were asked to identify the effect of benzodiazepine use on their 
driving ability, both when they initially started benzodiazepines and at the current 
time (Table 4). At both time points, over half the respondents in each group 
reported they detected no effect on driving ability. During initial use, and at the 
current time, the chronic users were most likely to report that using 
benzodiazepines worsened their driving ability. The sample was also asked if they 
took any precautions to keep themselves safe whilst driving; a range of precautions 
were listed to choose from (Table 4). The intermittent users were the most likely 
group to state either that they didn’t take any precautions, or that they did not 
drive at all or immediately after they had taken a benzodiazepine. There were a 
variety of other precautions reported by respondents in the ‘other answer’ section 
including: "I waited until I was aware of the effects and comfortable with the drug 
before driving on it", “I paid more attention to my surroundings”, and “I minimised 
driving, I never drink any alcohol at all when driving, I plan my routes in advance to 
help with memory issues, I got a GPS to help with memory issues”. 
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Table 3. Self-reported Impairment to driving ability in Benzodiazepine Users, at 
commencement of Benzodiazepine use and at current time, and Safety Precautions 
taken whilst driving. 
 
  Short-term 
Users (n=24) 
Intermittent 
Users (n=55) 
Chronic Users 
(n=50) 
Initial detected impairment  
Survey Question: “When you first started taking benzodiazepines (e.g. for the first 
month), how did you think they impacted on your driving ability?” 
No effect 52.9% (n=9) 67.4% (n=31) 51.3% (n=30) 
Worsened 17.6% (n=3) 13.0% (n=6) 30.8% (n=12) 
Improved 11.8% (n=2) 2.2% (n=1) 12.8% (n=5) 
Not applicable 17.6% (n=3) 17.4% (n=8) 5.1% (n=2) 
Currently detected impairment  
Survey Question: “How do you think your use of benzodiazepines currently  
impacts on your driving ability?” 
No effect 62.5% (n=10) 60.9% (n=28) 68.4% (n=26) 
Worsened 18.8% (n=3) 8.7% (n43) 21.1% (n=8) 
Improved 6.3% (n=1) 8.7% (n=4) 7.9% (n=3) 
Not applicable 12.5% (n=2) 21.7% (n=10) 2.6% (n=1) 
Precautionsa  
Survey Question: “Whilst taking benzodiazepines have you taken any safety 
precautions in regards to driving?” 
I did not take any precautions 20.8% (n=5) 30.9% (n=17) 30.0% (n=15) 
I did not drive at all 25.0% (n=6) 29.1% (n=16) 8.0% (n=4) 
I did not drive immediately after I 
had taken a benzodiazepine 
25.0% (n=6) 27.3% (n=15) 20.0% (n=20) 
I drove more slowly 12.5% (n=3) 12.7% (n=7) 14.0% (n=7) 
aTwo answer options are not listed in this table due to small numbers of participants 
identifying this as a precaution used: ‘I stopped taking benzodiazepines’ (n=1) and ‘I took 
other things to counter any side-effects’ (n=6). 
 
 
 
Chapter 8: The Subjective Experiences of Chronic Benzodiazepines Consumers | 170 
 
 
 
Open Ended Questions 
Respondents were initially asked to indicate whether they worried about using 
benzodiazepines. Percentages of each group reporting ‘worry’ are as follows: short-
term users (68.4%, n=13), intermittent users (35.4%, n=17), and chronic users 
(43.2%, n=19). Respondents were then invited to comment further on this answer. 
Answers from two open-ended questions were organised into the following 
themes; addiction and dependence, ability to manage usage, withdrawal, stigma 
and availability, positive effects of benzodiazepine use, negative effects of 
benzodiazepine use, and provision of benzodiazepine information. For each theme, 
selected quotes that were a representative and/or an interesting example of this 
theme are presented. 
Addiction and Dependence 
Concerns about addiction to and dependence on, benzodiazepines emerged across 
all three user groups. Many respondents seemed aware of the risk of addictions, or 
had experienced this themselves, and made statements highly indicative of 
dependence: 
They are highly addictive and it does scare me that eventually I will 
have to stop usage….Ch181 
I feel that the only reason I’m on benzodiazepines is that I can’t 
stop. Ch224 
I often find myself thinking about them or wanting them, fully 
aware that they are not necessary. Int191 
It seems that my panic attacks have increased in frequency and 
intensity, and I end up popping a Xanax as I am scare to ride 
through the panic attack on my own. St71 
Several respondents indicated they felt unable to function normally without 
benzodiazepines: 
I don’t think I would be able to function normally without it. Ch55 
It felt essential that I took them. Ch59 
I find I cannot cope day to day without them. Ch181 
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I’m glad I only used Diazepam for a brief time due to how much it 
can change you. St11 
I feel I am a prisoner of the drug…St73 
There was a concern, mostly amongst chronic users, that changing attitudes 
towards benzodiazepines would make access difficult. These opinions were also 
indicative of dependence, i.e. worry about how one would cope if availability was 
limited. 
I worry that my doctor will cut off supply/I worry that there might 
be a disaster of some kind and I won’t be able to get any. Ch58 
I have stockpiled some [Xanax] which should last me through until 
the end of 2014. Ch112 
I worry it will no longer be available in the future. Int49 
Worried that I will become addicted and not be able to get more. 
Int114 
Likewise some respondents identified that their use was recreational, or in excess of 
what they had been prescribed.  
I’ve been using benzodiazepines recreationally for 18 months or 
so...In the last 6 months I’ve been using Xanax, oxazepam, 
temazepam, occasionally diazepam… Ch155 
…I can easily consume 100mg of diazepam and stay awake 
hanging out with my mates. Int191 
Realisation of how easy it would be to rely on the drug beyond 
what it’s prescribed for. St11 
I’m only supposed to take it no more than once per day, but some 
days I need it twice. St52 
 
Ability to Manage Usage 
Conversely, there were a few respondents, usually intermittent users, who reported 
they were able to limit their benzodiazepine use, or stated that they did not find 
them addictive.  
I have yet to feel any addictive effect myself, but have watched 
others crave it as they would with smoking…Ch40 
Chapter 8: The Subjective Experiences of Chronic Benzodiazepines Consumers | 172 
 
 
 
I do not find this medication (diazepam) addicting or feel the need 
to use it in a recreational setting. Int49 
I only take it when needed, might be every day for a couple of 
weeks, sometimes none for months. Int233 
I know these drugs are addictive and would never use them more 
than rarely for that reason. Int234 
 
Withdrawal 
Many of the respondents, particularly chronic users, reported difficulty 
withdrawing, fear of future withdrawals, and rebound symptoms when reducing 
use. 
I have tried numerous attempts at dosing down in a tapering 
program to move me over to a lesser benzo such as Valium. Ch42 
I tried to wean off but failed. Ch140 
The withdrawal is far too painful and makes it very hard to get off 
it. Ch152 
…I started having really powerful withdrawal symptoms such as 
unbearable anxiety, depression, and feeling so out of it I didn’t 
know if I was dreaming or awake. Ch218 
As someone now withdrawing my family has suffered watching the 
terrible side effects these medications can have, mood swings, and 
onset of depression after your last dose. St238 
 
Stigma and availability 
Another theme that emerged was that benzodiazepine users often felt stigmatised 
for seeking benzodiazepines, even if their own use was within therapeutic 
guidelines. 
Certain doctors are ignorant or morally opposed to prescribing me 
this horrible drug. Ch42 
The worst part for me is feeling like a criminal when I have to ask 
my GP for a repeat prescription. Ch47 
It is harder for valid patients to acquire their medicine. It is very 
effective for my ailments and as a patient I should not be penalised 
for others misuse. Int49 
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Positive Effects of Benzodiazepine Use 
There were some respondents who reported positive benefits of benzodiazepine 
use. Some respondents identified that benzodiazepines were efficacious in treating 
the conditions they were prescribed for. Others found they experienced minimal 
side-effects, or that the positive outcomes outweighed the side-effects they did 
experience. 
I couldn’t sleep without them. Ch62 
In my case, if I need PRN benzodiazepines, I believe the side effects 
(which in me are minimal), far outweigh the effects of anxiety and 
panic. Ch102 
I struggle daily with horrible panic disorder, depression, anxiety, 
and ADHD. Benzo’s give me a release from this. Ch162 
I have been taking this medication for a long time, and do not feel 
that it affects me other than in a positive way. Ch205 
I have been on Xanax for over 25 years, and if it wasn’t for this 
medication, I doubt I would be here today, due to the panic and 
anxiety attacks I have. Haven’t had any real side effects from it, 
and only take it when necessary. Ch220 
The positives outweigh the negatives for me especially if I use 
them sparingly. Int63 
I do believe when I have an anxiety attack that the best way to fix 
it is with Diazepam. Int110 
 
Negative Effects of Benzodiazepine Use 
Conversely, there were high numbers of respondents, particularly in the chronic 
user group, who reported negative side-effects, detrimental effects on health and 
well-being, and worry about the long-term consequences of benzodiazepine use. 
Wrecks my motivation during the day and causes weight gain and 
my medication is only just holding for sleep. Not so happy. Ch231 
I have had no positive effects, I have only had negative side effects; 
physical, emotionally, financial and cognitively. Ch235 
Afraid clumsiness or lowered concentration can put me in danger 
while driving, crossing roads etc. Int151 
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I’m worried that if I keep taking even the low dose I take I might 
get Alzheimer’s. I think that my memory is not as good as it used 
to be. Int179 
It impacts on my ability to think clearly and feel. Int232 
 
Provision of Benzodiazepine Information 
There was a small subset, of the chronic users only, who indicated feeling ill-
informed about the potential ramifications of benzodiazepine use. Some of these 
respondents felt they had not initially been educated satisfactorily, whilst others 
reflected that in hindsight they would choose a different course of treatment. 
I wish I had known then how very addictive these medications are. 
Ch47 
I wish that I had never taken them. Ch58 
I was prescribed these without any indication of what daily use 
could do. To be honest I think my prescriber was surprised to 
discover there was a withdrawal syndrome associated with them. 
Ch221 
I was placed on this drug almost seven years ago with no idea 
what it was or what the impact would be on my life long term. 
Ch235 
I believe I would have been better off never taking it to begin with. 
St71 
 
DISCUSSION 
Results from this study reveal a group of people who for a variety of positive and 
negative reasons, rely strongly on benzodiazepines. This sample was categorised 
into three groups, and as expected, the groups differed on dose, duration, and 
frequency of use. Across all three levels of chronicity there were many who were 
using benzodiazepines in excess of the duration and frequency recommended by 
clinical guidelines. Attitudes to benzodiazepines were divided with many expressing 
that they wished to reduce benzodiazepine use due to the negative effects, but had 
difficulty in achieving this. Conversely, others felt that the positive benefits of using 
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benzodiazepines outweighed the negatives. Many of the most chronic 
benzodiazepine consumers felt they were not adequately informed about pros and 
cons of using benzodiazepines when they commenced the medication.  
The self-reported reasons for use of benzodiazepines, in the majority did not 
clinically indicate the use of benzodiazepines as an ongoing treatment. Most of the 
sample reported that they were using benzodiazepines solely for sleep (n=59, 
45.7%) or anxiety (n=54, 41.9%) problems, with only a small group reporting use for 
other or multiple reasons (n=16, 12.4%). When considering the treatment 
guidelines for anxiety and insomnia, cognitive behavioural therapy (CBT) is usually 
considered the first line treatment (Royal Australian College of General 
Practitioners, 2015b). Benzodiazepines are not indicated for mild to moderate 
anxiety, and are suggested be used only in situations where rapid symptomatic 
relief is required. In insomnia, benzodiazepines are suggested to be used only for 
short-term treatment (i.e. less than four weeks) and using the lowest possible dose 
(Royal Australian College of General Practitioners, 2015b). It is not known whether 
other treatments, such as CBT, have been utilised by this sample. However, the 
duration of benzodiazepine use in this group is far lengthier than what is usually 
recommended for the treatment of anxiety or insomnia. Even the most 
benzodiazepine-naïve group in the study, the short-term users, had an average 
length of use spanning almost six months, and on average they used about half the 
days in a month. The chronic user group had use spanning on average over 8 years, 
used most days in a month, and had an average monthly dosage of over 900mg 
(diazepam equivalent). Moreover, half the sample were within the high 
psychological distress range (K-10 score>21, n=51, 52%); the presence of these high 
scores may suggest that the treatment received by individuals (including 
benzodiazepines) is not adequately addressing their concerns. In this sample, the 
use of benzodiazepines is not concordant with common treatment guidelines, and 
their efficacy in providing symptomatic relief remains unclear. This raises the 
question of why use in this sample is so chronic, and how this can be more 
consistently managed. 
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Statements made by this sample were often indicative of benzodiazepine 
dependence, and a common obstacle to ceasing use, was experience, or avoidance 
of, withdrawal symptoms. Many individuals, particularly in the chronic and short-
term user groups reported overwhelming symptoms of withdrawal including: ‘mood 
swings’, ‘seizures’ ‘unbearable anxiety and depression’, ‘ringing in the ears’, 
‘nausea’, ‘light-headedness’, ‘shaking’ and ‘muscle twitches’. There were some in 
the group who reported working on gradual dose reduction with their GPs, but 
many found this very difficult, and often relapsed at times of high demand. 
Evidently, many consumers in this study did not have the adequate resources to 
help them overcome withdrawal symptoms in order to cease benzodiazepine use. 
 A meta-analysis examining strategies that assist with benzodiazepine reduction, 
compared routine care (standard GP care plus assessment) with; brief interventions 
(such as provision of information pamphlets), gradual dose reduction, and 
psychological interventions, such as relaxation training and targeted cognitive-
behavioural techniques (Parr, Kavanagh, Cahill, Mitchell, & Young, 2009). Both 
gradual dose reduction and brief interventions achieved higher cessation rates than 
routine care. The addition of psychological interventions to gradual dose reduction, 
was more effective than gradual dose reduction alone, at both cessation (OR 1.82, 
95%CI 1.25-2.67) and follow-up (OR 1.88, 95%CI 1.19-2.97). There was little 
evidence to support the use of pharmacotherapy in benzodiazepine cessation. More 
recently, a scoping review (Pollmann, Murphy, Bergman, & Gardner, 2015), 
reviewed 139 articles that examined strategies used for deprescribing 
benzodiazepines. Deprescribing is described as a collaborative approach to 
discontinuing therapies that are no longer efficacious, or are doing the patient 
harm. Pharmacological interventions were the most common type of strategy 
reported in the studies reviewed (n=42 57%). Psychological strategies were studied 
in only 14% (n=10) of trials. Gradual dose reduction was included in 80% (n=60) of 
the discontinuation strategies. Over all of the strategies implemented, effects were 
mixed with 47% rated as having positive outcomes, 41% having negative outcomes, 
and 12% being mixed. The authors conclude that there is a lack of clarity in how 
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best to deprescribe benzodiazepines. Furthermore, they report that the outcome of 
interest in these studies is most commonly whether the benzodiazepine has been 
ceased, and other clinical outcomes, such as reduced falls risk, or improved quality 
of life, are less frequently investigated. These findings illustrate that benzodiazepine 
deprescribing is not approached consistently, nor are the most efficacious 
techniques, researched and provided the most intently. .  
One barrier to deprescribing is the capacity of the clinician to deliver the most 
efficacious intervention. For example, it is possible that for GPs, providing 
deprescribing interventions may be beyond their scope and practical capacity. 
Considering this, research is increasingly looking to alternative ways to support 
benzodiazepine cessation; for example, recent research examined the impact of 
direct to consumer education material (Martin & Tannenbaum, 2017; Tannenbaum, 
Martin, Tamblyn, Benedetti, & Ahmed, 2014). The resource used in this instance 
was the 8-page EMPOWER booklet, which documented benzodiazepine safety 
information, inspiring peer stories, suggestions for alternative treatments, and 
gradual tapering instructions. In the initial trial (Tannenbaum et al., 2014), 
participants included 303 long-term benzodiazepine users (aged 65-95 years), 
recruited through a pharmacy; of these, 148 participants were mailed the 
information booklet, the rest formed the control group. At the 6 month follow-up, 
only 5% of the control group had discontinued benzodiazepines, whilst 27% of the 
intervention group had discontinued benzodiazepines (adjusted OR 8.3, 95% CI 
3.3—20.9), and another 11% had achieved dose reduction. There were also other 
promising results, for example 62% of those who had completed the trial had 
initiated conversations about benzodiazepine discontinuation with their doctor or 
pharmacist. A later follow-up study (Martin & Tannenbaum, 2017), examined 
whether cognitive capacity affected the efficacy of the EMPOWER education 
brochure. From the initial trial, 261 participants continued this phase of the 
research, and all patients, including the previous control group, were given the 
EMPOWER brochure. Participants were divided based on their scores on the 
Montreal Cognitive Assessment, as having either normal cognition or mild cognitive 
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impairment (MCI). Follow-up data was collected one week, six weeks and 6 months 
after each participant received the brochure. Discontinuation was achieved in 
similar rates in both groups; 38.1% in the normal cognition group, and 32% in the 
MCI group (adjusted OR 0.79%, 95%CI 0.45-1.38). The MCI group showed the same 
capacity to change their beliefs related to benzodiazepine use, and to initiate 
conversations with their health care providers. The authors conclude their findings 
indicate that clinicians should be encouraged to use the EMPOWER brochure to 
assist with benzodiazepine cessation, including in patients with cognitive decline. 
Overall this type of research shows that utilising clever, and complimentary 
interventions can have a positive effect on benzodiazepine reduction, and 
overcome some of the barriers to traditional benzodiazepine deprescribing. These 
types of interventions also encourage the involvement of other health 
professionals, such as pharmacists, whose role in benzodiazepine deprescribing in 
Australia is mostly medication management, and patient education. In this sample, 
common misconceptions about the efficacy of benzodiazepines, also seemed to 
lead to their overuse. Some patients identified that they felt benzodiazepines were 
the best option to manage symptoms, for example “I do believe that when I have an 
anxiety attack that the best way to fix it is with Diazepam, although it’s not always 
available for me to do so.” Many also identified that they lacked other ways to cope, 
particularly ones that are as seemingly efficient as benzodiazepines. A similar 
theme, described as ‘the purpose and importance of benzodiazepines’ was found in 
a comparable qualitative study (Cook, Biyanova, Masci, & Coyne, 2007). The study 
of 50 older adult benzodiazepine users (age range 61-95 years), identified that 
many in the sample described benzodiazepines as necessary to maintaining normal 
life, and these patients anticipated that their quality of life would be much poorer 
without benzodiazepines. A parallel study by the same authors, examined the 
attitudes of GPs (n=33) to prescribing benzodiazepines for older adults; similar 
beliefs emerged for both patients and physicians. GPs tended to minimise the 
problems associated with benzodiazepine use, and justified their ongoing use, 
particularly with the emphasis that in older patients, discontinuation causes undue 
suffering, with little benefit (Cook, Marshall, Masci, & Coyne, 2007). In a similar 
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study looking at the attitudes of GPs initiating new scripts, it was found GPs often 
felt overwhelmed by the patient’s psychosocial problems, felt there was a lack of 
other viable solutions, and thus prescriptions were driven by a need to help 
(Anthierens et al., 2007). In both these studies, and the current one, similar feelings 
of helplessness seem to emerge for both the prescriber and patient.  
In light of these findings, it seems necessary that both prescribers, and in turn 
patients, are educated on the limitations of benzodiazepine use, and the efficacy of 
alternative treatments. For example, CBT is established as an effective, and first line 
treatment for various mental health conditions (Hofmann, Asnaani, Vonk, Sawyer, & 
Fang, 2012), and often has improved efficacy compared to benzodiazepines, and 
certainly less side-effects (Mitchell, Gehrman, Perlis, & Umscheid, 2012). Quality 
standards developed by the National Institute for Health and Care Excellence 
(NICE), aim to improve the outcomes of care in areas identified as needing quality 
improvement. For example, in relation to anxiety, the NICE standard recommends 
the use of psychological interventions as first line treatment in preference to 
pharmacological treatments (National Institute for Health and Care Excellence, 
2014). These evidence based standards can be used by medical practitioners to 
guide best practice around prescribing benzodiazepines, and most importantly 
encourage the use of the least intrusive, and effective interventions. Whilst the 
limitations of benzodiazepines must always be communicated perhaps what is 
lacking is adequate endorsement regarding the relative efficacy of psychological 
interventions. 
A brief investigation revealed overall the sample was not very knowledgeable about 
the potential side-effects of benzodiazepines. This is surprising given many of the 
group have been using for multiple years, and thus should have been exposed to 
this information on a number of occasions. The least commonly reported source of 
regulated information was the medication warning label on the box. Within 
Australia, benzodiazepines are required to be dispensed with a specifically worded 
sedation warning label on the box, with the aim of increasing consumer caution, 
and thus reducing accident risk. Unfortunately, it appears that the tendency for 
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medication labels to pass unnoticed or not be understood, decreases their efficacy. 
Recent research that tracked eye movements whilst participants studied a 
medication vial, explored how the action of noticing or attending to a label, was 
associated with later remembering this information (Sundar, Becker, Bello, & Bix, 
2012). It was found that during viewing, participants often failed to fixate on the 
prescription warning labels. Regardless of age, subjects were more likely to later 
recognise the labels if they had fixated on them earlier (p=0.02). However, attention 
to a warning label is irrelevant if that information cannot then be understood. An 
Australian population literacy survey indicated that almost 60% of Australians aged 
15 to 74 do not have the necessary literacy skills to understand health information 
such as medicine labels (Australian Bureau of Statistics, 2008). Ley (1995) examined 
existing research on medicine warnings and directions, and concluded that 
medication labels are noticed on average by only 50% of people, that only 20% of 
people read beyond the first line of the warning, almost 25% of warnings are not 
understood by their target audience, and only about 50% of people actually heed 
the warning or caution. There is some evidence that simplifying warning 
information, and adding pictorial explanations may assist with understanding 
medication labels. A study of 500 adults in the USA, aimed to explore how 
understanding of medication labels differed across three methods of delivery – 
standard drug warning labels, simplified text, and simplified text plus pictorial icons 
(Wolf et al., 2010). It was found that compared to the standard warning labels, 
there was a significantly increased frequency of correct interpretations for labels 
with both simplified text (adjusted OR 2.64, 95%CI 2.00-3.48) and simplified text 
plus icons (adjusted OR 3.26, 95%CI 2.46-4.32). For people with low literacy the use 
of simplified information plus pictorial icons was associated with improved 
understanding of labels, compared to labels with simplified information only 
(adjusted OR 3.22, 95%CI 139-7.50). The final element of efficacy for these warning 
labels, is whether they result in any meaningful behaviour change. Very recently, a 
study in France (Orriols et al., 2016) examined the impact of changed medication 
labelling on the association between benzodiazepines and z-drugs, and accident 
risk. Over the last decade in France, a coloured pictogram medication label has been 
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implemented, which indicates one of four levels of risk in terms of a medication’s 
effect on driving performance. For the study, data were extracted from 3 French 
databases and included 69,353 responsible and 73,410 non-responsible drivers 
involved in traffic accidents. The association between benzodiazepine use and 
accidents was examined at four time points; prior to the pictogram introduction 
(2005), during the initial use of the pictogram (2007), and at two time points post 
pictogram introduction (2008 and 2010). Benzodiazepine anxiolytics were 
associated with an increased risk of responsibility for traffic accidents during the 
pre-intervention period (OR 1.42 95%CI 1.24–1.62). This association disappeared 
during the time of the pictogram implementation (OR 1.08, 95%CI 0.93-1.26), but 
became significant again at the two post-intervention time points (2008; OR 1.19, 
95%CI 1.03-1.37 and 2010; OR 1.35, 95%CI 1.18-1.54). The authors concluded that 
the sizeable impact of benzodiazepines on traffic accident risk, warrants the 
attempt to improve medication labelling. However, in the French study, there were 
minimal effects of the pictogram in reducing accident risk, and the authors question 
the efficacy of this as a safety measure. In summary, various research indicates that 
there are several barriers to the efficacy of medication warning labels in reducing 
harm. This is affirmed by the current study where medication warning labels were 
rarely identified as a source of medication knowledge. Changes to medication 
labelling in Australia have been gradual, but it is suggested that as with the French 
study by Orriols et al. (2016) any changes should be accompanied by robust 
research that establishes whether changes to warning labels result in a subsequent 
reduction in harm.  
The number of respondents that reported health professionals as a source of 
information about negative side-effects was also limited, with only about one third 
of each group reporting they were informed by their doctor, and approximately 
one-fifth by the pharmacist. Likewise, in response to the open-ended questions, 
some individuals identified they did not feel adequately informed about the 
potential risks and side-effects of using benzodiazepines. Similar findings occurred 
in earlier mentioned sample of older adults, most of whom reported that their 
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doctors had not discussed the negative side-effects of benzodiazepines, which in 
turn was taken to imply the implicit approval of the doctor in the safety of 
benzodiazepines (Cook et al., 2007). It is not clear from the current data whether 
these low figures are an accurate indication that this education is not taking place, 
or whether it has occurred but been dismissed or forgotten – perhaps due to the 
memory impairing effects of benzodiazepines. Either way, it must be ensured that 
key benzodiazepine information is provided to, and retained by patients. With 
estimates that 40-80% of medical information provided to patients is forgotten 
immediately (Kessels, 2003), it is clear that steps must be taken to circumvent this. 
Evidence suggests the provision of both oral and written basic information, aids 
recall (Kessels, 2003). With respect to benzodiazepine prescriptions, it is suggested 
that standardised, consumer-friendly, written and pictorial information should be 
required to be provided. This should be provided firstly by the prescriber to ensure 
the patient is fully informed before the prescription occurs, but should be also be 
supported by pharmacists. Evidence shows that patient outcomes are improved 
when prescribers and pharmacists work together collaboratively (Pharmacy Guild of 
Australia, 2012; Zillich, McDonough, Carter, & Doucette, 2004). These processes 
would ensure firstly, that benzodiazepine information is provided consistently, and 
secondly, that the likelihood of recalling this information is maximised.   
Despite a low level of knowledge about side-effects, it was not unusual for the 
group to experience these symptoms. The short-term and chronic users were more 
likely to report that they had experienced a range of common side-effects (daytime 
drowsiness, poor concentration, light-headedness, memory loss, slurred speech, 
and confusion). For some individuals these side-effects did not abate as use 
continued. Differential development of tolerance to benzodiazepines occurs, 
although it is not fully understood; tolerance to the anticonvulsant and hypnotic 
effects occurs relatively quickly, and tolerance to the anxiolytic and amnestic effects 
occurs more slowly, if at all. However, self-reported experience of side effects 
indicates that for many, tolerance has not developed completely to 
benzodiazepines. Current recommendations suggest that any ongoing use of 
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benzodiazepines should occur only with regular cost-benefit analyses (Royal 
Australian College of General Practitioners, 2015b). Experience of these adverse 
side-effects should be a trigger for health professionals to engage in this discussion, 
and any ongoing benzodiazepine use should be accompanied by increased clinical 
observation (Royal Australian College of General Practitioners, 2015b). 
The main concerns that arise from this study, are that benzodiazepine use is often 
far from best practice, and that users are not always thoroughly educated as to the 
potential negative effects of benzodiazepines. When considering the solution to 
these issues, it is evident that there are many good recommendations that already 
exist (Royal Australian College of General Practitioners, 2015a, 2015b). 
Unfortunately, in the main, these are non-mandated policies and implementation is 
left largely to the individual, or organisation, with varying outcomes. A recent meta-
analysis by Sirdifield and colleagues found a number of factors, such as patient 
characteristics and GP attitudes to other treatments, have led to general 
practitioners’ “ambivalent attitudes” and “inconsistent management strategies for 
prescribing benzodiazepines” (Sirdifield et al., 2013: p.6). It seems that what is 
required, is to draw the large body of benzodiazepine literature into a legally and 
professionally binding protocol, for the improved management of benzodiazepines.  
It is proposed that one approach to standardising benzodiazepine prescription could 
include replicating the opiate contracts that are typically used in the management 
of pain relief (Queensland Government Drug Dependence Unit, 2010). The aim of 
medication contracts is to ensure that both patient and doctor have effectively 
communicated regarding the risks and benefits of a medication. There have already 
been attempts to modify contracts for benzodiazepine use, for example the recent 
Royal Australian College of General Practitioners’ guidelines (Royal Australian 
College of General Practitioners, 2015b); this contract, whilst thorough, may be too 
complex for day to day use. A proposed alternative is provided in Table 4, this has 
been modified from the Queensland Government Opiate contract, and in light of 
the low health literacy identified in Australia (Australian Bureau of Statistics, 2008) 
the language simplified (Queensland Government Drug Dependence Unit, 2010). 
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Whilst opiate contracts usually focus on dependence risk, the findings of this 
research illustrate the importance of additional considerations in a benzodiazepine 
contract. It is suggested that a benzodiazepine contract should particularly facilitate 
the opportunity to have open discussion regarding the limitations of 
benzodiazepines, specifically the risks associated with ongoing use, and the 
discussion of alternate treatment approaches, such as CBT. Benzodiazepine 
contracts could also be used in conjunction with a real-time reporting system, which 
would not only reduce issues like doctor shopping, and high risk drug interactions, 
but would also provide quick transfer of information to other health professionals. 
Table 4. Proposed Benzodiazepine Medication Contract to assist with Maintaining 
Therapeutic Usage. 
 
UNDERSTANDING BENZODIAZEPINES 
I, (name)_______________________________________  understand 
that a benzodiazepine is being prescribed to help me with my:  
(insert presenting problem)__________________________________ 
________________________________________________________.  
 I understand that benzodiazepines may only be one part of treating 
this condition  
 My doctor and I agree to the following ideas about my use of 
benzodiazepines: 
Prescription 
 I will only take the benzodiazepine at the dose stated by my 
doctor. I will not change my dosage without talking to my 
doctor first. My dosage is: 
____________________________________________________ 
____________________________________________________ 
 I need to keep my benzodiazepines safe. Lost or stolen 
prescriptions or medicine will not be replaced by my doctor. 
 I will only get benzodiazepine scripts from the doctor who signs 
this contract, or other doctors in the same practice (if agreed 
upon). 
 I understand that I cannot have early prescriptions. 
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 I agree to tell my doctor if I have ever had a problem with 
alcohol or drugs, or if I have ever been involved in illegal activity 
related to any drugs including prescription medicines. 
 I know that giving my medicine to other people is illegal and 
could be unsafe for them.  
Side-effects and long-term consequences 
 My doctor respects my right to make choices about my 
condition and will explain the risks, benefits, and side effects of 
any treatment.  
 Most people do not have any serious problems with 
benzodiazepines when used as directed, but there can be side 
effects. My doctor has said what these are, and given me a copy 
of them in writing, and I will tell him or her if I experience them.  
 I understand that using benzodiazepines for more than 4 weeks 
could affect my health. For this reason my doctor and I will work 
on other ways of treating my condition.  
Treatment Plan 
 My doctor will keep reviewing the symptoms that I have. I will 
make another appointment by the (date)  ___ to 
review my progress.  
 I understand that benzodiazepines are best for short-term use 
only. My doctor and I have talked about other ways of managing 
my symptoms. The next steps I will take to find other 
treatments are:  
__________________________________________________ 
__________________________________________________ 
__________________________________________________ 
__________________________________________________ 
 My doctor and I will discuss the ongoing risks and benefits of 
using benzodiazepines. If we decide they are no longer helpful, 
or if I fail to abide by this contract, they may stop prescribing 
benzodiazepines or change the treatment plan. 
 
Patient Signature:_____________________________________ 
Name: _____________________________Date: ____________ 
Medical Practitioner Signature: __________________________ 
Name: _____________________________Date: ____________ 
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It is not uncommon for both research and popular media to focus on the negative 
aspects of using benzodiazepines. It is less often acknowledged that there are those 
who are able to use benzodiazepines ‘as required’ and to stop using them without 
problems (Baldwin et al., 2013). There was such a group of patients in the current 
study, often the intermittent users, who reported that the benefits of 
benzodiazepine use outweighed any negatives, that they were able to use only 
occasionally, and that they received symptomatic relief. Benzodiazepines were 
described as ‘the only thing that helps’, ‘effective and safe’, and even ‘life-saving’. 
Nevertheless, many patients reported that they felt stigmatised when seeking a 
benzodiazepine prescription. Despite the highly negative publicity regarding 
benzodiazepines, it is vital health professionals remain aware that many patients 
receive genuine benefits from using benzodiazepines. Standardised procedures for 
all patients seeking benzodiazepines would reduce the likelihood of any individuals 
feeling stigmatised.  
The major limitation of this study is that it explorative in nature; a more rigorous 
qualitative approach would allow increased confidence in the themes that have 
been identified. However, the study does add to the substantive body of 
experimental benzodiazepine research, by adding often missed information about 
the views and experiences of benzodiazepine consumers. Recently, there has been 
growing recognition that quantitative and qualitative research methods, can be 
complementary rather than exclusive (Pope, van Royen, & Baker, 2002). In this 
study, themes were developed out of the respondents’ open-ended responses. 
Because development of themes occurred post-data collection, it became evident 
at this time that extra information would have helped to inform and explain some 
of these research themes. For example, a commonly identified theme was that 
respondents’ struggled with withdrawal symptoms. In order to better understand 
this, information about interventions received (e.g. gradual dose reduction, or 
psychological interventions) would have helped to clarify respondents’ experiences. 
Despite this, the aim of the open-ended questions was to be exploratory in nature. 
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Some of the themes identified by this research could form the basis for a more 
detailed area of study. 
Results of this study suggest there is a population of chronic benzodiazepine 
consumers who are using for durations and dosages far beyond clinical guidelines. 
Whether benzodiazepines remain efficacious in this group is undetermined, but 
unlikely. Emerging from this study were three key opportunities to intervene with 
benzodiazepine users - currently it is not clear whether these interventions 
consistently occur in a meaningful way. Firstly, many individuals reported that they 
felt inadequately informed about the risks when beginning benzodiazepines. 
Providers of this information need to account for the amnestic properties of both 
benzodiazepines, and the conditions for which they are prescribed – information 
needs to be provided repeatedly and in both written and oral forms. Secondly, 
many of the respondents experienced side-effects of benzodiazepines. Continuing 
use of benzodiazepines should always be accompanied by ongoing discussions of 
risks and benefits, and reporting of side-effects can be used as a cue for such 
discussions. Finally, withdrawal symptoms were identified as a significant barrier to 
cessation of use, those wishing to reduce benzodiazepine use should be provided 
with both gradual dose reduction, and alternative coping techniques. Despite 
benzodiazepine guidelines being first implemented over 35 years ago (Committee 
on the Review of Medicines, 1980), it seems that they are not regularly adopted in 
practice. Currently there are comprehensive, evidenced-based guidelines available 
to direct prescription of benzodiazepines (Royal Australian College of General 
Practitioners, 2015a, 2015b). It seems what is lacking is a standardised application 
of these guidelines. It is proposed that a benzodiazepine medication contract could 
be used to guide both prescribers, and patients in the safe use of benzodiazepines.  
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CHAPTER 9: GENERAL DISCUSSION 
The focus of this thesis was to investigate the relationship between benzodiazepine 
use of varying chronicity, and experience of safety incidents. The first study 
investigated benzodiazepine use in a general population. Benzodiazepine use was 
classified as short-term, intermittent, or chronic. Experience of incidents was 
explored across a continuum including cognitive failures, minor injuries, and major 
accidents. The second study explored the unique effects of chronic benzodiazepine 
use on safety, in a group of people who inject drugs (PWID). PWID are a population 
group already at a high risk of safety incidents, due to risk factors such as particular 
demographic characteristics and the impairing effects of polydrug use. It was found 
that in both the general population and PWID, benzodiazepine use was uniquely 
and independently associated with a higher risk of safety incidents. In the third 
study, the subjective experiences of regular benzodiazepine users were 
investigated. There was a focus on how the perceptions and attitudes of 
benzodiazepine users varied with different chronicity of use. The research questions 
and relevant findings are summarised below (Table 1). 
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Research Findings 
Table 1. Core Research Questions and Related Findings and Conclusions 
Research Question Chapter(s) Key Findings 
(U=Finding significant in univariate results only; m=Finding 
remained significant in multivariate results) 
Conclusion 
What are the associations 
between ongoing 
benzodiazepine use and 
various incident types – in the 
general population and people 
who inject drugs (PWID) 
6,7 General Population Sample: 
Chronic benzodiazepine users experienced increased 
rates of general accidentsm, retrospective memorym, and 
prospective memory problemsu. 
A high monthly dose of benzodiazepines was associated 
with increased risk of traffic accidents in the last 12 
monthsu. 
PWID: 
Regular benzodiazepine users experienced significantly 
more major accidentsm, and retrospectivem and 
prospective memoryu problems than low use users. 
Benzodiazepine users are at an increased risk of safety 
incidents, after controlling for a variety of other 
demographic, health and drug use variables. 
Is benzodiazepine use 
associated with each of the 
incident types listed above in 
the same way, or are some 
incident types more 
susceptible to benzodiazepine 
use? 
6,7 
 
Benzodiazepine users experienced increased rates of 
cognitive failures and major accidents. 
No significant effects associated with benzodiazepines 
were found for minor accidents. 
Benzodiazepine use did not affect all incident types 
uniformly. Minimal prompting and poor recall of minor 
injuries may have affected findings.  
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Research Question Chapter(s) Key Findings 
(U=Finding significant in univariate results only; m=Finding 
remained significant in multivariate results) 
Conclusion 
What effect does chronicity of 
benzodiazepine use have on 
experience of incident types?  
 
6,7 Comparisons between three categories of 
benzodiazepine chronicity showed chronic users had 
higher rates of incidents than intermittent users.  
There were no differences between chronic and short-
term users 
Pattern of benzodiazepine use is important. Long-term, 
daily users were the most likely to experience problems. 
Is experience of incidents 
associated more strongly with 
dosage, or pattern (duration 
and frequency) of 
benzodiazepine use? 
 
 
 
6,7 
Dosage had a significant effect on two variables only; 
traffic accidents in last 12 monthsu and prospective 
memoryu. Chronic benzodiazepine use was associated 
with a broad range of incident types in both the general 
population and PWID. 
Chronic benzodiazepine use is an important target for 
harm reduction.  
What do regular consumers 
know about the side-effects of 
benzodiazepines? 
8 Only 3.1% (n=3) of the entire sample, were able to 
correctly identify 10 side-effects of benzodiazepines.  
Knowledge of common benzodiazepine side-effects is 
poor, even in those who have been using for some time. 
From what sources is 
information about side-effects 
obtained? 
 
8 The most commonly reported source of information for 
all groups was ‘the information in the box’  
Low numbers of respondents reported they had received 
information from their doctor or pharmacist 
Steps should be taken to ensure information is provided 
routinely, and information should be provided in both 
verbal and written format to maximise recall. 
What detrimental effects do 
benzodiazepine consumers 
detect? 
 
8 Short-term and chronic users most commonly reported 
experience of negative side-effects, and often did not 
experience a resolution of symptoms. Approximately half 
the sample reported no effect of benzodiazepines on 
their driving ability. Chronic users were most likely to 
report using benzodiazepines worsened driving ability. 
Despite many of the sample reporting they experienced 
continuing side-effects, subjective benzodiazepine-
related impairment on driving ability was not noted 
consistently across the cohort. It is possible this may be 
an effect of impaired meta-cognition (e.g. the ability to 
detect impairment).  
Do people take any precautions 
regarding benzodiazepine use 
and driving? 
 
8 Most commonly, the sample did not implement any 
precautions whilst driving. The most common 
precautions used were not driving at all, or immediately 
following, benzodiazepine use. 
 
Precautions reported by the sample were sensible, with 
many choosing not to drive when using benzodiazepines. 
This may be the reason few respondents reported 
impairment to driving ability (see above). 
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Research Question Chapter(s) Key Findings 
(U=Finding significant in univariate results only; m=Finding 
remained significant in multivariate results) 
Conclusion 
What are the general worries 
and concerns that regular 
benzodiazepine consumers 
experience (related to their 
benzodiazepine use) 
8 Open-ended questions were organised into the following 
themes: Addiction and dependence, ability to manage 
usage, withdrawal, stigma and availability, positive 
effects of benzodiazepine use, negative effects of 
benzodiazepine use, and provision of benzodiazepine 
information. 
Many of the sample reported symptoms indicative of 
benzodiazepine dependence. Withdrawal symptoms 
were a significant barrier to ceasing use. Whilst many of 
the cohort reported negative experiences of 
benzodiazepine use, there was also a small group who 
reported that using benzodiazepines had a generally 
positive effect. Many reported regularly feeling 
stigmatised, when seeking benzodiazepine prescriptions. 
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Outcomes from the General Population Sample 
Reported benzodiazepine use within Study 1 and 3 was high. Data from the general 
population indicated dose, frequency, and duration of benzodiazepine use was 
often chronic in nature. This is despite clinical guidelines repeatedly emphasising 
that benzodiazepines should be used at the lowest effective dose, and for the 
shortest time period possible (National Health and Medical Research Council, 1991; 
Royal Australian College of General Practitioners, 2015b). Recent Australian studies 
indicate that benzodiazepine use has plateaued over the last 20 years (Hollingworth 
& Siskind, 2010; Islam, Conigrave, Day, Nguyen, & Haber, 2013; Stephenson, 
Karange, & McGregor, 2013). However, population utilisation still remains high, and 
statistics may be affected by the popularity of different formulations at different 
times, and a move towards larger quantity private prescriptions (Islam et al., 2013). 
Whilst these population trends show a decrease in Australian benzodiazepine use, 
data from the current study indicates that at the individual level, there are still 
many who use in a manner contrary to clinical indications. 
Symptoms reported in the qualitative study were often consistent with 
benzodiazepine dependence, for example, many reported escalating 
benzodiazepine use and strong withdrawal symptoms. Lader (2011) suggests there 
are two main groups of people who become benzodiazepine dependent; those who 
are initially prescribed benzodiazepines to manage symptoms and then are 
maintained on the dose by prescribers (involuntary/iatrogenic dependence), and 
then those who actively seek benzodiazepines for intentional abuse of their 
psychotropic properties. Of those involved in the current studies, there are most 
certainly some that fall into each category. This chronic and dependent use of 
benzodiazepines indicates that there are shortfalls in the procedures surrounding 
the management of both licit and illicit benzodiazepine use. 
Whilst benzodiazepine use in the general population sample was high, information 
from the qualitative study suggests that many did not want to be using at this 
frequency. Many of the respondents communicated a desire for their 
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benzodiazepine use to be different, but had difficulty achieving this, and expressed 
comments such as: “I feel that the only reason I’m on benzodiazepines is that I can’t 
stop”, “I wish that I had never taken them”, and “the withdrawal is far too painful 
and makes it very hard to get off it”. What these patients are describing is 
ambivalence about continued benzodiazepine use. Ambivalence is a key concept in 
the motivational interviewing framework (Miller & Rollnick, 2012), which 
emphasises using a patient’s own conflicted feelings or attitudes to encourage 
change. The times when patients express dissatisfaction about benzodiazepine use, 
are key opportunities to start a discussion about the risks and benefits of continuing 
use. Unfortunately, despite the ambivalence about continuing benzodiazepine use 
that many of this cohort report, it seems that they are lacking the support to 
progress with their withdrawal from benzodiazepines.  
Evidence from all three studies indicated that those who use benzodiazepines in the 
most chronic manner, were at the greatest risk of negative consequences. Chronic 
users experienced more safety incidents and self-reported more negative 
symptoms, compared to those who used only intermittently over the same time 
period. Chronicity of use had a greater association with safety incidents than the 
dosage used. These findings are at odds with the commonly held belief that regular 
users of medications become tolerant to all of the effects of that medication. It is 
known that the development of tolerance to benzodiazepines develops 
differentially; developing quickly for some effects, e.g. hypnotic and anticonvulsant 
effects, and more slowly or not at all for others, e.g. anxiolytic and amnestic effects 
(Vinkers & Olivier, 2012). Evidence from the current study suggests that long-term 
benzodiazepine users do not develop tolerance to many of the problematic side 
effects of benzodiazepines. This was evidenced both objectively, through the 
elevated experience of safety incidents, and subjectively, through the report of 
continued negative effects. Practically, this indicates that chronic benzodiazepine 
users do not become immune to the risks of using benzodiazepines, and that they 
should be regularly reminded of this by health professionals. Requests for repeat 
prescriptions should be a prompt to discuss the risks and benefits of continued use. 
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Given that chronic users experienced increased incidents when compared to 
intermittent users, there is some indication that a reduction in frequency of use 
may be a valuable harm reduction technique. This is also consistent with guidelines 
that recommend regular breaks in benzodiazepine dosing to reduce the likelihood 
of dependence (Royal Australian College of General Practitioners, 2015b). However, 
it must be acknowledged that this places high demands on the practitioner 
managing the withdrawal, who may often not have originally initiated the 
prescription. More specialised services may be required to meet these demands. 
Outcomes from the PWID sample 
In the sample of people who inject drugs, almost one-third of the group had used 
benzodiazepines daily for at least the last six months. Clinical guidelines recommend 
against the prescribing of benzodiazepines to people who misuse both legal and 
illegal drugs, due to the high risk of adverse events occurring. When 
benzodiazepines are combined with other depressant drugs, such as alcohol or 
opioids, there is a risk of central nervous system depression, which can result in 
injury or death (Jones, Mogali, & Comer, 2012). Additionally, people who have 
previously misused drugs, are at a greater risk of becoming problematic 
benzodiazepine users (Tvete, Bjorner, Aursnes, & Skomedal, 2013). As such it is 
recommended that benzodiazepine use is not initiated in polydrug users, and that if 
they are already using benzodiazepines then cessation of use should be a priority 
(Royal Australian College of General Practitioners, 2015b). Despite these 
recommendations, benzodiazepine use within the PWID cohort was high, though it 
was not clear whether benzodiazepines were obtained from licit or illicit sources.  
Finding regular benzodiazepine use in high risk populations is not uncommon. The 
National Opioid Medication Abuse Deterrence (NOMAD) project examined the use 
of major drug types, before and after the introduction of an abuse deterrent 
sustained-release oxycodone formulation (Reformulated OxyContin®). In one 
sample resulting from the NOMAD study, 606 people who regularly tamper with 
pharmaceutical opioids were examined (Degenhardt et al., 2015). Before the 
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introduction of the Reformulated OxyContin®, 72% of the cohort had used 
benzodiazepines in the past month. Post-introduction there was a reduction in use 
of most types of opioids and a statistically significant decrease in the use of 
benzodiazepines, with 66% reporting benzodiazepine use in the past month. 
Despite the downward trend, benzodiazepine use in this group was extremely high 
at both time points. 
Similarly, the Pain and Opioids in Treatment (POINT) project, examines those who 
use prescribed opioids for the management of chronic non cancer pain (CNCP). 
Again, use of benzodiazepines in this group is contraindicated, due to low efficacy in 
treating symptoms, and a high risk of complications through drug interactions. In a 
sample of 1,220 CNCP patients, the group was evenly divided between those who 
had never used, who had previously used, or were current benzodiazepine users 
(Nielsen et al., 2015). In the one-third (33%) of the group that had used a 
benzodiazepine in the past month, 53% were using daily. Benzodiazepine use was 
associated with poorer health outcomes and high utilisation of health services.  
Findings from these studies, show three cohorts who are high risk benzodiazepine 
users; people who inject drugs (current study), illicit opioid users (NOMAD study; 
Degenhardt et al., 2015), and prescribed opioid users (POINT study; Nielsen et al., 
2015). Research into the concomitant effects of benzodiazepines and opioids first 
occurred in the 1970s (Kleber & Gold, 1978). Continually, the association between 
combined benzodiazepine and opioid use, and increased harm has been 
established; for example increased risk of overdose (Darke, Ross, & Hall, 1996) and 
poor mental health (Eiroa-Orosa et al., 2010). Many years on from the initial 
research, there are clear recommendations to limit the use of benzodiazepines in 
these high risk groups. However, research in multiple cohorts, including the current 
one, shows the prevalence of benzodiazepine use in these populations is still 
extremely high. What is evident from these findings is that the quality prescribing of 
benzodiazepines is failing, in both general and high risk populations.  
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The Incident Continuum 
One of the aims of this thesis was to include safety incidents with varying severities, 
in order to comprehensively explore the effects of benzodiazepines on safety. These 
incidents included accidents requiring medical attention, minor injuries, and 
cognitive failures. In both the general and PWID populations, there were significant 
effects of benzodiazepine use on major accidents and cognitive failures. However, 
no significant associations were found between benzodiazepine use and minor 
injuries. Whether this lack of association is a valid finding, or resulted from some 
bias in reporting is unclear. The reporting of minor injuries could be influenced by 
individual differences related to recall, definition, and saliency of events. However, 
incidents occurred in the current general population sample at comparable rate to a 
UK population sample (Wadsworth, Moss, Simpson, & Smith, 2005); and as 
expected incident rates were significantly increased in the PWID sample. This 
suggests that there was not consistent under-reporting of incidents that occurred in 
the current samples. The survey questions related to minor injuries were taken 
directly from the work of Wadsworth and colleagues (e.g. Wadsworth et al., 2005). 
However, the use of this question (e.g. ‘in the last 12 months how frequently have 
you had minor injuries (e.g. cuts and bruises) that did not require medical attention 
from anyone else?’) is quite non-specific and requires the participant to make a 
decision about what constitutes a minor injury. Future research examining minor 
injuries may benefit from the development of a specific measurement tool. For 
example, the Prospective Retrospective Memory Questionnaire (Crawford & Smith, 
2003) used in this thesis, asks respondents to indicate how often they experience 
particular specific memory failures. A similar format, providing specific examples of 
minor injuries, may help respondents with recognition and recall. The accurate 
identification of minor injuries, may also be aided by the use of real-time 
technology. For example, a phone App could be used to prompt study participants 
to record any safety incidents that they experienced, at regularly occurring 
intervals. Real-time technology may also allow the exploration of relationships 
between the different incident types. There is some evidence that shows 
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associations between cognitive failures, and accidents (Larson, Alderton, Neideffer, 
& Underhill, 1997; Simpson, Wadsworth, Moss, & Smith, 2005), and it has been 
suggested that context or environment may influence whether or not a cognitive 
failure results in an accident (Simpson et al., 2005). However, further research is 
needed to better understand the causative relationships between cognitive failures, 
minor injuries, and major accidents.  
Strengths, Limitations, and Recommendations for future research 
A considerable strength of the current studies is that they examine benzodiazepine 
use within the context of other potentially confounding variables. Much of the 
existing benzodiazepine literature examines carefully crafted research samples – 
study respondents are often benzodiazepine-naïve individuals, with no other health 
conditions, or drug use. This does not allow the unique and potentially additive 
effects of benzodiazepines to be explored. In both the general and PWID samples, 
there was an array of variables that were associated with safety incidents. It is 
notable that even in the context of high severity injecting drug use, some 
substances that may be considered a low treatment priority, such as alcohol and 
cannabis, had significant associations with safety. This demonstrates that people 
who use benzodiazepines often have many factors that influence their health and 
well-being. From a harm reduction viewpoint, this highlights the importance of 
screening for, and reducing polysubstance use, even for legal substances such as 
alcohol and benzodiazepines. The main limitation of the general population study, 
was that despite varied participant recruitment methods, the sample size was small. 
Whilst trends emerged in this sample, a larger sample would allow these findings to 
become clearer. In hindsight, the survey length may have been too onerous for 
respondents, and therefore affected completion numbers. Also whilst there was the 
aim to capture a general population sample, it is possible that responder bias 
occurred. Specifically, those that completed the survey may have been compelled 
to do so due to a strong positive or negative sentiment towards benzodiazepines. 
Certainly, in the responses to the open-ended questions, polarised opinions 
towards benzodiazepines were evident. The current sample was also quite 
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weighted towards long-term benzodiazepine use; even the short-term user group 
had an average use that spanned 168 days. This may in part also have been due to a 
responder bias, where those who had only been using benzodiazepines for a short-
period of time has less intrinsic motivation to participate in the study.  
In order to compare across the different types and dosages of benzodiazepines used 
in the sample, a conversion to a diazepam equivalent dose was used. Whilst this 
conversion is useful for research purposes, it is not without limitations. The 
conversion to diazepam equivalent dose is based on doses with comparable clinical 
effects, and it does not account for variation between preparations, such as time to 
onset and duration of effects. Furthermore, using a diazepam equivalent dose 
means that the unique effects of each individual preparation cannot be explored, 
and interesting findings may be obscured. Despite this, the use of diazepam 
equivalent doses is still a useful, and commonly utilised strategy for research 
examining the benzodiazepines. The alternative to this is would be to have a very 
large sample size, with enough occurrences of each drug type, to allow comparisons 
to be made between preparations.  
One aspect that does not emerge from the current study is why the sample’s 
benzodiazepine use has continued in such a chronic manner. There are a range of 
causative reasons that could contribute to this, such as; clinically justified use, poor 
clinical management, failed attempts at cessation, doctor-shopping, or illicit 
purchases. Similarly, it is not known what deprescribing interventions were typically 
received by these benzodiazepine users. What is established, is that there are 
significant barriers to reducing benzodiazepine use, such as the overwhelming 
withdrawal symptoms described by the sample in chapter 8. Furthermore, not all 
outcomes associated with benzodiazepine reduction are positive; for example, 
evidence suggests that a mild cognitive deficit may remain for people who have 
previously been chronic benzodiazepine users (Barker, Greenwood, Jackson, & 
Crowe, 2004). These factors may mean that incentive to reduce benzodiazepine use 
remains low. Future studies should take a longitudinal approach in order to 
understand the progression of long-term benzodiazepine users, including the 
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reasons for initial and ongoing use of benzodiazepines, and the clinical involvement 
and interventions with these patients. Longitudinal cross-over studies, including 
alternate pharmacological treatments, and psychological therapies should focus on 
the beneficial effects of ceasing benzodiazepine use.   
Clinical Recommendations 
There have been numerous quality guidelines released to direct the process of 
benzodiazepine prescription (for example: National Health and Medical Research 
Council, 1991; Royal Australian College of General Practitioners, 2015a, 2015b). 
When considering the issues regarding problematic benzodiazepine use that have 
been identified in this study, a review of current benzodiazepine guidelines revealed 
that in most instances there were already suggested procedures to circumvent 
these problems. What seems to be lacking is a regular application of these 
guidelines. In the Royal Australian College of General Practitioner’s guidelines 
(2015b), much of the content focuses on achieving a more consistent approach to 
prescribing benzodiazepines.  
It is proposed that one approach to standardising benzodiazepine prescription could 
be by replicating the opiate contracts that are typically used in the management of 
pain relief (Queensland Government Drug Dependence Unit, 2010). There have 
already been attempts to modify a contract for benzodiazepine use (for example: 
Royal Australian College of General Practitioners, 2015b), although they are not yet 
regularly used in practice. The aim of a benzodiazepine contract would be to 
instigate a discussion regarding the limitations of benzodiazepines, particularly the 
risks associated with ongoing use, and to consider alternate treatment approaches, 
such as cognitive-behavioural therapy.  
Benzodiazepine contracts would guide the use of benzodiazepines and other 
therapies, through various stages of treatment. In order to reduce ongoing 
benzodiazepine use occurring without clear rationale, it is recommended that all 
benzodiazepine prescriptions should be accompanied by a benzodiazepine contract, 
that clearly documents agreed time frames and dates, for example when the 
Chapter 9: General Discussion | 205 
 
 
 
prescription will be reviewed or when alternative treatment is to commence. 
Benzodiazepine contracts would also improve communication between 
professionals, and could be used as a reference point for agreed upon principles (for 
example, a patient only obtaining prescriptions from one pharmacy). Importantly, 
benzodiazepine contracts would improve accountability for both patients and 
prescribers. They would provide a record that key benzodiazepine information has 
been discussed and agreed upon by both parties. Whilst prescriber autonomy and 
judgement will always be important, evidence from this study suggests that 
procedures surrounding benzodiazepine prescription need to be strengthened. 
Benzodiazepine contracts would ensure best practice standards are followed by 
individual prescribers, and the health profession as a whole.  
Findings from the current qualitative study indicated many respondents felt that 
benzodiazepines were the most effective treatment to manage their symptoms 
quickly. Likewise, recent research found that GPs often prescribed benzodiazepines 
as they felt this was the best way to assist their patients, who often had 
overwhelming psychosocial problems (Anthierens, Habraken, Petrovic, & 
Christiaens, 2007). Contrary to these beliefs, benzodiazepines are rarely indicted as 
a first line treatment choice. Perhaps what is often lacking at both the prescriber, 
and patient level, is an awareness of the relative efficacy of psychological 
treatments, usually cognitive-behavioural therapy, in managing many of the 
conditions for which benzodiazepines are commonly prescribed. Treatment of 
various conditions should always be guided by best practice treatment protocols, 
such as those produced by the National Institute for Health and Care Excellence, or 
the British Association for Psychopharmacology. Undeniably, psychological 
treatments are more intensive in terms of time requirements for both patient and 
prescriber, and for them to be utilised as recommended, there must be clear 
referral pathways available, and medical practitioners must be encouraged to use 
these as a first treatment option. If a benzodiazepine script is initiated, then it is 
suggested that an accompanying benzodiazepine contract is used to outline a plan 
for complementary non-pharmacological treatments to occur. 
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Finally, it should be acknowledged that benzodiazepines, whilst frequently vilified, 
can also be a highly effective and safe medication when used correctly. There were 
some individuals in this cohort who reported they were able to use benzodiazepines 
occasionally when needed, to effectively manage symptoms, with minimal side-
effects. The ongoing issue for prescribers is how to differentiate those who are 
receiving a positive effect, from the multitude of other problematic presentations. 
The use of a benzodiazepine contract as a standard measure, would reduce 
stigmatisation by ensuring everyone who receives a benzodiazepine prescription is 
treated equally.  
Table 2 summarises the key recommendations for managing benzodiazepine use at 
each stage of treatment; these are proposed based on the review and findings of 
the current study. These recommendations are supported by other relevant 
guidelines.  
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Table 2. Recommended Interventions during Benzodiazepine treatment, based on 
the findings of the current study and the extant literature. 
Stage of 
Treatment: 
Suggested Interventions based on findings 
from the current study: 
Supported 
by: 
R
A
C
G
P
1
 
N
IC
E2
 
B
A
P
3
 
Patients requesting 
symptomatic relief 
Comprehensive medical assessment    
Relevant treatment protocol followed    
Increased accessibility of Psychological 
services when indicated in treatment 
protocol 
   
New 
benzodiazepine 
script initiated 
Benzodiazepine Contract initiated, including 
an exploration of Pros and Cons of use 
 
 
 
 
 
 
Benzodiazepine Contract initiated, including 
an agreement on a review date 
   
Repeat 
benzodiazepine 
script requested 
Risk/benefit analysis of benzodiazepine 
continuation reviewed 
   
Standard policies for managing requests    
Long-term 
benzodiazepine 
users 
Review ongoing risks of use    
Emphasise benefits of reduction in use    
Initiate benzodiazepine contract if not 
already documented 
   
Set date for cessation of use    
Initiate alternative treatment for underlying 
conditions 
   
Patient 
withdrawing from 
benzodiazepines  
Gradual dose reduction    
Psychological interventions used to manage 
withdrawal symptoms 
 
 
  
Provide psychological interventions with 
efficacy in treating underlying condition 
   
Collaboration with 
other health 
professionals 
Real-time reporting systems    
Limit number of prescribers and 
pharmacies involved per patient 
   
Communication between health 
professionals via benzodiazepine contract. 
   
1 Royal Australian College for General Practitioners (Royal Australian College of General 
Practitioners, 2015b) 2National Institute for Health and Care Excellence (National Institute 
for Health and Care Excellence, 2014). 3British Association for Pharmacology (Baldwin et al., 
2013) 
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Conclusion 
Benzodiazepines are a divisive medication. They are fast-acting, effective, and low 
cost, which means that they will likely remain a popular treatment choice. However, 
there are also significant risks involved with their use, including dependence, health 
and safety issues, and cognitive decline. Despite clinical guidelines first being 
published over 35 years ago, the current research shows that the use of 
benzodiazepines is often not concordant with these guidelines. In both the general 
and high risk population samples studied here, benzodiazepine use was chronic in 
duration and frequency. The most chronic user groups had an increased experience 
of safety incidents, and this association remained after controlling for a range of 
confounding variables. It is important that enough autonomy in benzodiazepine 
prescribing is retained to allow for the individual needs of patients. However, the 
use of benzodiazepines is at a point where accountability of prescription must be 
increased. Benzodiazepine contracts are proposed as a method to ensure 
consistency and best practice in prescribing occurs. The use of a contract would 
ensure prescribers and patients had an open conversation about the risks and 
benefits of benzodiazepine use. This is essential given that many of the current 
sample reported feeling ill-informed about benzodiazepines, and correspondingly 
their assessed knowledge about benzodiazepine side-effects was low. To maximise 
understanding and recall, key benzodiazepine information needs to be provided 
repeatedly, in a way that is attention-grabbing, easily understood, and accessible in 
a range of different formats. Many in this sample of chronic benzodiazepine users 
expressed a desire to reduce their use. This ambivalence about use is an 
opportunity to instigate change that should not be missed. However, to manage 
current chronic benzodiazepine users, and to counter more restrictive 
benzodiazepine prescribing, there needs to be an increased provision of more 
specialised services. These services would need to target the management of 
benzodiazepine dependence and withdrawal, and importantly provide alternative 
treatments and strategies to the use of benzodiazepines. 
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APPENDIX 
BENZODIAZEPINE USE, HEALTH, & DRIVING SURVEY 
Benzodiazepines: Use, Accidents & Perceptions 
Thank you for your interest in this research. This study is part of a research project 
conducted by Aneliese Poorter (DPsych student) and Dr Raimondo Bruno at the 
University of Tasmania. This study has been cleared in accordance with the ethical 
review processes of the University of Tasmania and complies with the guidelines of 
the National Statement on Ethical Conduct in Human Research. Your participation is 
completely voluntary. 
What is the purpose of this study? 
The purpose of this study is to investigate the experience of people who take 
benzodiazepines (sleeping pills, tranquilisers). In particular, the study will look at 
driving practices, experiences of accidents and injuries, memory failures and 
personal perspectives regarding benzodiazepines. 
What will I be asked to do? 
Taking part in this study involves completing an online survey and should take about 
25 minutes, or slightly more or less depending on your experience with these 
medications. Questions ask about medication use, driving practices, recent 
accidents, and injuries you may have experienced, times when you have forgotten 
to do something and your own perceptions of the impact of benzodiazepines on 
your safety. 
What are the benefits of participating in this study? 
Your participation will also assist us to better understand the role of 
benzodiazepines in road safety. This information is of high importance to health 
professionals and policy makers, and will provide useful information to prescribers 
of these medications. Upon completion you may choose to be entered into a prize 
draw to win one of three $500 Coles-Myer gift vouchers. 
Are there any risks associated with participating in this study? 
This study involves no more than minimal risk to you, i.e., the level of risk 
encountered in daily life. No deception is involved in this study. However, should 
you become uncomfortable or upset whilst completing the survey, please stop the 
survey and seek assistance from Lifeline, on 13 11 14, which operates 24 hours a 
day, 7 days a week (within Australia). If you do not reside in Australia, you may find 
your local service provider on the International White and Yellow 
Pages, www.wayp.com. If you have any questions or concerns about your 
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benzodiazepine use as a result of completing this survey, you should discuss these 
with your regular doctor. 
It is also important for you to know that all questions are optional. Please skip any 
questions in this survey that you feel uncomfortable about answering. 
How will my confidentiality and privacy be maintained? 
Our server uses a 128bit encryption which is backed by Verisign, the world's largest 
security certificate provider. This is the same level of encryption used by banks and 
the Australian Tax Office. Therefore, the responses you provide will remain 
completely anonymous and confidential, as the risk of identification is negligible. 
However, you may also choose to use an anonymizer, which will mask your IP 
address. This will mean that both the computer you are using as well as the 
responses you provide will be completely unidentifiable. Anonymizers work by 
inserting a fake computer in between your computer and our server, hence masking 
your IP address. For more information, see: http://www.torproject.org/ & 
http://www.thefreecountry.com/security/anonymous.shtml 
How do I participate? 
Below you will find a short list of statements that you will be asked to agree to in 
order to indicate your willingness to participate in this survey. There are also some 
brief questions determining your eligibility for this study. After answering these 
questions you will be directed to the start of the survey. If you do not wish to 
participate, we thank you for your time - you can close this browser window to end 
this session. If you wish to discontinue your participation at any point during the 
study, you may do so by closing your internet browser. 
Concerns and complaints 
If you have any questions about this study, please contact Aneliese Poorter 
(apoorter@utas.edu.au) or Dr Raimondo Bruno at (Raimondo.Bruno@utas.edu.au) 
This study has been approved by the Tasmanian Social Science Human Research 
Ethics Committee. If you have concerns or complaints about the conduct of this 
study, you may contact the Executive Officer of the Human Research Ethics 
Committee (Tasmania) Network on 03 6226 7479 or human.ethics@utas.edu.au. 
The Executive Officer is the person nominated to receive complaints from research 
participants. Please quote Ethics Reference Number H0012343. 
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Please read the following statements: 
 I have read and understood the above information relating to this 
study. 
 I understand the nature and possible effects of this st udy. 
 I understand that this study involves answering questions about my 
benzodiazepine use, experiences of driving -related and other 
accidents and perceptions regarding benzodiazepines.  
 I understand that all questions are optional and that I may choose 
to not answer any questions that I am uncomfortable with.  
 I understand that all research data will be securely stored on a 
password protected server at the University of Tasmania.  
 I understand that my participation is voluntary and that I cannot be 
identified in any way. 
 
 
INFORMATION ABOUT YOU  
These first few questions ask some basic information about you. Remember this 
information will not be used to identify anyone, it simply helps us to create a 
picture of the people completing this survey. 
 
To help us determine that you are eligible to participate in this study, please 
indicate whether you agree with the following statements: 
Please choose the appropriate response for each item: 
 I agree I disagree 
I am at least 18 years of age   
I have taken a benzodiazepine in 
the past 12 months 
  
 
 
 
Respondents that did not tick ‘I agree’ to both statements could not access the 
remainder of the survey 
Respondents that did not agree with the above statements could not access the 
remainder of the survey 
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What is your gender? 
Please choose all that apply: 
 Female  
 Male  
 Transgender  
How old are you? 
Please answer age in years. Please write your answer here: 
 
What is your current residential postcode? 
Please write your answer here: 
 
What is your current marital status? 
Please choose only one of the following: 
 Never married  
 Married/Defacto  
 Widowed  
 Divorced  
 Separated but not divorced  
How would you best describe your household? 
Please choose only one of the following: 
 Single person household  
 Single parent household  
 You and spouse/partner with no children  
 You and spouse/partner with one or more children at home  
 Shared household  
 Living with parents  
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What is the highest level of school that you have completed? 
Please choose only one of the following: 
 Still at secondary school  
 Did not go to school 
 Year 8 or below 
 Year 9 or equivalent  
 Year 10 or equivalent  
 Completed HSC/HEC (Year 12 or equivalent)  
Have you completed any further qualifications? 
Please choose only one of the following: 
 No 
 No, still studying for first qualification  
 Yes 
What qualification/s are you currently studying for? 
Please choose all that apply: 
 Trade Certificate 
 Other Certificate (e.g. TAFE, Cert III etc.)  
 Associate or Undergraduate Diploma 
 Bachelor's Degree 
 Graduate Diploma/Certificate  
 Postgraduate Degree 
 Other:  
What is the highest level of further education you have reached so far? 
Please choose only one of the following: 
 Trade Certificate 
 Other Certificate (e.g. TAFE, Cert III)  
 Associate or Undergraduate Diploma 
 Bachelor's Degree 
 Graduate Diploma/Certificate  
 Postgraduate Degree 
 Other  
How would you best describe your current employment situation? 
Please choose all that apply: 
 Not Employed 
 Retired/Pensioner 
 Home Duties 
 Part time/Casual Work (less than 20 hours/week) 
 Full time work 
 Other:  
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What is the total of all wages/salaries, government benefits, allowances and 
other income that you usually receive per week or per year (before tax and 
other deductions)? 
Please choose only one of the following: 
 $1-$149 /week ($1-$7,799 / year) 
 $150-$249 / week ($7,800-$12,999 / year) 
 $250-$399 / week ($13, 000-$20,799 / year) 
 $400-$599 / week ($20,800-$31, 199 / year) 
 $600-$799 / week ($31,200-$41,599 / year) 
 $800-$999 / week ($41,600-$51,999 / year) 
 $1,000-$1,299 / week ($52,000-$67,599 / year) 
 $1,300-$1,599 / week ($67,600-$83,199 / year) 
 $1,600-$1,999 / week ($83,200-$103,999 / year) 
 $2,000 or more / week ($104,000 or more / year)  
 Nil income 
 Negative income 
 
Have you ever driven a motor vehicle? 
Please choose only one of the following: 
 No 
 Yes 
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KEY MEDICATION INFORMATION 
To help us customise this survey to you, please answer the following key questions 
about your medication use. 
What best describes your reasons for use of benzodiazepines? 
Please choose all that apply: 
 I'm taking them to help with my sleep 
 I'm taking them to help with my anxiety  
 I'm taking them to help with my pain  
 I'm taking them for some other reason 
Which of the following best describes your pattern of taking 
benzodiazepines? 
Please choose all that apply: 
 I've been taking them daily or almost daily, for less than a 
month 
 I've been taking them daily or almost daily, for more than a 
month 
 I've been taking them daily or almost daily, for a year or more  
 I've been taking them every now and then, for less than a 
month 
 I've been taking them every now and then, for more than a 
month 
 I've been taking them every now and then, for a year or more  
In the last year have you taken any of the following types of prescription 
medications (this includes prescription medications that may not have been 
prescribed for you)? 
Please choose all that apply: 
 Antidepressant or mood lifting medications (e.g. Zoloft, Prozac, 
Lovan) 
 Prescription pain killers or Opioids (e.g. Panadeine Forte, 
Oxycontin, Tramal)  
 Strong tranquilizers or Ant ipsychotics (e.g. Seroquel, Risperdal)  
 None of these 
 
 
The above question was used to determine which medications were examined in more 
detail later in the survey. 
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YOUR MEDICATION USE: BENZODIAZEPINES 
Please help us to get an idea of your benzodiazepine use by answering the following 
questions about when and how often you take them. 
In the past 12 months have you used any of the following benzodiazepines? 
Please choose the appropriate response for each item: 
 
The first names listed here are active ingredients in the 
medication. You may also know these medications by their 
brand name, some common brand names are l isted in 
b
r
a
c
k
e
t
s
. 
 
 
 1. 
Which best describes your use of alprazolam: 
Please choose only one of the following: 
 I take it every day 
 I take it for a brief period then stop  
 I only take it when I need it  
 
2. Which of the following best describes your use of alprazolam: 
Please choose only one of the following: 
 I'm taking it exactly as prescribed  
 I'm taking less than was prescribed  
 I'm taking more than was prescribed  
 I'm not prescribed this medicat ion 
 
No Yes 
Alprazolam (Alprax, Kalma, Ralozam, Xanax)    
Bromazepam (Lexotan)   
Clobazam (Frisium)   
Diazepam (Antenex, Valium, Valpam)    
Flunitrazepam (Hypnodorm)   
Lorazepam (Ativan)    
Nitrazepam (Alodorm, Mogadon)    
Oxazepam (Alepam, Murelax, Serepax)    
Temazepam (Normison, Temaze, Temtabs)    
For each of the active ingredients listed above that were answered ‘YES’, the following 
questions (1-8) were then asked (alprazolam provided as an example) 
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3. When do you typically take alprazolam: 
Please choose all that apply: 
 In the morning 
 In the afternoon 
 In the night 
4. In the last month how many days did you take alprazolam? 
Please write your answer here: 
 
  If you took it every day please put  '30'. If you did not take it at all, 
please put '0'. 
5. When you've taken alprazolam what has been your usual dose per day? 
Please write your answer here: 
 
If possible please record the total milligrams that you would 
usually take in one day.  
If you're unsure about how many milligrams you take, just 
type in the number of tablets  you have each day and describe 
the tablet. 
6. Approximately what date did you start taking alprazolam? 
Please enter a date: 
 
If you are unsure of the exact date you started, please pu t the 
first of the month. E.g. If you think you started in July 2012, 
select 1.7.2012. 
7. Approximately when did you finish taking alprazolam? 
Please enter a date: 
 
If you are unsure of the exact date you finished, please put the 
last day of the month. E.g. If you think you finished in July 
2012, select 31.7.2012. 
If you are still taking this medication, please enter today's date.  
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8. Did you take alprazolam yesterday? 
Please choose only one of the following: 
 Yes 
 No 
 
Following are some questions about how important benzodiazepines are in 
your life 
Please select the most accurate answer for the statements below: 
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How difficult would you find it to stop 
or go without your benzodiazepines?  
        
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Have you wished you could stop taking 
benzodiazepines? 
        
Have you worried about your use of 
benzodiazepines? 
        
Has the prospect of missing a dose 
made you anxious or worried  
        
Have you ever thought your use of 
benzodiazepines was out of control?  
        
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CURRENT LICENCE AND DRIVING 
We're interested in your experience on the road, so these next few questions are 
about your driving history. 
What licence or licences do you currently hold? 
Please choose all that apply: 
 Car: Learner's permit  
 Car: Provisional licence/P plates  
 Car: Full driver's licence 
 Car: Restricted licence  
 Heavy vehicle licence 
 Bus Driver's licence 
 Motorcycle: Learner's permit  
 Motorcycle: Provisional licence  
 Motorcycle: Full licence 
 Taxi or hire care licence 
 None 
 
How long have you had your longest driver's licence or permit? 
Please choose only one of the following: 
 Less than 6 months 
 Less than 1 year 
 1 to 2 years 
 2 to 3 years 
 3 to 5 years 
 6 to 10 years 
 Over 10 years 
How often do you drive a vehicle on the road, assuming an average week? 
Please choose only one of the following: 
 Less than once a week 
 At least one day a week 
 2 to 3 days a week 
 4 to 6 days a week 
 Every day of the week 
How far (kilometres) do you drive per week on average? 
Please write your answer here: 
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How many hours would you personally drive a vehicle on the road each 
week? 
Please write your answer here: 
  
What percentage of your driving would be on roads with a speed limit of 
80km/hour or more? 
Please choose only one of the following: 
 Less than 20% 
 20 to 50% 
 50% 
 51 to 80% 
 More than 80% 
ROAD ACCIDENTS 
The following section includes questions about traffic accidents that you may have 
been involved in. 
If you find this distressing remember that you may exit this survey at any time. 
Please contact lifeline on 13 11 14 if you feel like you want to talk to someone. 
In the last 12 months when you have been driving, how many close calls 
have you had (i.e. incidents that almost resulted in a crash but did not)? 
Please write your answer here: 
  
For how many of these 'close calls' do you think you were taking a 
benzodiazepine in the same time period? 
Please write your answer here: 
 
 
 
Appendix | 223 
 
 
 
When you have been driving, how many road crashes have you ever been 
involved in? 
Please choose only one of the following: 
 None 
 One 
 2-3 
 4-5 
 5-10 
 More than 10 
 
'Road Crash' includes any incident in which you were driving 
and which yourself or another person were injured  or where 
there was damage to property or vehicles.  
 
In the last 12 months when you have been driving, how many road 
crashes have you had? 
Please write your answer here: 
  
 
'Road Crash' includes any incident in which you were driving 
and which yourself or another person were injured  or where 
there was damage to property or vehicles.  
For how many of these accidents do you think you were taking a 
benzodiazepine in the same time period? 
Please write your answer here: 
  
Think of the most serious crash that you have had in the last 12 months, 
when you have been driving, and answer the following questions (questions 
a-h). 
a. Were you at fault for this crash? 
Please choose only one of the following: 
 Yes 
 No 
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b. Were you taking a benzodiazepine at the time of this accident? 
Please choose only one of the following: 
 Yes 
 No 
c. How many hours before the accident do you think you would have had 
a benzodiazepine? 
Please write your answer here: 
  
d. Was there another vehicle involved in this crash? 
Please choose only one of the following: 
 Yes 
 No 
e. What vehicle were you driving? 
Please choose only one of the following: 
 Car 
 Utility 
 4WD 
 Light Truck 
 Heavy vehicle 
 Motorcycle 
 Other  
f. What was the result of this crash? 
Mark the most serious result: 
 There was minor damage to a vehicle but no one was injured  
 There was major damage to a vehicle but no one was in jured 
 Someone was injured but did not need to be hospitalised  
 Someone died or needed to be hospitalised  
 None of the above 
 Don't know 
g. Where were you driving? 
Please choose only one of the following: 
 In a capital city  
 In a regional city/large town 
 In the country on a country road 
 In the country on highway/freeway 
 Off road (including rural use)  
 Don't know/can't recall  
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h. What speed zone were you driving in? 
Please choose only one of the following: 
 40km/hour 
 50km/hour 
 60km/hour 
 70km/hour 
 80km/hour 
 100km/hour 
 110km/hour 
 Don't know/can't recall  
How many times have you lost your licence due to traffic offences? 
Please choose only one of the following: 
 Never 
 Once 
 Twice 
 Three times 
 Four or more times 
How many licence demerit points have you lost in the last 12 months? 
Please choose only one of the following: 
 None 
 One 
 Two 
 Three 
 4-6 
 7-9 
 10-12 
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YOUR PERCEPTIONS OF BENZODIAZEPINES 
These next questions are asking for your personal opinions on how you think 
benzodiazepines might affect you. 
Tick all of the symptoms listed below that you think could be a side-effect of 
taking benzodiazepines: 
Please choose all that apply: 
 Nausea 
 Drowsiness 
 Sedation 
 Light-headedness 
 Double vision 
 Slurred Speech 
 Indigestion 
 Memory Loss 
 Ataxia (difficulty with coordination)  
 Constipation 
 
Please answer this question using your own knowledge only  
When you first started using benzodiazepines, how did you learn about the 
possible negative side effects? 
Please choose all that apply: 
 I wasn't aware of the side effects  
 The Doctor told me 
 The Pharmacist told me 
 I read the information in the box  
 I saw a warning label on the box  
 A friend/family member told me 
 The Internet 
 Other:  
 
Have you ever experienced any daytime drowsiness that you feel is related 
to your benzodiazepine use (e.g. feeling sluggish or difficulty getting going 
in the morning)? 
Please choose only one of the following: 
 Yes 
 No 
For each of the following questions about symptomology, if a respondent indicated that 
they had experienced the symptom, then the follow up question asking about change in 
the symptom was presented 
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Since you began taking benzodiazepines, has this daytime drowsiness: 
Please choose only one of the following: 
 Stayed the same 
 Worsened 
 Improved 
Have you ever experienced any poor concentration that you feel is related to 
your benzodiazepine use? 
Please choose only one of the following: 
 Yes 
 No 
Since you began taking benzodiazepines, has this poor concentration: 
Please choose only one of the following: 
 Stayed the same 
 Worsened 
 Improved 
Have you ever experienced any light-headedness that you feel is related to 
your benzodiazepine use? 
Please choose only one of the following: 
 Yes 
 No 
Since you began taking benzodiazepines, has this light-headedness: 
Please choose only one of the following: 
 Stayed the same 
 Worsened 
 Improved 
Have you ever experienced any memory loss that you feel is related to your 
benzodiazepine use? 
Please choose only one of the following: 
 Yes 
 No 
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Since you began taking benzodiazepines, has this memory loss: 
Please choose only one of the following: 
 Stayed the same 
 Worsened 
 Improved 
Have you ever experienced any slurred speech that you feel is related to your 
benzodiazepine use? 
Please choose only one of the following: 
 Yes 
 No 
Since you began taking benzodiazepines, has this slurred speech: 
Please choose only one of the following: 
 Stayed the same 
 Worsened 
 Improved 
Have you ever experienced any confusion that you feel is related to your 
benzodiazepine use? 
Please choose only one of the following: 
 Yes 
 No 
Since you began taking benzodiazepines, has this confusion: 
Please choose only one of the following: 
 Stayed the same 
 Worsened 
 Improved 
When you first started taking benzodiazepines (e.g. for the first month), how 
did you think they impacted on your driving ability? 
Please choose only one of the following: 
 No effect 
 Worsened 
 Improved 
 Not applicable 
If you selected improved or worsened, please specify briefly 
how your driving ability was impacted.  
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How do you think your use of benzodiazepines currently impacts on your 
driving ability? 
Please choose only one of the following: 
 No effect 
 Worsens 
 Improves 
 Not applicable 
 
If you selected improves or worsens, please specify briefly how your driving 
ability was impacted. 
 
Whilst taking benzodiazepines have you taken any safety precautions in 
regards to driving? 
Please choose all that apply: 
 I did not take any precautions  
 I did not drive at all  
 I did not drive immediately after I had taken a benzodiazepine  
 I drove more slowly 
 I stopped taking benzodiazepines  
 I took other things to counter any side-effects 
 Other:  
Do you worry about using benzodiazepines? 
Please choose only one of the following: 
 No 
 Yes 
If you answered yes, please explain briefly  
 
Do you feel that taking benzodiazepines has negatively impacted on your 
safety in any other way? Please explain briefly: 
Please write your answer here: 
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OTHER ACCIDENTS, BUMPS & BRUISES 
Another area that we are interested in is your experience of non-road related 
accidents (for licenced driver's road accidents are covered in an earlier section). 
These questions ask about any major injuries as well as more minor 'bumps and 
bruises'. 
Remember if you find this distressing, you can exit the survey at any time. Please 
contact Lifeline on 13 11 14 if you feel like you want to talk to someone. 
 
Thinking about the last 12 months, how many accidents have you had that 
required medical attention from someone else (e.g. a first aider, GP, nurse, 
or hospital doctor)? 
Please write your answer here: 
  
Thinking about your most recent accident that required medical attention, 
how were you injured? 
Please choose all that apply: 
 Being in contact with moving machinery  
 Being struck by a moving object  
 Being struck by a moving vehicle  
 Striking something stationary  
 Being injured whilst handling, lifting or  carrying 
 A slip, trip or fall on the same level  
 A fall from a height  
 Being trapped by something collapsing or overturning  
 Drowning or asphyxiation 
 Exposure to a harmful substance  
 Exposure to a fire  
 Exposure to an explosion 
 Being in contact with electricity 
 Being injured by an animal  
 An act of violence 
 Being injured whilst playing sport  
 Other:  
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Where were you injured? 
Please choose all that apply: 
 Face 
 Head 
 Neck 
 Hand 
 Arm 
 Torso 
 Back 
 Leg 
 Foot 
 Other:  
What sort of injury or injuries did you sustain? 
Please choose all that apply: 
 Amputation 
 Fracture/broken bone 
 Dislocation 
 Concussion 
 Internal injuries  
 Lacerations (open cuts or wounds)  
 Bruising 
 Burns 
 Poisoning or gassing 
 Sprain or strain 
 Injuries caused through contact with electricity  
 Injuries requiring resuscitation 
What medical attention did you require? 
Please choose all that apply: 
 Treated by a G.P.  
 Treated by a nurse at the G.P. surgery  
 Attended Accident & Emergency 
 Admitted to hospital for LESS than 24 hours  
 Admitted to hospital for MORE than 24 hours  
 Other:  
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In the last 12 months how frequently have you had minor injuries (e.g. cuts 
and bruises) that did not require medical attention from anyone else? 
Please choose only one of the following: 
 Not at all  
 Rarely 
 Occasionally  
 Quite frequently  
 Very frequently 
In the last month how frequently have you had minor injuries (e.g. cuts and 
bruises) that did not require medical attention from anyone else? 
Please choose only one of the following: 
 Not at all  
 Rarely 
 Occasionally  
 Quite frequently  
 Very frequently 
Approximately how many times have you visited your G.P. in the last 12 
months? 
Please write your answer here: 
  
Approximately how many times have you visited hospital as an outpatient in 
the last 12 months? 
Please write your answer here: 
 
 Approximately how many times have you visited hospital as an inpatient in 
the last 12 months? 
Please write your answer here: 
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YOUR MEMORY IN EVERYDAY SITUATIONS 
This questionnaire looks at the type of memory mistakes that people make in 
normal everyday life. We would like you to tell us how often these kind of things 
happen to you. 
Please choose the appropriate response for each 
item: N
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Do you decide to do something in a few minutes 
time and then forget to do it?  
     
Do you fail to recognise a place that you have 
visited before? 
     
Do you fail to do something you were supposed to 
do a few minutes later even though it's there in 
front of you, like take a pill or turn off the kettle?  
     
Do you forget to do something that you were told a 
few minutes before? 
     
Do you forget appointments if you are not 
prompted by someone else or by a reminder such as 
a calendar or diary? 
     
Do you fail to recognise a character in a radio or 
television show from scene to scene? 
     
Do you forget to buy something you planned to buy, 
like a birthday card, even when you see the shop?  
     
Do you fail to recall things that have happened to 
you in the last few days? 
     
Do you repeat the same story to  the same person 
on different occasions? 
     
Do you intend to take something with you, before 
leaving a room or going out, but minutes later leave 
it behind, even though it's there in front of you?  
     
Do you mislay something that you have just put 
down, like a magazine or glasses?  
     
Do you fail to mention or give something to a visitor 
that you were asked to pass on?  
     
Do you look at something without realising you 
have seen it moments before? 
     
If you tried to contact a friend or relative who was 
out, would you forget to try again later?  
     
Do you forget what you watched on television the 
previous day? 
     
Do you forget to tell someone something you had 
meant to mention a few minutes ago?  
     
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ALCOHOL USE 
Because Alcohol use can affect health and interfere with some medications, it is 
important we ask you some questions about your use of alcohol. Your answers will 
remain confidential so please answer as accurately as possible. 
Try to answer the questions in terms of 'standard drinks'. See the image below for 
common standard drink portions. 
Each of the following contains ONE standard drink: 
 
How often do you have a drink containing alcohol? 
Please choose only one of the following: 
 Never 
 Monthly or less 
 2-4 times per month 
 2-3 times per week 
 4 or more times a week 
How many drinks containing alcohol do you have on a typical day when you 
are drinking? 
Please choose only one of the following: 
 1 or 2 
 3 or 4 
 5 or 6 
 7 to 9 
 10 or more 
Appendix | 235 
 
 
 
How often do you have six or more drinks on one occasion? 
Please choose only one of the following: 
 Never 
 Less than monthly  
 Monthly 
 Weekly 
 Daily or almost daily  
In the past 12 months how likely is it that you have driven when over the 
blood alcohol limit (the limit that applies to your licence at the time)? 
Please choose only one of the following: 
 Definitely not 
 Very unlikely 
 Fairly unlikely 
 Fairly likely 
 Very likely 
 
OTHER DRUG USE AND DRIVING 
Because there are various drugs that can influence your driving ability, we are 
interested to know whether you have consumed certain drugs before driving. These 
next questions ask about some legal and illicit drugs. 
How often have you used cannabis in the past 12 months? 
Please choose only one of the following: 
 Never 
 Less than monthly  
 Monthly 
 Fortnightly 
 Weekly 
 More than once a week 
 Daily 
In the past 12 months how likely is it that you have driven when under the 
influence of cannabis? 
Please choose only one of the following: 
 Definitely not 
 Very unlikely 
 Fairly unlikely 
 Fairly likely 
 Very likely 
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How often have you used other illicit (illegal) drugs (e.g. speed, ecstasy, 
opioids) in the past 12 months? 
Please choose only one of the following: 
 Never 
 Less than monthly  
 Monthly 
 Fortnightly 
 Weekly 
 More than once a week 
 Daily 
In the past 12 months how likely is it that you have driven when under the 
influence of other illicit drugs (e.g. speed, ecstasy)? 
Please choose only one of the following: 
 Definitely not 
 Very unlikely 
 Fairly unlikely 
 Fairly likely 
 Very likely 
How often have you used non-prescription codeine-based painkillers (e.g. 
Mersyndol, Panadeine, Chemists Own Strong Pain Relief) in the past 12 
months? 
Please choose only one of the following: 
 Never 
 Less than monthly  
 Monthly 
 Fortnightly 
 Weekly 
 More than once a week 
 Daily 
In the past 12 months how likely is it that you have driven when under the 
influence of other non-prescription codeine based painkillers? 
Please choose only one of the following: 
 Definitely not 
 Very unlikely 
 Fairly unlikely 
 Fairly likely 
 Very likely 
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How often have you used prescription painkillers (e.g. morphine, 
oxycodone) in the past 12 months? 
Please choose only one of the following: 
 Never 
 Less than monthly  
 Monthly 
 Fortnightly 
 Weekly 
 More than once a week 
 Daily 
In the past 12 months how likely is it that you have driven when under the 
influence of prescription painkillers (e.g. morphine, oxycodone)? 
Please choose only one of the following: 
 Definitely not 
 Very unlikely 
 Fairly unlikely 
 Fairly likely 
 Very likely 
In the past 12 months how likely is it that you have driven when under the 
influence of prescription sleeping tablets or anti-anxiety medications (e.g. 
diazepam, temazepam, oxazepam)? 
Please choose only one of the following: 
 Definitely not 
 Very unlikely 
 Fairly unlikely 
 Fairly likely 
 Very likely 
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YOUR HEALTH 
In general how would you say your health is? 
Please choose only one of the following: 
 Excellent 
 Very good 
 Good 
 Fair 
 Poor 
The following questions are about activities you might do during a typical 
day. How much does your health limit you in these activities? 
Please choose the appropriate response for each item: 
 
Limited 
a lot 
Limited 
a little 
Not 
limited 
at all  
Moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling 
or playing golf  
   
Climbing several flights of stairs     
During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of your physical 
health? 
Please choose the appropriate response for each item: 
 
No Yes 
Accomplished less than you would like    
Were limited in the kind of work or other activities    
During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? 
Please choose the appropriate response for each item: 
 
No Yes 
Accomplished less than you would like    
Did work or other activities less carefully than usual    
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During the past 4 weeks how much did pain interfere with your normal 
work (including both work outside the home and housework)? 
Please choose only one of the following: 
 Not at all  
 Slightly 
 Moderately 
 Quite a bit  
 Extremely 
 Very severe 
These questions are about how you feel and how things have been with you 
during the past 4 weeks. For each question please provide the one answer 
that comes closest to the way you have been feeling. 
How much of the time during the past 4 weeks: 
Please choose the appropriate response for each item: 
 
A
ll
 o
f 
th
e
 
ti
m
e
 
M
o
st
 o
f 
th
e
 t
im
e
 
A
 g
o
o
d
 b
it
 
o
f 
th
e
 t
im
e
 
S
o
m
e
 o
f 
th
e
 t
im
e
 
A
 l
it
tl
e
 b
it
 
o
f 
th
e
 t
im
e
 
N
o
n
e
 o
f 
th
e
 t
im
e
 
Have you felt calm and 
peaceful? 
      
Did you have a lot of 
energy? 
      
Have you felt 
downhearted and blue?  
      
During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like 
visiting with friends, relatives etc.)? 
Please choose only one of the following: 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little bit of the time 
 None of the time 
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In the last 12 months has a health professional told you that you have any of 
the following: 
Please choose the appropriate response for each item: 
 
Yes No 
Chronic ongoing problems with pain    
Sleep Apnoea   
A neurological condition (such as Ep ilepsy or a Stroke)   
Chronic Lung Disease (like COPD or Emphysema)    
Depression   
Anxiety   
Dependence on a substance (like alcohol or other drugs)    
Some other mental health condition    
Any other chronic ongoing condition    
 
These questions ask about your mood over the last 4 weeks. 
For all questions please select the 
most appropriate response. In the 
last 4 weeks: 
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About how often did you feel tired 
out for no good reason? 
     
About how often did you feel 
nervous? 
     
About how often did you feel so 
nervous that nothing could calm you 
down? 
     
About how often did you feel 
hopeless? 
     
About how often did you feel 
restless or fidgety? 
     
About how often did you feel so 
restless that you could not sit still?  
     
About how often did you feel 
depressed? 
     
About how often did you feel that 
everything was an effort?  
     
About how often did you feel so sad 
that nothing could cheer you up?  
     
About how often did you feel 
worthless? 
     
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YOUR MEDICATION USE: ANTIDEPRESSANT OR MOOD-LIFTING MEDICATIONS 
In this section we ask about any antidepressant medications that you may be taking. 
Whilst the focus of this study is on benzodiazepines, it is important we know about 
antidepressants so we can account for any effect they might have on your health 
and well-being. 
In the past 12 months have you used any of the following antidepressant 
medications? 
Please choose the appropriate response for each item: 
 
No Yes 
Amitriptyline (Endep)    
Agomelatine (Valdoxan)   
Citalopram (Celapram, Celica,  Ciazil, Cipramil, Citalo)   
Clomipramine (Anafranil, Placil)    
Desvenlafaxine (Pristiq)    
Dothiepin (Dothep)    
Doxepin (Deptran, Sinequan)    
Duloxetine (Cymbalta)    
Escitalopram (Escicor, Esipram, Esitalo, Lexam, Lexapro)   
Fluoxetine (Auscap, Fluohexal, Lovan, Prozac, Zactin)    
Fluvoxamine (Faverin, Luvoz, Movox, Voxam)   
Imipramine (Tofranil, Tolerade)    
Mianserin (Lumin, Tolvon)    
Mirtazepine (Avanza, Axit, Mirtazon)    
Moclobemide (Amira, Aurorix, Clobemix)    
Nortriptyline (Allegron)    
Paroxetine (Aropax, Extine, Paxtine)    
Phenelzine (Nardil)    
Sertraline (Concorz, Eleva, Sertra, Setrona, Xydep, Zoloft)    
Tranylcypromine (Parnate)    
Trimipramine (Surmontil)    
Reboxetine (Edronax)    
Venlafaxine (Efexor-XR)   
 
The first names listed here are active ingredients in the medication. You 
may also know these medications by their brand name, some common 
brand names are listed in brackets.  
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YOUR MEDICATION USE: STRONG TRANQUILISERS OR ANTI-PSYCHOTICS 
This section asks about strong tranquilisers, such as quetiapine and risperidone, and 
how you may have used them. Whilst the focus of this study is on benzodiazepines, 
it is important we know about tranquilising medications so we can account for any 
effect they might have on your health and well-being. 
In the past 12 months have you used any of the following strong 
tranquilisers (such as quetiapine, risperidone)? 
Please choose the appropriate response for each item: 
 
No Yes 
Amisulpride (Amipride, Solian, Sulpriz)    
Aripiprazole (Abilify)    
Asenapine (Saphris)    
Chlorpromazine (Largactil)    
Clozapine (Clopine, Clozaril)    
Droperidol (Droleptan)    
Flupenthixol (Fluanxol)    
Fluphenazine (Modecate)    
Haloperidol (Serenace)    
Olanzapine (Zyprexa)    
Paliperidone (Invega, Invega Sustenna)    
Pericyazine (Neulactil)    
Quetiapine (Seroquel, Seroquel XR)    
Risperidone (Resdone, Resperdal, Rispa, Rixadone, Ozidal)    
Sertindole (Serdolect)    
Trifluperazine (Stelazine)    
Ziprasidone (Zeldox)   
Zuclopethixol (Clopixol)    
 
The first names listed here are active ingredients  in the medication. You 
may also know these medications by their brand name, some common 
brand names are listed in brackets.  
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YOUR MEDICATION USE: PRESCRIPTION PAIN-KILLERS OR OPIOID MEDICATIONS 
In this section we ask about any opioid medications that you may be taking. Whilst 
the focus of this study is on benzodiazepines, it is important we know about 
painkillers so we can account for any effect they might have on your health and 
well-being. 
In the past 12 months have you used any of the following opioid 
medications? 
Please choose the appropriate response for each item: 
 
No Yes 
Buprenorphine (Subutex, Suboxone, Norspan)    
Prescription-only Codeine (Panadeine Forte, 
Codalgin, Prodeine Forte)  
  
Fentanyl (Durogesic, Denpax, Actiq)    
Hydromorphone (Dilaudid, Jurnista)    
Methadone (Physeptone)   
Morphine (MS Contin, Momex, Ordine)    
Oxycodone (Oxycontin, Endone)    
Pethidine   
Tramadol (Tramal, Zydol, Durotram)    
 
The first names listed here are active ingredients in the medication. Y ou 
may also know these medications by their brand name, some common 
brand names are listed in brackets.  
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YOUR MEDICATION USE: OTHER MEDICATIONS 
In this section we ask about some selected other medications that you may be 
taking. Whilst the focus of this study is on benzodiazepines, it is important we know 
about these other medications so we can account for any effect they might have on 
your health and well-being. 
In the past 12 months have you used any of the following other medications? 
Please choose the appropriate response for each item: 
 
No Yes 
Acamprosate (Campral)    
Buspirone (Buspar)    
Buproprion (Prexaton, Zyban SR)    
Clonidine (Catapres)    
Doxylamine (Dozile, Restavit)    
Disulfiram (Antabuse)    
Lithium (Lithicarb, Quilonum SR)   
Melatonin (Circadin)    
Naltrexone (ReVia)    
Varenicline (Champix)    
Zolpiclone (Imovane, Imrest)    
Zolpidem (Dormizol, Somidem, Stildem, Stilnox, 
Zolpibell)  
  
 
The first names listed here are active ingredients in the medication. Yo u may 
also know these medications by their brand name, some common brand names 
are listed in brackets.  
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1. Which best describes your use of amitriptyline: 
Please choose only one of the following: 
 I take it every day 
 I take it for a brief period then stop 
 I only take it when I need it  
2. Which of the following best describes your use of amitriptyline: 
Please choose only one of the following: 
 I'm taking it exactly as prescribed  
 I'm taking less than was prescribed  
 I'm taking more than was prescribed  
 I'm not prescribed this medication 
3. In the last month how many days did you take amitriptyline? 
Please write your answer here: 
  
 
If you took it every day please put  '30' 
If you did not take it at all, please put  '0'.  
4. When you've taken amitriptyline what has been your usual dose per day? 
Please write your answer here: 
 
 
If possible please record the total milligrams that you would 
usually take in one day.  
If you're unsure about how many milligrams you take, just type 
in the number of tablets  you have each day and describe the 
tablet. 
5. Did you take amitriptyline yesterday? 
Please choose only one of the following: 
 Yes 
 No 
 
For each of the above sections on anti-depressants, strong tranquillisers, and pain killers,  
the active ingredients that were answered ‘YES’, were then followed with next 5 questions 
were then asked (amitriptyline provided as an example) 
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ANY OTHER COMMENTS? 
We're really interested in the positive and negative effects that 
benzodiazepines have on people's lives. The questionnaire can't capture all 
of this, so if there are any other comments you would like to make, please let 
us know in the space below. 
Please write your answer here: 
 
 
Thank you for completing this survey. Your participation is greatly appreciated. 
Study completion is estimated for 2014; for information on general study results 
please contact Aneliese at apoorter@utas.edu.au after this date. 
To thank you for your participation, you can choose to enter a competition to win 
one of three $500 Coles Myer Vouchers.  
Please enter the prize draw by clicking on the link below 
 
